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II. AIMS  
 
[1] Development of an improved degenerate oligonucleotide-primed (DOP) PCR-based 
representational whole-genome amplification method using quantitative real-time PCR 
(QRT-PCR). 
[2] Identification of an uncommon metastasis of Merkel cell carcinoma (MCC) cell carcinoma 
with the improved whole genome amplification and comparative genome hybridization 
(CGH) technique with DNA microarrays. 
[3] Determining changes in chromosome copy numbers of papillary thyroid carcinomas 
(PTC) of good disease outcome and an aggressive type of PTC derived from the same 
patient using CGH-microarray and QRT-PCR techniques. 
[4] Identification of gene markers based on copy number changes for classification PTCs of 
different disesase courses. 
[5] Determining the angiogenic phenotype of αIIbβ3 integrin-transduced human melanoma 
cells expressing integrin αvβ3 using DNA-microarray technology to reveal the underlying 
pathomechanism.
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III. ABBREVIATIONS 
 
AKAP13:  A-kinase anchor protein 13 
Arf6:   ADP-ribosylation factor 6 
APTC:  An aggressive type of papillary thyroid carcinoma 
ATC:   Anaplastic thyroid cancer 
BAC:   Bacterial artificial chromosome 
Bcl-2:   B-cell CLL/lymphoma 2 
bFGF:   Basic fibroblast growth factor 
BRAF:   v-raf murine sarcoma viral oncogene homolog B1 
CGH:   Comparative genome hybridization 
CHO:   Chinese hamster ovary 
COX-2:  Prostaglandin-endoperoxide synthase 2 
Dbl:   MCF.2 cell line derived transforming sequence 
DGGE:  Denaturing gradient gel electrophoresis 
DOP-PCR:  Degenerate oligonucleotide-primed PCR 
EIF4EBP3:  Eukaryotic initiation factor 4E-binding protein 3 
FGF7:   Fibroblast growth factor 7 
FISH:   Fluorescent in situ hybridization 
FTC:  Follicular thyroid carcinoma 
GAP:   GTPase-activating protein 
GEF:   Guanine nucleotide exchange factor 
GPTC:  Papillary thyroid carcinoma of good disease outcome 
HRAS:  v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
IRS-PCR:  Infrequent-restriction-site polymerase chain reaction 
IPTC:  Intermediate papillary thyroid carcinoma 
Ki-67:   Antigen identified by monoclonal antibody Ki-67 
KRAS:  v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LA-PCR:  Linker adapter polymerase chain reaction 
Lbc:   Lymphoid blast crisis oncogene 
LMP:   Ligation mediated polymerase chain reaction 
LOH:   Loss of heterozygosity 
MAPK:  Mitogen-activated protein kinase 
MAPKK:  Mitogen-activated protein kinase kinase 
MCC:   Merkel cell carcinoma 
MDA:   Multiple displacement amplification 
NRAS:  Neuroblastoma RAS viral (v-ras) oncogene homolog 
PAC:   P1-derived artificial chromosome 
PEP:    Primer extension preamplification 
PIK3CA:  Phosphatydilinositol 3-kinase, catalytic, alpha polypeptide 
PI3K:   Phosphatidylinositol 3-kinase 
PTC:   Papillary thyroid cancer 
PTEN:   Phosphatase and tensin homolog 
QRT-PCR:  Quantitative real-time PCR 
RET:   REarranged during Transfection proto-oncogene 
RT:    Reverse transcription 
RT-PCR: Reverse transcription-polymerase chain reaction 
SDA:   Strand displacement amplification 
SKY:   Spectral karyotyping 
SNP:    Single-nucleotide polymorphism 
SSCP:   Single-stranded confirmational polymorphism 
TB10:   Thymosin beta 10 
TLAD:  T7-based linear amplification 
TNM:   Tumour, node, metastasis 
TPO:   Thyroid peroxidase 
Tre-2:   Ubiquitin specific peptidase 6 
TSH:   Thyroid stimulating hormone 
VEGF-C:  Vascular endothelial growth factor C 
vWF:   von Willebrand factor 
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IV. ABSTRACT 
 
The technological advances in molecular biology have proven invaluable to the 
understanding of the pathogenesis of human cancer. The application of molecular technology 
to the study of cancer has not only led to advances in tumour diagnosis, but has also provided 
markers for the assessment of prognosis and disease progression. The amount of genomic 
DNA from archived clinical samples available for genetic studies can often be limited. 
Diverse whole genome amplification methods are applied to provide a sufficient amount of 
DNA for CGH, single nucleotide polymorphism (SNP) and microsatellite analyses. CGH 
allows identification of changes in relative copy number of DNA sequences (gains and losses) 
and provides information on the primary genetic changes. Currently the microarray-based 
CGH serves as an excellent method of display. In this thesis an improved DOP-PCR 
technique, and its application in the case of two clinical studies are described. The effect of 
αIIbβ3 integrin transfection onto gene expression pattern of human melanoma cells was also 
analysed. 
In genomic studies the reliability of the amplification techniques is particularly 
important. In PCR-based approaches, the plateau-effect can seriously alter the original relative 
copy number of certain chromosomal regions. To eliminate this distorting effect, we 
improved the standard DOP-PCR technique by following the amplification status with QRT-
PCR. With real-time detection of the products, we managed to eliminate DNA over-
amplification. Probes were generated from 10 different tumour samples by using non-
amplified and amplified genomic DNA with DOP-PCR and DOP-PCR combined with QRT-
PCR. To demonstrate the reliability of the QRT-PCR based amplification protocol, altogether 
152 relative copy number changes of 44 regions were determined. There was a 85.6% 
concordance in copy number alterations between the QRT-PCR protocol and the non-
amplified samples, while this value was only 63.8% for the traditional DOP-PCR. Our results 
demonstrate that this protocol preserves the original copy number of different chromosomal 
regions in amplified genomic DNA – more accurately than standard DOP-PCR techniques. 
This improved genomic amplification technique was also applied in two clinical cases.  
In the first case, MCC was diagnosed in a 79-year-old Caucasian woman. This 
malignant, neuroendocrin tumour was localized to the upper lip. After successful cryosurgery 
and a 7-year tumour-free period, a new tumour developed in her palatine tonsil. The regional 
 4 
 
lymph nodes were devoid of metastasis. After a long tumour-free period, an anaplastic 
carcinoma with neuroendocrine features developed in her palatine tonsil, raising the 
possibility of a late haematogenous metastasis, a second field tumour, or a second primary 
tumour. The genomic DNA obtained from the paraffin-embedded two tumours and unaffected 
lymphatic tissue was amplified with our improved DOP-PCR protocol for CGH and DNA 
microarray techniques to assess the genetic relationship of the tumours. The partly similar and 
partly different molecular patterns indicated a genetic relationship between the tumours, and 
excluded the possibility that the tonsillar tumour was a metastasis. Our results suggest that a 
genetically altered field was the reason for the development of the tonsillar cancer; thus, it can 
be pathogenetically regarded as a second field tumour.  
The improved DOP-PCR technique was also employed for the detection of molecular 
patterns of PTC of different disease courses. PTC is the most common type of thyroid 
cancers, making up about 80% of all types. Unlike some other tumours, the generally 
excellent outcome for PTC is usually not affected by spread of the cancer to the lymph nodes. 
All the same in some cases it transforms into a dedifferentiated invasive tumour with an 
unfavourable outcome. Our aim was to identify gene copy number alteration as a marker or 
set of markers in order to predict individual patient outcome more effectively than existing 
staging methods; for this reason, we performed CGH-array analysis of primary- and terminal-
stage APTCs, comparing them with PTC of good disease outcome (GPTC) obtained from 
paraffin-embedded tissue. On the basis of CGH-array and confirming QRT-PCR results, six 
regions were selected for further investigation of 34 PTCs of different disease courses. Two 
groups were constructed according to the disease groups: ’A’ group: 10 cases of GPTCs; ’B’ 
group: 14 cases of intermediate (IPTC) and 10 cases of APTCs (I/APTC). In the present 
study, Tre-2 oncogene was found to be over-represented in 80% of both the GPTC and the 
I/APTC groups. Thymosin beta 10 (TB10) was amplified in 62.5% of APTC, whereas in the 
case of the GPTC group, the ratio of DNA gains was only 20%. A similarly patterned 
difference, but with lower percentage rates, could be detected in our examined Image EST 
region, which is mapped to the AKAP13 gene. Two regions were under-represented in a 
different proportion: eukaryotic initiation factor 4E-binding protein 3 (EIF4EBP3) and 
KIAA0549 genes. The sixth examined gene, namely fibroblast growth factor 7 (FGF7), 
demonstrated both DNA gains and losses with a smaller rate.  
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Copy number changes of the above mentioned six loci alone are still not sufficient for 
classifying the tumours; however, on the basis of our results, the synchronous presence of the 
amplified TB10 and Image EST (Acc. No. R78712) regions could serve a good diagnostic – 
or possibly prognostic – marker for aggressive thyroid carcinoma.  
 In our other study we developed a cDNA amplification method within which – 
similarly to the whole genomic DNA amplification – the course of amplification was 
followed using QRT-PCR. With this approach low quantity RNA sample could also be 
reliably analysed, which is especially important in assessing gene expression pattern analysis 
for instance the molecular mechanisms in different tumours. 
In cancerous tissues new vessels are required to provide cancer cells with nutrients and 
are targets for invading cancer cells themselves. The transfection of the platelet integrin 
αIIbβ3 into human melanoma cells expressing integrin αvβ3 promoted their in vivo (but not in 
vitro) growth and cell survival. To reveal the underlying pathomechanism, we have analysed 
the angiogenic phenotype of αIIbβ3 integrin-transduced human melanoma cells expressing 
integrin αvβ3. The cDNA microarray analysis of the 19H cells revealed 12 down-regulated 
and 36 up-regulated genes. Three out of nineteen known genes, up-regulated significantly in 
αIIbβ3-transfected 19H melanoma cells, are endothelial cell-specific genes: CD34, endothelin 
receptor B, and prostaglandin I-2 synthase. We propose that the illegitimate expression of 
αIIbβ3 integrin in human melanoma cells already expressing αvβ3 integrin may alter their in 
vivo growth properties due to the modulation of their angiogenic phenotype.  
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V. INTRODUCTION 
 
5.1. Functional genomics in oncology 
Dramatic technological advances have resulted in overwhelming information on 
biological systems. Advances in manipulating and sequencing DNA triggered the last such 
leap. More than twenty years ago this technology began finding its way into biology 
laboratories and multiple landmark discoveries have followed, including the sequencing of the 
genomes of several prokaryotic and eukaryotic species. This, in turn, spawned a new interest 
in bioinformatics, structural biology, and high-throughput methods that would allow scientists 
to look at the response of the entire genome to physiological, pharmacological, and 
pathological changes. 
The development of our understanding of the cell and molecular biology of the 
neoplastic process has closely paralleled advances in our understanding of tumour cell and 
molecular biology of normal cells. The vast majority of the phenotypic and genotypic 
alterations seen in neoplasia—i.e., cells in the stage of progression—are a direct result of the 
primary characteristic of this stage, evolving karyotypic instability. The discoveries of 
chemical, physical, and biological carcinogenic agents and their actions have been among the 
most exciting and significant in our understanding of the causation of cancer and of many 
aspects of its prevention, but nothing has intrigued the biological scientist more than the 
molecular differences between cancer cells and normal cells. 
Many researchers have described a number of processes and functions in the cell and 
in molecular biology of preneoplasia and neoplasia, namely the following: glycolysis, 
regulation of gene expression, signal transduction, transcription factors, cell cycle, DNA 
methylation, apoptosis, telomerase mechanism, unique or mutant protein expression, unique 
lipids and carbohydrates. However, it is important to note that there is no single component of 
any of these processes that is ubiquitously abnormal in all neoplasms. However, the majority 
of neoplasms exhibit at least one defective process in each of those listed. A comparison of 
the cellular and molecular biology of preneoplasia with that of neoplasia does, however, 
emphasize the importance of an understanding of the molecular transition between these two 
stages as critical to our understanding of the ultimate formation of the cancer cell.  
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For the identification of chromosomal abnormalities, high-throughput methods are 
becoming more and more routine and they are comprising of fluorescent in situ hybridization 
(FISH) (1, 2), spectral karyotyping (SKY) (3), CGH (4), and microsatellite analysis (5). FISH 
has a prominent role in the molecular analysis of cancer and can be used for the detection of 
numerical and structural chromosomal abnormalities. The recently described SKY, in which 
all human metaphase chromosomes are visualized in specific colors, allows for the definition 
of all chromosomal rearrangements and marker chromosomes in a tumour cell. Protocols for 
the detection of chromosomal rearrangements by PCR and RT-PCR are described, as well as 
the technique of DNA fingerprinting, a powerful tool for studying somatic genetic alterations 
in tumourigenesis. A number of approaches to identify mutations are detailed, and include 
single-stranded confirmational polymorphism (SSCP) (6), denaturing gradient gel 
electrophoresis (DGGE) (7), the nonisotopic RNase cleavage assay (8), the protein truncation 
assay (9), and DNA sequencing (10). A change in DNA methylation status is commonly 
observed in cancer, and specific methodology for methylation analysis (11) is also provided 
by this volume. A reduction in telomere length, together with expression of the telomere 
maintenance enzyme, telomerase, has been described in case of a wide range of human 
cancers (12). The research field of the spotted DNA microarray is dealing with the structure 
and activity of genomes and global relationships between genotype and phenotype. The birth 
of the field can be traced back to three seminal papers (13-15). Similar interminable 
approaches have been used to monitor relative protein levels (16), protein functions (17), 
cellular activities (18), and molecular interactions (19). The analysis of gene expression 
represents a key area of research in the study of human cancer. Global RNA expression 
analysis using microarray technology (20) allows the identification of genes that are 
differentially expressed in tumour versus normal tissues (21). This is a powerful approach for 
identifying genes that are central to disease development or progression and can also identify 
new prognostic markers. 
In this thesis we describe a new QRT-PCR-based DOP-PCR method which is capable 
of preserving the original copy number of different chromosomal regions in amplified 
genomic DNA. Furthermore, genomic imbalances were detected by CGH with microarray to 
assess the genetic relationship between MCC and later appearing tonsillar tumour, in addition 
to molecular genetic markers in the case of PTCs of different disease courses. Finally, the 
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gene expression pattern of αIIbβ3 integrin transfected human melanoma cells was 
demonstrated to define molecular pathomechanism of increased melanoma growth and 
angiogenesis by DNA microarray technique.  
 
5.2. Quantitative real-time PCR 
5.2.1. Applications of QRT-PCR 
 
The ability to monitor the real-time progress of the PCR completely revolutionizes the 
way one approaches PCR-based quantification of DNA and RNA. The development of 
fluorescent detection systems, capable of monitoring PCR product accumulation has greatly 
improved the reliability of QRT-PCR. Quantitative PCR is aimed to determine the absolute or 
relative amounts of RNA or DNA sequences in a given sample. There is a well-established 
inverse correlation between the template concentration and the duration of the lag phase of the 
PCR. An entire generation of automated systems has been developed to exploit this. Using 
any of several different chemistries, the accumulation of PCR product is monitored until a 
predetermined threshold is reached. This lag time is then compared with a standard curve and 
a concentration calculated (22). Reactions are characterized by the point in time during 
cycling when amplification of a PCR product is first detected rather than the amount of PCR 
product accumulated after a fixed number of cycles. The higher the starting copy number of 
the nucleic acid target, the sooner a significant increase in fluorescence is observed. 
Advantages of this method not only include the elimination of differences in reaction mix 
volumes and conditions that may occur in separate samples, but importantly it also allows 
reference of RNA or DNA quantitation to an internal control. Consequently, this system of 
quantitation has the advantage in that it allows the quantitation of multiple sequences from a 
single sample and a single experiment of amplification without the need of standardization for 
each sequence. 
The QRT-PCR technology is now widely used, especially in such areas as therapeutic 
monitoring at the assessment of residual disease after treatment of leukemia and lymphoma 
(23-25), quality control, disease diagnosis (26), the detection of viral nucleic acids, regulation 
of gene expression (27), and the detection of gene amplification or deletion and of aneuploidy. 
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5.2.2. Determination of copy number changes in whole genome and validation of CGH-
array profiles 
 
PCR and QRT-PCR are now well-established methods for the study of nucleic acid 
sequences in histological material. QRT-PCR is the reliable detection and measurement of 
products generated during each cycle of the PCR which are directly in proportion to the 
amount of template prior to the start of the PCR process. 
The applications of QRT-PCR are diverse and numerous, including such areas as 
DNA/cDNA copy number measurement in genomic or viral DNA/RNA, functional genomics 
including mRNA expression analysis, allelic discrimination assays and confirmation of 
microarray data. Upstream modifications to the technique, including the use of laser capture 
microdissection, add an extra dimension in facilitating the production of homogenous cell 
populations from complex tissue sections for more accurate quantitative analysis. 
The challenge is to put the technology to full use by identification of the genetic 
changes that are important in human disease. Knowledge of these changes will permit the 
establishment of rapid, cost-effective tests for diagnosis and monitoring of disease as well as 
providing a basic understanding of their underlying causes. These developments will be 
enhanced by unravelling of the complete human genome and by improvements in techniques 
for gene amplification using histological samples. 
Data obtained from the microarray experiments need validation by independent 
techniques like QRT-PCR or metaphase CGH. To determine the relative copy number ratios 
of the genome and in order to strengthen the CGH-array data, QRT-PCR was applied in this 
study.  
5.3. Whole genome amplification techniques 
High-throughput genomic analysis requires large amounts of template; however, the 
typical yield of DNA from individual samples can be often limited. The primary drawback of 
the use of laser capture microscopy in DNA analysis is that microdissections yield insufficient 
nucleic acids due to low genomic DNA recovered from small sample sizes. With samples 
such as these, the ability to conduct sample amplification becomes imperative, to ensure that 
enough material is available for genetic analysis. There are three basic techniques to amplify 
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the entire genomic DNA: PCR-based approaches (28-38), strand or multiple displacement 
amplification (SDA or MDA) (39) and T7-based linear amplification (TLAD) (40).  
5.3.1. Strand or multiple displacement amplification (SDA or MDA) and T7-based linear 
amplification  
 
The SDA and MDA isothermal methods employ the unique biochemical properties of 
Phi29 DNA polymerase to amplify linear DNA. These techniques are based on the rolling 
circle amplification by which circular DNA molecules such as plasmids or viruses frequently 
replicate. These rolling circle amplification methods were initially adapted for the 
amplification of large circular DNA templates (41, 42) and more recently for the 
amplification of genomic DNA (39). The drawback of SDA is that the efficiency of 
amplification depends on the length of the template. T7-based linear amplification is 
applicable for the amplification of genomic DNA of varying fragment size and quality, and it 
is based on a protocol devised by Phillips and Eberwine for the amplification of mRNA for 
cDNA microarrays (40, 43).  
5.3.2. PCR-based genomic DNA amplification methods  
 
The inter-spread repetitive sequence PCR (38), was the first PCR-based genome 
amplification method, which used primers designed to anneal to Alu repeats within the 
genome. This strategy was further improved to amplify specific DNA flanked by Alu repeats 
by using the so-called Restricted-PCR technology (44). An alternative method (32), termed 
the linker adapter technique PCR (LA-PCR), involved restriction digestion of the DNA and 
ligation of adaptors to serve as priming sites for subsequent PCR. In principle the ligation 
mediated PCR (LMP) is very similar to the LA-PCR method (32, 33). Nonetheless, this 
approach has not been widely applied, likely due to technical difficultes involved. PCR-based 
genome amplification methods, primer extension preamplification (PEP) (34, 35) and DOP-
PCR (36, 37) techniques have been developed for the amplification of genomic DNA starting 
from as little as a single cell. The original PEP protocol involves a 50 cycle PCR program 
using a 15 bp long oligonucleotide primer; however, via this approach only ~78% of the 
genome from a single haploid cell can be copied (34).  
DOP-PCR and PEP protocols amplify DNA in an exponential fashion, making them 
highly susceptible to biases, and they have a tendency to specifically over-represent or down-
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represent certain sequences. The major disadvantage of PCR-based protocols is that this could 
distort the ratio of the starting genomic imbalances (45). Recently, Wang et al. have described 
a modified DOP-PCR protocol for balanced amplification of genomic DNA (46), however the 
amplification status has not been followed during PCR. In their protocol genomic DNA was 
digested with a restriction enzyme and tagged linkers were ligated to the products before 
amplification. 
5.3.2.1. Degenerate oligonucleotide-primed PCR  
 
The DOP-PCR technique is increasingly being applied for simultaneous amplification 
of multiple loci in target DNA using oligonucleotide primers of partially degenerate 
sequences (36); however, the amplified DNA does not cover the genome completely. 
Contrary to other PCR-based amplification methods (Alu-PCR, IRS-PCR), DOP-PCR is a 
species-independent technique. The protocol is adapted for the use of microdissected, 
formalin-fixed and paraffin-embedded tissue in comprehensive genetic analyses (47).  
As is shown in Figure 1/a, primers used for DOP-PCR contain a variable binding 
region with a sequence of six randomly combined nucleotides which is flanked by a stringent 
primer binding region at the 5’-end (ten nucleotides) and a main primer binding region at the 
3’-end (six nucleotides) which defines the specificity of the reaction.  
 
 
 
 
  
 
                                              Figure 1/a Sequence of the DOP-PCR primer 
 
The amplification procedure is divided into two steps (Figure 1/b). During the first 
step, eight PCR cycles are performed at low stringency conditions (annealing temperature, Ta: 
30°C). These conditions allow a frequent annealing of the DOP primer, which is primarily 
mediated by the short specific sequence at its 3’-end and by the adjacent central cassette of 
degenerated nucleotides. Eventually a pool of many different DNA sequences is generated 
which should represent a statistically distributed subpopulation of the genomic DNA. During 
the second step a more stringent annealing temperature is applied and the annealing 
  
CCGACTCGAG5’- NNNNNN ATGTGG -3’
Stringent primer binding region
Variable binding region
Main binding region
aria i i g region
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temperature is raised to 62°C, allowing amplification only after specific base pairing of the 
full length primer sequence. After complete DOP-PCR reaction, a high amount of similar 
DNA fragments will be generated with DOP-primer sequences at both ends. 
 
 
 
 
 
 
 
 
 
 
 
 
                                 Figure 1/b Reaction mechanism of DOP-PCR 
 
In our improved protocol of DOP-PCR, direct amplification of genomic DNA can be 
performed without any pretreatment of the samples. Our protocol includes QRT-PCR to 
follow the cycling status which results in a more reliable and reproducible sample 
amplification. 
DOP-PCR is a simple method for whole genome amplification in comprehensive 
genetic studies (21) such as metaphase CGH (4), array CGH (48), SNP genotyping (49), 
microsatellite genotyping (5), SSCP (6), loss of heterozygosity (LOH) (50), and sequence 
analysis (10), that is increasingly being applied for simultaneous amplification of multiple 
loci in target DNA. DOP-PCR utilizes oligonucleotide primers with partially degenerate 
sequences close to their 3’ end (36). DOP-PCR is a species-independent approach, which 
produce sufficient amounts of DNA for analysing clinical tumour samples, for prenatal 
diagnosis and for many other investigations. A comparison of several DOP-PCR methods is 
also described by Larsen et al. (47). Not only the amount but also the quality of genomic 
DNA obtained from various samples is impediment for further studies. For example, paraffin-
embedded tissues often provide partially degraded low-quality DNA. Unfortunately, PCR-
First reaction step under low stringency conditions
Second reaction step under high stringency conditions
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based protocols often result in misrepresentation of the genome, with some regions over-
represented or even lost. The reliability of PCR-based amplification mostly depends on the 
exponential phase during cycling. At the late cycles of amplification, the original copy 
number of chromosomal regions can be changed and the method provides false results. The 
plateau effect (51, 52) is the result of a marked shift of the overall mass balance in favor of 
the reaction product. Different factors seem to be responsible for the attainment of the plateau 
rather than a single factor or parameter, as re-addition of presumably exhausted reagents at 
late cycles did not cause the reaction to proceed with increased efficiency (53). The plateau 
effect is caused by the accumulation of product molecules, usually it is the consequence of the 
significant degree of annealing between complementary strands of the products, rather than 
between the primers and template. Furthermore, the finite amount of enzyme molecules 
present is unable to extend all the primer-template complex in the given extension time (54).  
5.4. DNA microarray techniques and comparative genome hybridization 
5.4.1. DNA microarray technology 
 
Microarray technologies as a whole provide new tools that transform the way 
scientific experiments are carried out. In place of conducting experiments based on results 
from one or a few genes, while microarrays allow for the simultaneous interrogation of 
hundreds or thousands or tens of thousands of genes.  
Microarrays are microscope slides that contain an ordered series of samples (DNA, 
RNA, protein, tissue). The type of microarray depends upon the material placed onto the 
slide: DNA microarray, RNA microarray; protein microarray; and tissue microarray. Since 
the samples are arranged in an ordered fashion, data obtained from the microarray can be 
traced back to any of the samples. This means that genes on the microarray are addressable. 
The number of ordered samples on a microarray can reach up to a hundred thousand. A 
typical microarray contains several thousands of addressable genes. DNA printed or spotted 
onto the slides can be chemically synthesized long oligonucleotides or enzymatically 
generated PCR products. The slides contain chemically reactive groups (typically aldehydes 
or primary amines) that help stabilizing the DNA onto the slide, either by covalent bonds or 
electrostatic interactions. An alternative DNA chip technology allows the DNA to be 
synthesized directly onto the slide itself by a photolithographic process. This process has been 
commercialized and is widely available.  
 14 
 
DNA microarrays are used to determine the expression levels of genes in a sample 
(expression profiling) and have been highly successful in a variety of genomic analyses (55), 
ranging from the detection of SNPs (56) to functional genomics (57-59). Furthermore, DNA 
microarrays can be used to detect and map copy number changes in regions of the genome. 
5.4.2. Development of CGH method 
 
CGH is an in situ hybridization technique used to characterise chromosomal 
abnormalities where there is a loss (deletion) or gain (amplification) of genetic material (4). It 
is based on the competitive hybridization of labelled tumour DNA and normal DNA to 
normal metaphase chromosomes. CGH is not useful for the detection of balanced 
translocations or inversions where there is no overall gain or loss of material. The main 
advantage of CGH compared with conventional cytogenetics is that it is not necessary to 
obtain metaphase chromosome spreads from the tumour under investigation. Thus, CGH is 
ideally suited to the analysis of samples where it is difficult to obtain good quality metaphase 
chromosomes. Unlike conventional cytogenetics, CGH is applicable to the study of archival 
tumour specimens (frozen and paraffin). Recently, using a DOP-PCR method it has been 
possible to amplify sufficient DNA for CGH even from minute amounts of starting material 
and in turn this means that CGH can now be regularly performed on microdissected samples. 
It is now possible to microdissect small pre-malignant lesions and to begin to unravel the 
genetic changes that might characterise the early changes leading to malignancy. 
5.4.3. CGH combined with microarray technique 
 
CGH has already showed a significant impact on the field of cancer cytogenetics as a 
powerful tool for detection of chromosome copy number aberrations even in epithelial solid 
tumours, in the case of which it is hard to elucidate tumour specific genome alterations by 
conventional cytogenetic methods. However, the resolution of CGH to metaphase 
chromosomes can provide only limited resolution at 5-10 Mb level for detection of copy 
number losses and gains, and at 2Mb for amplifications. To circumvent this limitation, an 
innovative strategy, called matrix-CGH (60) or array-based CGH (61) has been devised. CGH 
using cDNA microarray was also reported to be useful for detection and mapping of gene 
amplification and homozygous deletions (62). In array CGH, chromosomal targets are 
replaced by arrays consisting of well-defined genomic clones such as BAC, PAC or cosmid 
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clones, which are spotted onto a microscopic slide-glass using robotic devices. Since the 
clones spotted on slide-glass contain sequence information directly connecting with the 
genome database, we can easily obtain particular biological aspects of genes mapped within 
regions involved in copy number aberrations detected by array-CGH, facilitating 
identification of genes responsible for cancer. 
5.5. Molecular pathomechanism of different tumour types 
5.5.1. Merkel cell carcinoma 
 
The Merkel cells are found in the skin and in those parts of the mucosa derived from 
the ectoderm (63). These cells are the origin of a rare, malignant neuroendocrine tumour that 
occurs predominantly in the sun-exposed areas of the skin called MCC (64-70). Local 
reccurence, and regional or distant metastasis generally develop within a short period of time. 
Oropharyngeal metastasis is very rare, and metastasis to the palatine tonsil has been described 
in only one case (71). A perioral or intraoral localization of the MCC is very infrequent: (64, 
72) to date, 10 cases of MCC of the lip (73) and 14 cases of intraoral MCCs have been 
described (64, 74, 75). During the past decade, our co-workers at University of Szeged treated 
and followed up an elderly woman with MCC of the upper lip. After a long tumour-free 
period, an anaplastic carcinoma with neuroendocrine features developed in her palatine tonsil, 
raising the possibility of a late haematogenous metastasis, a second field tumour, or a second 
primary tumour. 
The term ”secondary field tumour” was introduced in 1953 by Slaughter et al. who 
examined slides from patients with head and neck cancer (76). It was observed that all of the 
epithelium beyond the margins of the tumours displayed histologic alterations, and 11% of the 
patients were found to have more than one independent area of malignancy. The authors 
concluded that the mucosa of the head and neck had undergone a change, perhaps due to 
carcinogen exposure, and was therefore more susceptible to the development of foci of 
malignant transformation. Organs in which field cancerization has been described since then 
are the oral cavity, oropharynx, larynx, lung, oesophagus, colon, skin, vulva, cervix, breast, 
renal pelvis, ureter and bladder (77-80). 
The determination of molecular patterns of first and second tumours has become a 
valuable tool to explore the relationship between them: similar aberrations indicate a 
metastasis, partly different aberrations indicate a second field tumour, and different 
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aberrations denote a second primary tumour (78-80). We identified the molecular patterns 
with CGH with microarray technology. Array-based CGH consists of a series of mapped 
artificial bacterial chromosomes or sequenced human cDNA clones on glass slides, to which 
DNA from test and control samples is hybridized (81-83).  
Previous CGH studies of MCCs have identified divergent regions that are affected, with 
a small number of similarities between the samples analysed. Recurrent chromosomal 
imbalances detected by CGH analysis were loss of 3p, 4p15-pter, 10q, 13q and 17p and gains 
of 1q, 3q, 5p, 6, 8q, 18 and 20 (84-87). In this study, we detected some of the previously 
found regions and also numerous novel regions with chromosomal imbalances.  
5.5.2. Classification of the thyroid carcinomas 
 
There are four types of thyroid cancer some of which are much more common than 
others: Papillary and/or mixed papillary/follicular thyroid carcinoma (PTC) (78%); Follicular 
and/or Hürthle cell (FTC) (17%); Medullary (4%); Anaplastic (ATC) (1%). Thyroid cancer 
can occur in any age group, although it is most common after age 30 and its aggressiveness 
increases significantly in older patients. The majority of patients present with a nodule on 
their thyroid and far less than 1% of all thyroid nodules are malignant. 
5.5.2.1. Papillary and anaplastic thyroid carcinoma 
 
The most frequent thyroid cancer is PTC, and this type is one of the most curable 
cancers with ten year’ survival rates (at about 80-90%). Cervical metastasis (spread to lymph 
nodes in the neck) are present in 50% of small tumours and in over 75% of the larger thyroid 
cancers. The presence of lymph node metastasis in these cervical areas causes a higher 
recurrence rate but not a higher mortality rate. Distant metastasis (spread) is uncommon in 
PTC, but during follow-up 6 to 11% of PTC patients develop distant metastases. Although 
patients may live for long time with distant metastases, this does significantly worsen 
prognosis. About one-third of patients with distant metastases survive for 10 years. That is 
two-third of them die in ten years. An other form of aggressive disease outcome is local 
recurrance and invasion. Age is important for both predicting development of distant 
metastases and for influencing long-term survival.  
The least common type of thyroid cancer is ATC which has a very poor prognosis. ATC 
tends to be found after it has spread and is not cured in most cases. Anaplastic tumour has a 
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very low cure rate and most patients with ATC do not live one year from the day they are 
diagnosed. ATC often arises within a more differentiated thyroid cancer or even within a 
goiter. It seems a generally accepted hypothesis, that they originated from differentiated 
thyroid cancers. Cervical metastasis (spread of the cancer to lymph nodes in the neck) are 
present in the vast majority (over 90%) of cases at the time of diagnosis. The presence of 
lymph node metastasis in these cervical areas causes a higher recurrence rate and is predictive 
of a high mortality rate. Anaplastic cancers invade adjacent structures and metastasize 
extensively to cervical lymph nodes and distant organs such as lung and bone.  
5.5.2.2. Diagnostic molecular markers in papillary and anaplastic thyroid carcinomas 
 
Tumour markers can be used to screen a healthy population or a high-risk population 
for the presence of cancer, to make a diagnosis of cancer, to determine the prognosis of the 
patient, or to monitor the course in a patient during follow-up. Several studies have 
investigated tumour markers in PTC, and some studies have reported them as promising for 
predicting prognosis, but no warranted markers for PTC have been established. At present 
thyroglobulin is the only tumour marker of PTC being routinely used to determine the 
effectiveness of thyroid cancer treatment and to screen for recurrence.  
To identify prognostic genetic markers (polymorphic microsatellites, SNPs, changes in 
gene expression or in gene copy number) which are associated with poor prognosis has been 
in the focus of several studies. Recently Siironen and co-workers analyzed the expression of 
COX-2, MMP-2, VEGF-C, Bcl-2, Ki-67 and p21 by immunohistochemistry in 72 samples (36 
with aggressive and 36 with benign form) (88), and Gerdes et al. have demonstrated that Ki-
67 expression associated with tumour grade and number of mitoses (89). None of these 
proteins showed superior classification over TNM. Therefore more studies and more robust 
techniques are needed to predict the progression of the agressive form.  
The frequency of LOH on each chromosome arm was determined in 24 patients 
samples with poor prognosis and in 45 survived cases by Kitamura et al. (90). They found 
significantly higher frequencies of LOH on 1q, 4p, 7q, 9p, 9q and 16q loci among the poor 
outcome patient population, however finer resolution of possible genetic markers were not 
identified. Loss of heterozigocity at the TPO gene locus has been implicated as a cause of the 
organification defect typical of benign and malignant thyroid tumours (91, 92). Amplification 
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of the phosphatidylinositol 3-kinase (PIK3CA) gene is relatively common and may be a novel 
mechanism in activating the PI3K/Akt pathway in some thyroid tumours (93). 
All three RAS genes (NRAS, KRAS, HRAS) can be mutated in PTC (94), and Ras 
mutations and RET/PTC rearrangements are associated with aggressive tumour phenotypes 
(95-99). The RET gene is found to be rearranged in approxymately 40% of PTCs (100-103). 
Some authors have desribed BRAF mutation in thyroid tumours (104-110). The majority of 
ATCs with papillary components are derived from BRAF-mutated PTC, and this indirectly 
supports the notion that PTC with RET/PTC rearrangements do not progress to ATC. 
RET/PTC rearrangements activate multiple downstream signaling pathways, including the 
RAS-RAF-MAPKK-MAPK pathway, do not progress to ATC; whereas PTC with BRAF 
mutation which activates fewer signaling pathways than RET/PTC, can progress to ATC 
(111). Expression of RET/PTC1 and RET/PTC3 oncogenes was identified in both benign and 
malignant studies (112), while RET protein expression has been evaluated in PTCs (113). 
TRK gene chromosomal rearrangements are found in 10% of PTCs (114, 115). The tumour 
suppressor gene, p53, is rarely mutated in well differentiated PTC and FTC, but is mutated at 
a moderate rate in poorly differentiated PTC and at a very high rate in ATC (116-119) but not 
in its PTC precursor. This indicates that development of ATC is due to further p53 mutation 
in the setting of an oncogenic mutation such as BRAF (111).  
Since no ideal examination method or protocol has been developed by which the 
circumstances of development and outcome of PTC were able to be defined exactly – which 
is necessary for the use of aimed therapeutic medicine –, we performed CGH-array analysis of 
a primary- and terminal-stage APTC, comparing it to GPTC obtained from paraffin-
embedded tissue to identify gene copy number alteration as markers which might predict the 
outcome of an individual patient better than done by TNM classification alone.  
5.5.3. The effect of αIIbβ3 integrin on increased angiogenesis and tumour growth in 
melanoma 
 
Progression of human melanoma is a highly efficient process compared to other 
malignant tumours since a few millimeters thick tumour (a very small primary in the case of 
other malignancies) can colonize regional lymph nodes or visceral organs. It is therefore 
extremely important to understand the molecular mechanisms behind this highly aggressive 
behavior. Previous studies indicated that the autocrine growth regulation of melanoma 
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acquired at the switch from a less invasive radial to a more invasive vertical growth phase 
involves bFGF expression (120, 121).  
Some studies have demonstrated that increased expression of αvβ3 integrin in 
activated endothelial cells promotes angiogenesis and its blockade promotes endothelial cell 
apoptosis (122-124). 
Integrins are ubiquitous transmembrane α/β heterodimers that mediate diverse 
processes requiring cell-matrix and cell-cell interactions such as tissue migration during 
embryogenesis, cellular adhesion, cancer metastases, and lymphocyte helper and killer cell 
functions (125). Platelets express 3 members of the ß1 subfamily (αIIβ1, αvβ1, and αv1β1) that 
support platelet adhesion to the ECM proteins collagen, fibronectin, and laminin, respectively 
(126-129), and both members of the β3 subfamily (αvβ3 and αIIbβ3). Although αvβ3 
mediates platelet adhesion to osteopontin and vitronectin in vitro (130, 131), it is uncertain 
whether it plays a role in platelet function in vivo. By contrast, αIIbβ3, a receptor for 
fibrinogen, vWF, fibronectin, and vitronectin, is absolutely required for platelet aggregation. 
Because αIIbβ3 plays an indispensable role in hemostasis and thrombosis, it is among the 
most intensively studied integrins. Expression of αIIbβ3 is restricted to cells of the 
megakaryocyte lineage. In megakaryocytes, αIIbβ3 is assembled from αIIb and β3 precursors 
in the endoplasmic reticulum (132) and undergoes posttranslational processing in the Golgi 
complex, where αIIb is cleaved into heavy and light chains (133). αIIbβ3 can support the 
adhesion of unstimulated platelets to many of its ligands when they are immobilized in vitro, 
platelet stimulation is required to enable αIIbβ3 to mediate platelet aggregation by binding 
soluble fibrinogen and vWF (134).  
Different integrins may crosstalk with each other, thereby regulating each other's 
function. For instance αIIbβ3-mediated signaling in CHO cells influences β1 integrin-
mediated cell adhesion and spreading (135). This phenomenon of transdominant signaling 
appears to involve MAPK activity. Activation of myosin light chain and lipid kinases by the 
MAP kinase pathway and the Rho family of GTPase is modulated by integrin activity, which 
provides a link between the extracellular matrix and effect on cell shape and motility that 
ultimately influences tumour cell invasion. Although the relationship between integrin 
receptors and metastasis is variable, an increase in β3 integrin expression directly correlates 
with progression of melanoma (136, 137).  
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Studies have demonstrated that the megakaryocyte specific αIIbβ3 integrin is 
expressed in cultured cell lines derived from solid tumours and this integrin is expressed both 
in vitro and in vivo (138-144). Compared to expression of αvβ3, expression of αIIbβ3 is much 
lower and decreases with cell culture in vitro (145). 
The αIIbβ3 integrin (GpIIbIIIa) is the predominant adhesion receptor of platelets and 
the expression of the integrin αIIb chain is megakariocyte-specific. It is involved primarily in 
platelet activation, since it is expressed in a low affinity state and binds fibrinogen only upon 
activation. The illegitimate expression of αIIbβ3 integrin in human melanoma has been 
described (146, 147), involved in the same phases of tumour progression as αvβ3. 
The transduction of αIIbβ3 into αvβ3-expressing human melanoma cells did not affect 
the in vitro growth, but promoted the in vivo growth of tumour cells due to decreased 
apoptosis (147). We have postulated that one possible factor behind the increased in vivo 
growth is vascularization. Therefore, we have analysed the gene expression changes of 
αIIbβ3-transfected human melanoma clones with special attention to their angiogenic 
phenotype. 
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VI. MATERIALS AND METHODS 
 
6.1. Tissue specimen and genomic DNA isolation 
6.1.1. Samples for the improved DOP-PCR technique 
 
Melanoma tissues were obtained from the Department of Dermatology, University of 
Debrecen, Hungary. Primary melanoma (location: face) and metastatic tumour (location: 
lymph node) were removed from the same patient at the same time. The relative amount of 
tumour cells was a minimum of 70% in all lesions as confirmed after hematoxylin and eosin 
staining by light microscopy. High–molecular-weight DNA was extracted according to a 
standard procedure starting from 50 mg of tissue (46, 148). Chromosomal CGH and image 
analyses were performed as described earlier in details elsewhere (148). 
Epidermoid, bronchioloalveolar lung carcinoma, 2 renal cell carcinoma, and 2 
colorectal carcinoma specimens were obtained from the Institute of Pathology, Szeged 
University. Conn and Cushing adenoma samples were obtained from Semmelweis University, 
Budapest. DNA was purified by using the DNA purification kit from Macherey-Nagel 
(Düren, Germany) according to the manufacturer’s instructions. 
6.1.2. Samples for the Merkel cell carcinoma study 
 
Between 1970 and 2003, 4418 patients with malignant orofacial tumours were treated 
in Department of Dentistry and Oral Surgery at University of Szeged. One of these patients 
suffered from MCC. A 79-year-old Caucasian woman presented with a tumour in her upper 
lip. She was an outdoor worker and never smoked. She was disturbed only about the 
aesthetics. The physical examination revealed a 2–3-cm firm, compact mass in the skin of the 
upper lip on the left side. It was sharply separated from its surroundings and had a 
teleangiectatic surface (Figure 2).  
 
 
                 Figure 2. MCC developed in the skin of the upper lip 
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The tumour was classified as stage T2. No regional lymph-node metastasis was 
detected. Surgical resection of the tumour and removal of the regional lymph nodes were 
suggested, but she refused it. As an alternate therapy, a biopsy was taken, and cryotherapy 
was applied according to the standard protocol. The histological and immunohistochemical 
characterization was done in the Department of Pathology at Medical University of Szeged. 
Light microscopy revealed that the tumour was confined to the dermis and was sharply 
separated from the epidermis. The tumour cells were arranged in nests and cords. 
Cytologically, the tumour cells were monomorphic, the nuclei were round and the chromatin 
pattern was finely granular and “dusty”. The nucleoli were small; often two or even three 
were detected. The cytoplasm was scanty. The mitotic rate was high (six to ten figures/ high-
power field). The Grimelius staining was negative. The results of immunostainings are shown 
in Table 1. The histological and immunohistochemical features pointed to MCC of the lip. 
Following the histological diagnosis, distant metastases in the lungs and bones were searched 
for, with negative results.  
 
Immunohistochemical 
markers 
Lip 
tumour 
Tonsillar 
tumour 
AE1/AE3 +++ +++ 
Cytokeratin 20 20 
Paranuclear dots +++ ++ 
Chromogranin ++ + 
Synaptophysin - - 
TTF - - 
HMB-45 - - 
CEA - - 
Lymphoid markers - - 
 
Table 1. Immunohistochemical findings 
 
In the 7-year follow-up, the patient was in a tumour-free condition. After 7 years, she 
was admitted to the County Hospital in Kecskemét with a left palatine tonsillar tumour. This 
tumour was resected in part, and the regional lymph nodes were removed. Histologically, the 
tumour displayed features of anaplastic carcinoma.  
The morphological appearance of the tumour resembled that of the MCC of the lip. A 
further excision was performed 3 months later. The morphological and immunohistochemical 
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features of the tonsillar tumour were essentially the same as observed 3 months earlier. The 
patient died at home on the 20th postoperative day. Autopsy was not performed. 
Paraffin-embedded tumour tissues and unaffected lymph nodes (200-500 mg) were 
deparaffinated in hexane, and washed with ethanol. DNA was purified by using the DNA 
purification kit from Macherey-Nagel (Düren, Germany) according to the manufacturer’s 
instructions. 
6.1.3. Papillary thyroid carcinoma samples 
 
PTC was detected in a 63-year-old male patient; carcinoma was confirmed by 
cytology and other investigations. Total thyreoidectomia and lege artis ablatio with 131I were 
performed; unfortunately, after eight months, local recidiva developed. A necessary 
reoperation was carried out by the University of Debrecen; despite the operation, however, the 
tumour spread into the pharynx, main vessels, and pleura, and the patient died three months 
later. On the basis of histology results, anaplastic dedifferentiation was detected. The primary- 
and terminal-stage APTC samples obtained from the above patient were analysed compared 
GPTC and normal thyroid tissue in further QRT-PCR studies. The disease course of the 
female patient with GPTC providing control samples in some experiments was followed 
strictly for five years after operation and radioiodine ablation.  
Other PTC samples included in further studies and normal thyroid tissues were 
obtained from the Department of Pathology University of Debrecen, Jósa András County 
Hospital in Nyíregyháza, Erzsébet Hospital in Hódmezővásárhely, County Hospital in 
Kecskemét and Pándy K County Hospital in Gyula. Two disease course groups of our cases 
were created: the GPTC (group A): patients with no recurrance and no metastases, all of them 
are disease free up to now. There were 10 patients of GPTC, all of them were female. Mean 
age was 42.1 years (range: 27-52 years) at the time of the operation. Median follow-up was 
4.8 years (range: 3-7). The second group was the I/APTC (group B) (14 intermediate – i.e. 
metastasis developed only in cervical lymph nodes, by which the survival rate is much higher 
than by APTC, and 10 malignant APTCs. This group B consisted of 24 patients (17 female, 7 
male). Patients with cervical (12) and regional (mediastinal) lymph node (2), pulmonary (6), 
bone (3) metastases, trachea infiltration (1), and local invasion (4) in different combination. 
The mean age of patients of the I/APTC group was 48.3 years (range: 13-76 years) at the time 
of the operation. Median follow-up was 6.8 years (range: 9 months-17 years). Eight of them 
died, and the mean survival time following operation was 5.6 years (range: 9 months-22 
years). 
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Paraffin-embedded tissues (500 mg) were deparaffinated in hexane and washed with 
ethanol. DNA was purified by the DNA purification kit from Macherey-Nagel (Düren, 
Germany), according to the manufacturer’s instructions.  
6.2. DNA and RNA quantity measurement 
The quantity of genomic DNA and total RNA was assessed spectrophotometrically by 
NanoDrop (Rockland, DE, USA). Genomic DNA was used for microarray analysis and for 
QRT-PCR. 
The WM983B cell line that does not express αIIbβ3 on the cell surface was a kindly 
provided to us by M. Herlyn (The Wistar Institute, Philadelphia, PA). Mock transfected 
WM983B cells (3.1P) and αIIb and β3 transfected WM983B cells (19L and 19H) have been 
described in a study by Trikha M. et al. (147). 19H transfected cell line was subcloned by 
limited dilution to obtain 7D7 and 8F3 subclones. The parental cell line was grown in RPMI-
1640 medium supplemented with 5% FBS and antibiotics (Sigma Chemical Co., St. Louis, 
MO) in a 5% CO2 humidified atmosphere at 37°C. Transfected cells were maintained in 
medium containing G418 (Gibco BRL, Gaithersburg, MD).  
 RNA isolation from 5x106 cells was carried out with the RNA isolation kit of 
Macherey-Nagel (Düren, Germany) according the manufacturer’s instruction. The RNA 
concentration was assessed spectrophotometrically by NanoDrop (Rockland, DE, USA) and 
the quality was checked by electrophoresis. RNA was stored at -80°C in the presence 30 U of 
Prime RNAse inhibitor (Fermentas, Vilnius, Lithuania). Total RNA was used for RT, 
microarray analysis and for QRT-PCR. 
6.3. Quantitative real-time PCR 
6.3.1. Preparation of DOP-PCR amplified and overamplified genomic DNA 
 
Genomic DNA (20 ng from native tissue and 100 ng from paraffin embedded tissue) 
was amplified with a modified version of the DOP-PCR protocol by using a RotorGene 3000 
QRT-PCR instrument, (Corbett Research, Mortlake, Australia), to follow the amplification. 
The DNA concentration was assessed spectrophotometrically by NanoDrop (Rockland, DE, 
USA). Reactions were performed in a total volume of 100 µl. The cycling parameters were as 
follows: heat start at 95 oC (15 min); 8 cycles denaturation at 94 oC (50 s); annealing for 2 
min from 45 oC to 72 oC with a 0.2 oC/s ramp; and, extension at 72 oC (90 s). After 8 cycles, 
the reaction mix was divided into two 50 µl aliquots and SybrGreen was added to both (1x 
final concentration, Molecular Probes, Eugene, USA). The following cycling protocol was 
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performed in a real-time PCR instrument: denaturation at 95 oC (40 s); annealing at 58 oC 
(60s); and, extension at 72 oC for 80 s. To avoid over-amplification of the products, cycling 
was terminated just before the reaction reached the plateau (i.e., at 13-15 cycles); in contrast, 
the over-amplified genomic DNA was obtained from PCR with 21 cycles. 
The PCR products were purified with PCR-purification columns (Bioneer, Daejeon, 
Korea). In the reactions, UN primer (5’-CCGACTCGAGNNNNNNATGTGG-3') was used in 
1 µM concentration (36). The reactions were performed with ExTaq DNA polymerase in 1X 
buffer (Takara, Tokyo, Japan) in the case of MCC, while the reactions were performed with 
1x ABsolute QPCR Mixes (ABgene, Surrey, UK) in case of confirmation of improved DOP-
PCR and PTC. 
6.3.2. Determination of the differences in relative copy numbers of the genome 
 
QRT-PCR was carried out in a final volume of 20 µl with 20 or 100 ng (DNA 
obtained from native or paraffin-embedded tissues accordingly) non-amplified or amplified 
genomic DNA in a RotorGene 3000 instrument (Corbett Research, Mortlake, Australia). The 
reactions were performed with 5 pmol/each forward and reverse gene-specific primers in 1x 
ABsolute QPCR Mix (ABgene, Surrey, UK) with SybrGreen (1 µM final concentration, 
Molecular Probes, Eugene, USA) with the following protocol: heat start for 15 min at 95 °C, 
45 cycles of 25 s denaturation at 95 °C, 25 s annealing at 59 oC and 25 s extension at 72 oC. 
Fluorescent signals were collected after each extension step at 72 oC. Curves were analysed 
with the RotorGene software, using dynamic tube and slope correction methods, while 
ignoring data from cycles close to baseline. Primers were designed by using the 
PrimerExpress software (Applied Biosystems, Foster City, CA, USA). Relative ratios were 
normalized to the Ct values of the metallopeptidase 1 gene as an internal control - in the case 
of primary and metastatic melanoma samples confirming improved DOP-PCR technique -, 
and calculated with the Pfaffl method (149). The sequences of PCR primers used in this study 
were deposited to http://160.114.60.33/Data1/. All the PCRs were performed three times in 
separate runs. 
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6.3.3. Confirmation of CGH–microarray results 
 
The confirmatory QRT-PCR was performed on a RotorGene 3000 instrument with 
previously described protocol (detailed in the 6.3.2. subsection of this thesis). Relative ratios 
were normalized to the Ct values obtained with the dihydrofolate reductase gene probe in the 
case of MCC and alpha1-fetoprotein transcript factor and H3 histone (family 3A) in the case 
of PTCs and calculated with the Pfaffl method (149). PCR primers used are listed in Table 2. 
All the PCRs were performed 4 times in separate runs. 
 
Table 2. Sequences of the oligonucleotides (5’-3’) used in the case of MCC, tonsillar tumour and thyroid 
carcinomas 
 
Gene (Accession No.) Chrom. location Forward primer Reverse primer
Product 
size (bp)
Steroid 5-alpha-reductase 2 (M74047 ) 2p23 CAGAAGCCCCAAGCAACTTT CCTTCTTGAACAGGTCCTGAGAA 69
Hepatocyte nuclear factor-3 alpha  (U39840) 14q12-q13 CTCAAGAGTTGCTTGACCGAAA GGGCCATCTGTGGGTAGAGA 67
Zinc finger protein (AF020591) 19q13.43 GAAATTTCCCTGCCAGACCTT CATGAAGCCCCACTCTGAGAGT 73
Androgen receptor (dihydro-testosterone 
receptor) (M23263)
Xq12 CGGAAATGATGGCAGAGATCA TGGGCTTGACTTTCCCAGAA 66
C8FW phosphoprotein (AJ000480) 8q24.13 GGACGATACCCCTTCCATGA GTCCACGCCGAATTTTGG 61
Cardiac myosin binding protein-C (U91629) 11p11.2 GCCTAAATCCGAGCATCTGTTT TGCACTCTCAGGGAATTTGAGA 70
EST (N22765) 15q14 CCTGATTCCAGAAAAGCAAGTGT CACTGAGATTACCGGGCATGA 76
Cytochrome P450, subfamily XIA (M14565) 15q22 CTGGTGCAAGTGGCCATCTA AATTTTCCGGGTCGAAGAAGA 64
EST sim. to phosphatidylcholin transfer 
protein (AA933627) 17q23
CACAAGGCTATGCACAAAGCA GGAAACTGAGGCGTCAAGATG 68
Dihydrofolate reductase (BC070280) 5q14 CTGTCATGGTTGGTTCGCTAAA TGCCGATGCCCATGTTC 60
Tre-2 (X63547) 17p13 TCCAGCGGCCCATTTG AGGGCGTGGAAAAACGAGAT 57
Thymosin beta 10 (BC016731.1) 5q31.3 AATCGCCAGCTTCGATAAGG GGTCGGCAGGGTGTTCTTC 67
Image EST (R78712) 15q25 GGTCATGTGTCGTGAAATATTATTGTT CCCGGCTGAGATTTTACATTTT 76
Euk. Initiation factor 4EBP3 (AF038869) 5q31.3 ACCTGGCATGTGGAGTTACAGA TGGATGCCCCAGGAAGAG 70
KIAA0549 (AB011121) 2q33 TTGCCTGGACAGTTACAGTTTCC AATCGGACAATTTAACGTTGTACTACTC 87
Fibroblast growth factor 7 (M60828) 15q15-q21.1 GAACAAAATTTCTAATGCTGCTCAAG CATCAATCACTGTTGCTATCTTATATACAAG 93
Alpha 1-fetoprotein transcription factor 
(U93553) 1q32.1
GGTGTCCAGGAACAAGTCAATG CTCTGTCTGCTGCGGGTAGTT 71
H3 histone, family 3A (BC081561) 1q41 TGCAGGAGGCAAGTGAGGC CTGGATGTCTTTTGGCATAATTGTT 101
Merkel cell carcinoma and tonsillar tumour
Thyroid carcinomas
 
 
6.4. Preparation of microarray probes 
6.4.1. Preparation of genomic DNA probes for array hybridization of MCC 
 
100 ng purified DNA was labelled with another round of PCR in the presence of Cy3-
dUCTP (0.05 mM) in a total volume of 50 µl with the same parameters for 20 cycles as in the 
second PCR. In all these reactions, UN primer (5’-CCGACTCGAGNNNNNNATGTGG-3') 
was used in 1 µM concentration. The reactions were performed with ExTaq DNA polymerase 
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in 1X buffer (Takara, Tokyo, Japan). The labelled PCR products were purified with the PCR 
purification kit (Bioneer, Daejeon, Korea). The eluted DNA was dried in a Speed-Vacuum. 
6.4.2. Preparation of genomic DNA probes for array hybridization of PTC samples 
 
 Three microgramms of amplified genomic DNA was fragmented with AluI restriction 
endonuclease, then it was tailed with dTTP resulting an oligo dT sequence at the 3’-ends of 
the products. Afterwards, a special capture oligo was ligated to the tailed DNA according to 
Genisphere DNA labeling system (Genisphere, Hatfield, PA). 
6.4.3. Generation of microarray probes for human melanoma cells 
 
Four microgramms of total RNA was reverse transcribed using poly-dT primed 
Genisphere Expression Array 350 Detection system (Genisphrere, Hatfield, PA) in 20 µl total 
volume using 20 Unit RNAsin (Fermentas), 1x first strand buffer and 200 Units of RNAse H 
(-) point mutant M-MLV reverse transcriptase (Fermentas). All the other probe preparation 
steps were done according the manufacturer’s instruction (Genisphere).  
6.5. Microarray construction and array hybridization  
6.5.1. Human cDNA microarray construction 
 
Construction and use of microarrays were performed as previously described (43, 
150). Briefly, 3200 cDNA inserts from human cDNA libraries (melanoma, lymphocytes, 
heart and mixed tissue libraries) were amplified and purified with MultiScreen-PCR plate 
(Millipore), resuspended in 50% dimethylsulfoxide/water and arrayed on FMB cDNA slides 
(Full Moon BioSystems, Sunnyvale, CA) by using a MicroGrid Total Array System 
(BioRobotics, Cambridge, UK) spotter with 16 pins in a 4 x 4 format. DNA elements were 
deposited in duplicate. The diameter of each spot was approximately 200 µm. After printing, 
DNA was UV crosslinked to the slides (Stratagene, Stratalinker, 700 mJ).  
6.5.2. CGH-array hybridization in the case of MCC 
 
The labelled DNA was reconstituted in ChipHybe hybridization buffer (Ventana 
Discovery, Tuchon, USA) containing 20 µg human Cot DNA and 5 µg salmon sperm DNA 
(Invitrogen). Hybridization was performed on human cDNA microarrays having 3200 gene-
specific samples in duplicate in 200 µl by using the Ventana hybridization station (Ventana) 
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at 42 oC for 8 h. (151, 152). After hybridization, the slides were washed twice in 0.2X SSC at 
RT for 10 min, and then dried. 
6.5.3. Array hybridization in the case of thyroid tumours and human melanoma cells 
cDNA was hybridized onto human cDNA microarrays in a Ventana hybridization 
station (Ventana Discovery, Tuchon, State) by using the ‘‘antibody’’ protocol. First 
hybridization was performed at 42°C for 6 hr in ‘‘Chiphybe’’ hybridization buffer (Ventana) 
and then 2.5 µl of Cy5 capture reagents (thyroid tumours), while in other experiments 2.5 µl 
of each Cy5 and Cy3 capture reagents (MCC investigation) were added to the slides in 200 µl 
Chiphybe hybridization buffer (Ventana) and incubated at 42°C for 2 hr. After hybridization, 
the slides were washed in 0.2 x SSC twice at RT for 10 min and then dried and scanned. In 
the case of thyroid tumours the probe and control samples were hybridized onto separate 
slides, while they were hybridized onto the same cDNA microarrays in the case of MCC 
analysis. 
6.6. Array data analysis 
The presented data were calculated from the results of 4 data points obtained from two 
separate labelling and hybridization protocols. The slides were scanned with confocal laser 
scanner (ScanArray Lite, GSI Lumonics, Billerica, MA, USA). Image files were analysed 
with the GenePix Pro 3.0.5. program (Axon, Union City, CA, USA). The background 
corrected intensity data was filtered for flagged spots and weak signal. After automatic 
flagging, manual flagging was performed to exclude spots having irregularities, such as 
scratches and dust particles. Technical replicates on the same array were averaged. Data were 
excluded in cases where technical replicates were significantly different. Data obtained by the 
median of feature pixels were accepted only if 30 % of pixels were above 2 x standard 
deviation of the background intensity. Normalization was performed using the print-tip 
LOWESS method (153). Next we used the one-sample t-test in order to determine the genes 
to be regarded as changed in copy number. Logarithm was taken from each ratio to fulfill the 
t-test’s requirement for a normal distribution. Genes for which the mean of log-ratios across 
the biological replicates was equal to zero at a significance level α=0.05 are considered to 
have an unchanged copy number. On the other hand, genes having a p-value smaller than α 
and the average-fold change (over- or under-representation) of the four data points were at 
least 2.0-fold were considered as changes in DNA copy number or gene expression.  
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VII. RESULTS AND DISCUSSION 
 
7.1. Improved DOP-PCR-based representational whole genome amplification using 
QRT-PCR 
The amount of genomic DNA available for genetic studies can often be limiting. DOP-
PCR is an appropriate method for overcoming these limitations by efficiently performing 
whole genome amplification. We have presented a more reliable PCR-based genome 
amplification procedure, developed as an alternative sample amplification method which 
follows the amplification status by QRT-PCR. With real-time detection of the products, DNA 
over-amplification could be diminished. After initial amplification of the genome, SybrGreen 
dye is added to the reaction mix and a second amplification step is applied in a QRT-PCR 
instrument. The cycling is performed until the reaction reaches the plateau (Figure 3). 
 
                 
Figure 3. Whole genomic DNA amplification using
QRT-PCR. Diagram of the primary, metastatic
melanoma tissue and normal peripheric lymphocyte. The
amplification halted at the 13th cycle, the amplified
genomic DNA (2) was generated in the exponential
phase of the reaction; the over-amplified genomic DNA
(1) was isolated from reactions halted at the 21st cycle;
Number 3 denotes for the non-template control.  
 
To compare the original gene copy number of different templates generated by using the 
traditional DOP-PCR and with the protocol using QRT-PCR, 44 genes were selected for 
confirmation by using QRT-PCR analysis in case of two melanoma samples. Genes were 
selected on the basis of metaphase CGH data performed earlier (154). The QRT-PCR was 
performed on DNA samples obtained from primary and metastatic melanoma tissues resected 
from the same patient along with normal DNA prepared from peripheral blood of a healthy 
individual  as  a  control.  Altogether 88  relative  copy  numbers  were  determined  on  three  
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Table 3. Comparison of copy number changes of several gene loci obtained from primary and metastatic tumour 
samples relative to normal tissue by using non-amplified and different amplified genomic DNA as templates. 
Light gray: altered relative copy number at certain chromosomal regions in the amplified sample compared to 
control, non-amplified sample. 
 Chrom. Location Gene product (Acession No.)
Loss of chromosomal regions                                                     
primary 0,43 (0,21) 0,27 (0,28) 2,20 (0,39)
metastatic 0,44 (0,12) 0,27 (0,03) 0,31 (0,13)
primary 0,50 (0,07) 0,39 (0,03) 0,31 (0,05)
metastatic 0,48 (0,01) 0,33 (0,03) 0,48 (0,07)
primary 0,50 (0,08) 0,50 (0,06) 1,77 (0,10)
metastatic 0,51 (0,02) 0,44 (0,12) 1,44 (0,00)
2p23 Anaplastic lymphoma kinase (Ki-1) (NM_004304) metastatic 0,57 (0,03) 0,56 (0,28) 0,28 (0,13) deletion
10q26.13-q26.3 dedicator of cytokinesis 1 (NM_001380) primary 0,58 (0,34) 0,52 (0,06) 0,74 (0,05) deletion
2p23 Anaplastic lymphoma kinase (Ki-1) (NM_004304) primary 1,11 (0,07) 0,68 (0,03) 2,77 (0,95) no change
primary 1,16 (0,09) 0,50 (0,17) 0,74 (0,16) no change
metastatic 0,60 (0,01) 0,40 (0,09) 0,54 (0,06) deletion
primary 0,87 (0,04) 0,52 (0,03) 1,47 (0,05) no change
metastatic 0,64 (0,06) 0,59  (0,02) 1,25 (0,07) deletion
primary 0,83 (0,02) 0,53 (0,22) 1,63 (0,93)
metastatic 0,85 (0,16) 0,58 (0,25) 0,69 (0,29)
primary 0,89 (0,06) 0,92 (0,03) 0,90 (0,12)
metastatic 0,82 (0,31) 1,13 (0,08) 0,72 (0,06)
primary 0,76 (0,04) 0,86 (0,38) 0,90 (0,12)
metastatic 0,90 (0,07) 0,82 (0,32) 0,75 (0,10)
primary 1,07 (0,11) 0,69 (0,14) 0,48 (0,12)
metastatic 1,33 (0,18) 0,90 (0,36) 0,49 (0,14)
primary 1,01 (0,10) 0,49 (0,16) 0,66 (0,25)
metastatic 1,17 (0,32) 0,59 (0,65) 0,65 (0,15)
primary 0,86 (0,01) 1,10 (0,02) 1,27 (0,23)
metastatic 0,77 (0,07) 1,03 (0,2) 0,57 (0,05)
primary 1,03 (0,11) 0,99 (0,16) 0,99 (0,31)
metastatic 1,14 (0,17) 1,11 (0,06) 1,24 (1,03)
primary 1,20 (0,19) 0,97 (0,16) 0,48 (0,06)
metastatic 1,18 (0,20) 0,91 (0,05) 0,35 (0,30)
primary 1,05 (0,23) 0,82 (0,07) 0,87 (0,06)
metastatic 1,31 (0,04) 1,10 (0,03) 0,41 (0,06)
primary 1,18 (0,12) 0,51 (0,02) 1,01 (0,55)
metastatic 1,03 (0,10) 0,56 (0,01) 0,44 (0,06)
primary 1,19 (0,06) 0,80 (0,03) 1,22 (0,15)
metastatic 1,31 (0,05) 1,11 (0,06) 0,93 (0,12)
primary 1,24 (0,09) 0,82 (0,01) 1,34 (0,03)
metastatic 1,43 (0,04) 1,12 (0,16) 0,99 (0,31)
primary 1,15 (0,12) 0,71 (0,03) 1,22 (0,10)
metastatic 1,14 (0,04) 0,89 (0,06) 1,17 (0,10)
primary 0,90 (0,14) 0,35 (0,27) 0,62 (0,25)
metastatic 0,98 (0,19) 0,60 (0,48) 0,80 (0,04)
primary 1,23 (0,15) 1,10 (0,11) 1,17 (0,24)
metastatic 1,30 (0,07) 1,05 (0,11) 1,14 (0,10)
primary 1,03 (0,13) 0,84 (0,20) 0,67 (0,13)
metastatic 1,14 (0,13) 0,97 (0,14) 0,63 (0,03)
primary 1,35 (0,13) 1,31 (0,14) 2,27 (2,07)
metastatic 1,22 (0,10) 1,42 (0,05) 2,16 (1,91)
primary 0,89 (0,12) 0,68 (0,11) 0,91 (0,02)
metastatic 0,82 (0,10) 1,02 (0,05) 0,48 (0,06)
primary 1,28 (0,04) 2,00 (0,17) 0,82 (0,11)
metastatic 1,34 (0,12) 1,73 (0,03) 0,78 (0,15)
primary 1,24 (0,06) 1,12 (0,10) 0,99 (0,41)
metastatic 1,11 (0,04) 0,93 (0,18) 0,45 (0,06)
primary 1,05 (0,18) 0,67 (0,01) 0,50 (0,06)
metastatic 1,03 (0,11) 0,83 (0,07) 0,51 (0,02)
primary 1,10 (0,37) 1,37 (0,09) 1,41 (0,11)
metastatic 1,11 (0,22) 1,31 (0,05) 0,75 (0,24)
primary 1,46 (0,12) 0,68 (0,10) 0,50 (0,01)
metastatic 1,41 (0,04) 0,87 (0,08) 0,55 (0,08)
primary 1,22 (0,09) 0,76 (0,03) 0,68 (0,25)
metastatic 1,22 (0,17) 0,91 (0,03) 0,65 (0,05)
primary 0,96 (0,00) 0,60 (0,08) 0,82 (0,11)
metastatic 0,91 (0,25) 1,00 (0,00) 1,01 (0,05)
primary 1,25 (0,11) 0,49 ( 0,02) 1,11 (0,34)
metastatic 1,40 (0,12) 0,50 (0,07) 1,31 (0,03)
primary 1,20 (0,06) 1,31 (0,21) 0,80 (0,11) no change
metastatic 1,13 (0,07) 0,97 (0,24) 2,89 (0,12) amplification
7p15 CG1 (U97198) primary 1,14 (0,13) 0,79 (0,05) 1,71 (0,30) no change
4p14 Amyloid beta precursor prot. binding B2 (BC027946) primary 1,03 (0,11) 1,49 (0,07) 0,55 (0,11) amplification
3q26.31 N-acetylated a-linked acidic dipeptidase 2 (AF040990) primary 1,34 (0,09) 1,05 (0,17) 1,65 (0,40) no change
7p15 CG1 (U97198) metastatic 1,52 (0,08) 0,92 (0,00) 2,63 (0,78) no change
4p14 Amyloid beta precursor protein-binding B2 (BC027946) metastatic 1,50 (0,13) 1,51 (0,08) 0,81 (0,03) amplification
10q26.13-q26.3 dedicator of cytokinesis 1 (NM_001380) metastatic 1,52 (0,07) 0,43 (0,00) 0,86 (0,24) deletion
3q26.31 N-acetylated a-linked acidic dipeptidase 2 (AF040990) metastatic 1,56 (0,06) 1,67 (0,18) 1,09 (0,15) amplification
primary 1,80 (0,21) 0,80 (0,04) 1,14 (0,19)
metastatic 2,08 (0,20) 0,86 (0,09) 1,48 (0,02)
primary 1,71 (0,05) 1,60 (0,32) 1,23 (0,16)
metastatic 1,58 (0,05) 1,69 (0,31) 2,33 (0,28)
primary 1,56 (0,15) 1,91 (0,03) 1,74 (0,03)
metastatic 1,54 (0,12) 2,48 (0,65) 0,71 (0,38)
primary 1,61 (0,21) 1,64 (0,17) 1,09 (0,10)
metastatic 1,62 (0,21) 1,72 (0,62) 0,85 (0,07)
primary 3,12 (1,10) 1,61 (0,05) 1,69 (0,22)
metastatic 2,02 (0,40) 1,49 (0,12) 0,95 (0,20)
primary 1,69 (0,06) 1,74 (0,04) 4,23 (1,98)
metastatic 2,08 (0,22) 2,14 (0,06) 0,62 (0,02)
primary 1,75 (0,03) 1,65 (0,02) 4,77 (2,47)
metastatic 2,64 (1,08) 2,46 (0,67) 1,73 (0,56)
Metaphase CGHNon-amplified      SD
DOP-PCR+ QRT-PCR 
SD
DOP-PCR          
SD
Roundabout, axon guidance receptor (BC057243) 3p12
Type of 
melanoma
2q31.1 Recepin (U03644)
15q25 Image EST R78712 (R78712)
2q32-33 amyotrophic lateral sclerosis 2 (AB011121)
14q31
no change
20q13.12 Image EST 364782 (AA034412) no change
5q21.3 F-box, leucine-rich repeat protein 17 (BC063316) amplification
6p12.2 Polycystic kidney, hepatic disease 1 (AY074797) amplification
17q11.2-q12 Amiloride-sensitive cation channel 1(BC075043) amplification
17q23
no change
no change
no change
no change
no change
no change
no change
no change
no change
no change
no change
no change
no change
no change
deletion
deletion
deletion
no change
deletion
no change
no change
no change
no change
no change
Galactocerebrosidase (D86181)
19q13.3-4 Electron-transfer-flavoprotein b (X71129)
1p33-34.1 Mitotic centromere-associated kinesin (U63743)
15q23-25 Neuromedin B precursor (M21551)
15q15-q21.1 Fibroblast growth factor 7 (M60828)
7q31 Met proto-oncogene (J02958)
RNA pol. transcriptional regulation mediator (U78082)
16p12-13.2 Epithelial amiloride-sensitive Na channel g (X87160)
Ribonuclease k6 precursor gene (U64998)
14q22.3-q23.1 Retinoblastoma-binding protein 1 (S66427)
14q23-24.1
5q11.2 Integrin, alpha 2 (M28249)
12q14.3
17p13
17p13.1
11p15.5
10p12.1
2p25.3
Chaperonin cont. t-complex polypept. 1b (AF026293)
Human clone 23665 (U90913)
15S-lipoxygenase (U78294)
 p27-BWR1B (AF037066)
G protein-coupled receptor 158 (AY528411)
Myelin transcription factor 1-like (BC071612)
Genes with no change
9p23-p24.3 Prot. tyrosine phosphatase, receptor D (NM_130392)
Breast carcinoma amplified sequence 3 (BC001250) amplification
1p36.21 Cardiodilatin-atrial natriuretic factor (AL021155) amplification
6p25.2 Cell death protein (RIP) (U50062) amplification
UV-B repressed sequence, HUR 7 (X98307) no change
Gains of chromosomal regions
18q21.3-q22
Apolipoprotein A-I precursor (X02162)
CD48 antigen (B-cell membrane protein) (M37766)
1p31 Leptin receptor (U66497)
11q23
16p13.3. N-methylpurine-DNA glycosylase (M74905)
14q11.2-13.1
11q13.1-13.3 Cell cycle checkpoint control protein (U53174)
4p14 Ubiquitin carboxyl-terminal hydrolase L1 (X04741)
9q33.1 astrotactin 2 (BC010680)
1q23
amplification
19q13.3 OTK18 (D50419) no change
no change
2q35 Fibronectin 1 (X02761)
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different templates: non-amplified as control, amplified with DOP-PCR and ampified with 
our protocol: DOP-PCR in combination with QRT-PCR (Figure 3). In traditional DOP-PCR 
protocol we applied 21 cycles for each reaction, however genomic DNA was PCR amplified 
with our combined DOP-PCR-QRT-PCR method in 13-15 cycles, which were sufficient to 
reach early saturation phase. The copy numbers of selected genes were normalised to the copy 
number of the metallopeptidase 1 gene. This single copy gene did not show any alteration in 
copy number in either melanoma sample and gave reproducible results in all cases. Relative 
copy number change resulted being less than 0.5 meant loss of genetic material (heterozygous 
loss). If this value was greater than 1.5, it was defined as gain or gene amplification at that 
certain chromosome location (duplication of one allele). The results of the confirmatory QRT-
PCR are shown in Table 3. 
Genomic changes (no change, loss or gain of copy number) were determined for all 
the 44 genes in each method on both samples (primary melanoma and metastatic tumour) and 
all the 88 values were compared to each other. In case of the QRT-PCR protocol 88.6% of the 
copy number changes matched the non-amplified samples, while traditional DOP-PCR 
resulted in only 63.6% accuracy. The correlation coefficient for the comparison of the non-
amplified and the DOP-PCR amplified genomic DNA was only 0.27, while this value was 
significantly increased to 0.65 when the same protocol was used, but the amplification status 
was followed by QRT-PCR. 
To demonstrate the differences in relative copy numbers, which were obtained with 
different amplification methods, a scatter plot was prepared (Figure 4). In case of our 
combined method most of the genes had relative copy numbers similar to those of the non-
amplified method, while traditional DOP-PCR distorted the relative copy numbers detected in 
the non-amplified samples. 
To strengthen the extension of the preliminary observations a larger number of tumour 
types were further analysed. Amplified samples from epidermoid, bronchiolo-alveolar lung 
carcinoma, two renal cell carcinoma, two colorectal carcinoma, Conn and Cushing adenoma 
samples were processed as described above. Copy number changes of eight different 
chromosome regions were followed by QRT-PCR. Non-amplified and amplified samples 
obtained from traditional DOP-PCR technique and from our improved protocol were 
analysed. The results of copy number changes can be seen at http://160.114.60.33/Data2/. 
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Figure 4. Scatter plot of relative copy number of genes in primary and metastatic melanoma samples obtained 
with three different protocols. Values of copy number changes are in log2 scale. Only those genes were selected 
of which the values by any of the protocols were above +0.58 and below -1. The black squares and triangles 
mean those values which are different from the relative copy numbers of non-amplified samples. 
 
In the case of the analysed eight tumour samples there was 84.4% concordance in 
copy number alterations between the QRT-PCR protocol and the non-amplified samples, 
while this value was only 64.0% for the traditional DOP-PCR (Figure 5). 
 
 
 
 
 
 
 
 
 
 
Figure 5. Comparison of relative copy number of amplified samples genes to the original copy number 
(   : change in original copy number of genes        : no change in original copy number of genes)  
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In conclusion, our method improved the traditional DOP-PCR technique for whole 
genome amplification. Improved reliability of the QRT-PCR-controlled DOP-PCR was 
confirmed by the analysis of 152 copy number changes in ten tumour samples. We assume 
that one of the most distorting effects of the DOP-PCR technique in the study of amplified 
genomic DNA is the over-amplification of the products. Over-amplification has a dramatic 
distorting effect on the original genomic rearrangements and can generate false result. This 
effect can be decreased by adding QRT-PCR to the original protocol. Since DOP-PCR is a 
widely used technique and the preservation of the original genome set is especially important 
in genomic studies, therefore we propose to include QRT-PCR to follow and control the 
amplification status. 
7.2. A second field metachronous MCC of the lip and the palatine tonsil 
MCCs are highly divergent when analysed for chromosome aberrations (84, 86, 87). 
Reported recurrent chromosomal imbalances detected by CGH analysis were loss of 3p, 10q, 
13q and 17p and gains of 1q, 3q, 5p and 8q (87). In the present study, we could also detect the 
loss of 3p and 17p, but none of the above-mentioned amplified regions could be confirmed 
(Table 4, Figure 6).  
 
Table 4. Common and individual gains and losses of MCC and the tonsillar tumour detected by CGH. 
 
 Deletion Amplification 
both tumour 
1p36, 1p31, 1p13, 1q21-23, 1q32, 1q42.13, 2p13, 2p11.2, 
2q35, 3p21, 3q13.2, 3q14.3, 3q26-28, 4p16, 4q21, 5q35, 
6p21, 6q24, 7q21, 8p21, 8q24, 9p12, 9q34, 11p11.2, 
11q13, 11q23.3, 12q24.1, 14q11.2, 15q23-24, 16p13-12, 
16q24, 17p13, 17q12, 17q23, 18q12, 18q21, 19p13, 
20p13, 21q22, 22q13.1, X monosomy 
2p23, 10p15 
Merkel cell 
carcinoma 11p11.2, 11q12.3, 12q13, 16p13.1, 17q21.1, 17q25 
2p25, 12q12, 
15q14 
mesopharynx
1p34.1-32.2, 1p21-22, 1q42, 2q37, 4p16.3, 4q28.3, 
5q11.1, 5q22, 5q31-32, 7p14, 8p22-24.13, 10q21.1, 
11pter-p15.5, 12q14.3, 14q11.2, 14q31-32, 15q11-13, 
16q23-24, 17q21.3-q23, 20q13.1, 21q22.13, 22q11 
_ 
 
In another study, only 3 of the 10 MCCs exhibited common gains and losses and they 
shared a gain of 8q21-q22 and a loss of 4p15-pter (86). In the present study, the 4p16 region 
was also found to be deleted in both the primary and secondary tumours. Unfortunately, to 
date no known tumour suppressor gene has been mapped to this region (Table 5). Speleman’s 
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group detected losses involving the entire chromosome 10 or partial loss of the chromosome 
10 long arm in one-third of the MCC cases they analysed with a possible loss of 
heterozygosity (LOH) of 10q23, including the PTEN tumour-suppressor gene (85). In our 
case, deletion of this region was not observed in either tumour sample. 
 
 
 
Figure 6. Copy number aberrations found using microarray CGH analysis and real-time polymerase chain 
reaction of primary MCC and the tonsillar cancer. Boxes on the left side of each chromosome ideogram show 
regions of reduced copy number (losses of DNA in the tumour genome). Circles on the left side of each 
chromosome ideogram show regions of increased copy number (gains of DNA in the tumour genome). Filled 
boxes denote MCC and empty boxes tonsillar tumour 
 
In previous observations, series of MCCs showed no evidence of high-level 
amplification (87). Recurrent gains of chromosomes 1, 6, 18q and 20 were detected in 2 cases 
(84). In our case, only 2 regions, 2p and 10p were commonly over-represented. In a very 
recent study, 19 primary MCCs were analysed by CGH and in 13 samples extensive gains and 
losses were detected (155). It was shown that a majority of the alterations were gains, while 
only a few common losses were detected, mainly in regions 4q, 13q and 16q. Neither of our 
gains was found in any of the 19 cases they analysed. Most of the losses were detected in at 
least one case reported in the above-mentioned study, but the 13 MCCs exhibited a very 
heterogenous pattern, with diverse regions with losses. 
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Our CGH results revealed several new and a few other previously known 
chromosomal regions that have been presumed to be involved in the pathogenesis of MCC. 
We found 2 common gains and 41 common losses in the 2 samples. However, in 31 
chormosome locations we observed differences in gene copy numbers between the 2 tumours. 
From the results obtained by CGH analysis, we believe that the mesopharynx cancer and the 
MCC of the lip derived from the same, genetically altered field, thus the mesopharynx cancer 
can be regarded as a second field tumour. From the results obtained by CGH analysis, we 
hypothesize that Merkel cells in two adjacent anatomical sites, i.e. in the lip and 
mesopharynx, underwent same precancerous genetic alteration, and both tumours arose from 
a common cell clone. If our hypothesis is correct, the mesopharynx cancer can be regarded as 
a second field tumour. 
 
Table 5. Apoptotic genes and tumour supressors mapped to regions with common chromosomal aberrations. 
(Apoptotic and tumour suppressor genes in bold character. Apoptotic and tumour suppressor related genes in 
italics in brackets.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several oncogenes and tumour-suppressor and apoptotic genes were assumed to be 
changed in their copy number, and many of them were mapped to the regions having changes 
in their copy number in one or both of the tumours (Tables 5 and 6).  
 
11p11.2 (MADD)   
11q13 
DPF2, BAD, FADD 
(RELA, CCND1, 
RAD9A) 
DOC-1R, MEN1 (ST3, 
CCND1, SHANK2) 
11q23.3   THY1 
12q24.1 (SCA2)   
16p13-12 ASC TSC2 
16q24   WFDC1, GAS8, MGC15419, CBFA2T3
17p13   TP53, HIC1, OVCA2, DPH2L1 
17q12 (CCR7) (MPP3) 
18q21 (BCL2) DCC, SERPINB5 (E2F5) 
19p13   DIRAS1 (TJP3, SMARCA4, GIPC3) 
21q22 (MX1)   
22q13.1 (HMOX1) ST13 
Xp22.1 (SH3KBP1)   
Xq12   ING2 
Xq28   RPL10 
1p36 DFFB, TP73, CASP9 (CDC42, MFN2) 
UBE4B, TUSC3, 
PRDM2, C1orf1, ALPL 
(E2F2, TP73) 
1p31   CLCA2 
1p13   ST7L 
1q21-23 
MCL1, DAP3, 
TNFSF6 (MUC1, 
APCS, CRP, SELL) 
  
2p13   MAD 
3p21.3 (CCR3) RASSF1, BAP1 (SEMA3B) 
3q26-28 (ETV5, OPA1) TSBF1 
4p16   (GAK) 
4q21 (SNCA)   
5q35   (PDLIM7) 
6p21 BAK1, TNF (HSPA) (CDKN1A) 
6q24   SASH1 (PLAGL1) 
8p21 BNIP3 (CLU) PDGFRL (CNOT7, PDLIM2) 
8q24   (RNF139) 
9q34 TRAF2 (ABL1)   
 Chromosome 
location Apoptotic genes Tumor supressors 
 Chromosome 
location Apoptotic genes Tumor supressors 
In both tumorIn both tumour
Tumour sup Tumour suppresso
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Table 6. Apoptotic genes and tumour supressors mapped to regions with chromosomal aberrations specific to 
MCC or tonsillar tumour. 
 
 
 
 
 
 
 
 
 
 
 
The limitation of this list is that in these cases the deletions of the genes themselves 
were not proven in this study; only those regions were determined which were located to 
certain regions or proximity to regions where DNA segments on the microarrays originated. 
The micorarray-based CGH techniques used in this study could result in distorted data, 
especially when paraffin-embedded tissue is the target. Another limitation of this study is that 
the deleted regions were determined by using hybridizations based on complementary cDNA 
- genomic DNA annealing events, which could generate more biases. As a consequence of the 
above problems, we determined the reliability of the results obtained by the CGH microarray 
by using QRT-PCR. 10 genes were selected to follow the copy number changes by QRT-
PCR. Out of the 10 genes, one exhibited no changes in the copy number found by CGH 
microarray analysis in all cases: the dihydrofolate reductase gene. This was therefore used an 
internal control. The copy numbers of all the other 9 genes (sequences and chromosome 
locations are listed in Table 2, accesion numbers are listed in Table 7) were related to this 
inner control. We used DNA purified from normal lymphoid tissue as control and determined 
copy number changes of the other two tumours (Table 4, Figure 6). 
We confirmed the deletions in 7 cases for both tumours and 2 were confirmed for only 
MCC. Although the number of the confirmatory QRT-PCRs were limited and therefore does 
not allow determination of the reliability of the CGH methods, the main purpose of the study 
 Chromosome 
location Apoptotic genes Tumor supressors 
In Merkel cell carcinoma 
11p11.2 (MADD)   
12q13 (CDK2, KRT18, NR4A1, WNT1)   
17q25 BIRC5   
In Mesopharynx 
1p34.1-32.2   FABP3 
3p22-21   ADPRTL3 
5q11.1 (LOC145908)   
5q22   MCC 
5q31-32   C5orf7 
10q21.1 (CDC2)   
11pter-p15.5 (CTSD, HRAS) MRVI1 
14q31-32 SIVA   
16q23-24 (LOC145908) CBFA2T3 
21q22.13   RUNX1 
22q11 BID MYO18B 
Tumour sup
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was to determine the relation of the two tumours, not a precise determination of the deleted 
regions. 
 
Table 7. Confirmation of CGH data by QRT-PCR. Only two common losses could not be confirmed. Gains are 
indicated as grey background. 
 
Microarray data 
confirmed by QPCR Clone name Accesion No.
Chrom. 
location Distance
Steroid 5-alpha-reductase 2 (SRD5A2) M74047 2p23 31724 
Hepatocyte nuclear factor-3 alpha U39840 14q12-q13 36052 
Zinc finger protein  AF020591 19q13.43 63450 
Androgen receptor (dihydrotestosterone 
receptor) 
M23263 Xq12 63075 
C8FW phosphoprotein AJ000480 8q24.13 126404 
ESTs, Highly  similar to Phosohatidylcholine 
transfer protein  AA933627 17q23 54340 
both tumour 
Cytochrome P450, subfamily XIA M14565 15q23-24 70670 
EST N22765 15q14 no data Merkel cell 
carcinoma Cardiac myosin binding protein-C U91629 11p11.2 49310 
  
 
We confirmed the deletions in 7 cases for both tumours and 2 were confirmed for only 
MCC. Although the number of the confirmatory QRT-PCRs were limited and therefore does 
not allow determine the reliability of the CGH methods, the main purpose of the study was to 
determine the relation of the two tumours, not a precise determination of the deleted regions. 
In summary, the partly different molecular patterns obtained by CGH, the similar 
histological features, and the close proximity to the primary tumour indicate that the tonsillar 
cancer was a second field tumour. The common origin was further confirmed, because out of 
3 early markers (9p, 3p and 17p) two of them (9p and 17p) were common in both cancer 
samples, one (17p) bearing the p53 tumour suppressor marker gene. The common copy 
number changes do not support the possibility that the tonsillar cancer was a second primary 
tumour. The tonsils are very rare and unusual sites of metastatic disease in MCC. There are 
three reports in the literature describing oropharyngeal metastasis of a MCC (71, 156, 157). In 
all these reports, the metastasis occurred within 24 months after resection of the primary 
tumour. In our case, it was clinically very unlikely that the tonsillar tumour was a metastasis 
of the MCC of the lip, because no local recurrence or regional lymph node metastasis or 
distant haematogenous metastases were observed in the 7-year follow-up. In harmony with 
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the clinical situation, the molecular patterns of the 2 tumours were not similar, therefore the 
possibility of a metastasis could be rejected. Although the concept of second primary tumours 
and field cancerization has been formulated for oral and oropharyngeal squamous cell 
carcinomas (78), our results indicate that Merkel cells in adjacent anatomic sites may also be 
the targets of field cancerization. 
7.3. Determination of several copy number changes in different genomic DNA of thyroid 
carcinoma based on disease course 
We obtained genomic DNA from paraffin-embedded samples of primary- and 
terminal-stage APTC of a sixty-three-year-old male patient (by the latter, histology indicated 
dedifferentiation), which genomic DNA was amplified by our improved DOP-PCR technique. 
As a follow-up, relative DNA losses and gains were determined for each tumour sample by 
normalizing the intensities to the values obtained after hybridization with labeled probes from 
GPTC. The CGH-array analysis were performed on human cDNA microarray containing 
3200 gene-specific cDNA samples in duplicate on glass slides. 
Specific primers were designed for thirty chromosomal regions exhibiting changes 
(deletion or amplification) in order to confirm our CGH results using QRT-PCR, which was 
performed on the original, non-amplified genomic DNA. We found that 3 out of the 30 
regions (FGF7, EIF4EBP3, KIAA0549) indicated the same changes (DNA losses) in both 
tumours and corresponded to CGH-array results. In one case (Image EST-Acc. No. R78712), 
the QRT-PCR results corresponded to the CGH-array data of primary APTC; and at further 
examination, DNA gain was detected in the case of terminal-stage APTC when it was 
compared to the copy number of normal thyroid tissue. These results demonstrated a 
difference in chromosome copy numbers of primary and terminal-stage APTC. 
Further on, two additional gene loci were identified with changes only within 
terminal-stage APTC, namely Tre-2 oncogene and TB10, which were positive in each thyroid 
carcinoma during immunohistochemical experiments – especially in the case of ATC (158). 
Only one region – Tre-2 oncogene – out of six regions was confirmed as over-represented in 
the case of GPTC.  
Thirty two additional thyroid carcinomas examined as well. QRT-PCR analysis was 
performed on the non-amplified genomic DNA of 32 PTCs as well as the first GPTC and the 
first terminal-stage APTC, upon which the CGH-array analysis was carried out. The copy 
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number of the six regions described above (Table 8) was determined on 34 thyroid carcinoma 
genomes altogether (10 GPTCs; 14 IPTCs, 10 APTCs); we compared it with two normal 
thyroid samples, and the relative ratios were normalized to the copy numbers of the alpha1-
fetoprotein transcription factor and the H3 histone (family 3A) as internal control genes 
separately.  
Since we could not detect a significant difference in the examined six regions – in the 
copy numbers of IPTC and APTC samples, these two groups were treated as one group 
(I/APTC) (that is where the patient had a lymph node metastasis in the cervical areas or some 
other distant metastasis /spread: lung, bone/, suffered from local recurrance, died because of 
their PTC).  
 
Table 8. Copy number alterations in different disease course thyroid carcinoma. Dark gray denotes 
DNA gains common amplification of TB10 and Image EST, while light gray denotes separately amplification. 
 
Chrom. Loc.
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
1.35 (0.20) N 3.28 (1.93) A 0.75 (0.07) N 0.58 (0.26) N 0.99 (0,10) N 0.39 (0.16) D
1.31 (0.32) N 1.26 (0.32) N 2.62 (0.88) A 0.59 (0.19) N 0.86 (0.35) N 0.53 (0.15) D
1.29 (0.17) N 0.46 (0.15) D 1.80 (0.31) A 0.54 (0.13) D 0,74 (0.18) N 0.31 (0.06) D
1.12 (0.41) N 0.49 (0.25) D 2.63 (1.14) A 0.46 (0.18) D 0.52 (0.16) D 0.35 (0.10) D
1.14 (0.30) N 0.98 (0.34) N 1.64 (0.28) A 1.10 (0.25) N 1.13 (0.24) N 0.69 (0.23) N
0.95 (0.27) N 0.67 (0.26) N 2.74 (0.80) A 0.58 (0.22) N 0.45 (0.05) D 0.89 (0.39) N
1.88 (0.13) A 1.27 (0.34) N 3.14 (0.95) A 0,00 D 1.11 (0.10) N 0.52 (0.08) D
1.18 (0.35) N 0.64 (0.56) N 2.24 (0.83) A 0.48 (0.04) D 0.91 (0.31) N 0.40 (0.35) D
0.70 (0.22) N 0.89 (0.22) N 0.69 (0.64) N 0,09 (0.07) D 1.65 (0.27) A 0.18 (0.07) D
2.96 (1.18) A 0.81 (0.29) N 2.19 (0.12) A 0.64 (0.36) N 0.97 (0.32) N 1.20 (0.43) N
2.95 (1.10) A 0.90 (0.32) N 1.28 (0.46) N 0.52 (0.26) D 0.49 (0.15) D 0.63 (0.15) N
2.02 (0.60) A 0.70 (0.34) N 3.82 (0.30) A 0.36 (0.09) D 0,47 (0.23) D 0.64 (0.23) N
1.79 (0.63) A 0.54 (0.28) D 3.99 (1.16) A 0.40 (0.21) D 0.49 (0.23) D 0.55 (0.26) D
3.03 (0.99) A 2,36 (0.94) A 1.51 (0.37) A 1.33 (0.26) N 0.65 (0.16) N 0.79 (0.23) N
1.13 (0.29) N 0.66 (0.18) N 3.93 (1.96) A 0.39 (0.09) D 0.40 (0.14) D 0.20 (0.06) D
0.83 (0.13) N 3.64 (1.64) A 2.82 (0.17) A 1.06 (0.26) N 5.26 (0.54) A 1.14 (0.33) N
0.92 (0.41) N 1.09 (0.41) N 1.26 (0.21) N 0.82 (0.25) N 1.03 (0.21) N 0.79 (0.26) N
4.87 (1.08) A 2.38 (1.07) A 5.00 (1.51) A 1.08 (0.19) N 8.14 (0.84) A 0.85 (0.31) N
4.27 (1.19) A 1.86 (0.97) A 2.33 (0.72) A 1.14 (0.35) N 1.16 (0.12) N 0.37 (0.10) D
1.32 (0.29) N 1.30 (0.73) N 3.24 (0.84) A 2.03 (0.54) A 1.18 (0.28) N 0.73 (0.17) N
1.67 (0.34) A 2.25 (1.27) A 1.73 (0.43) A 3.39 (1.04) A 1.90 (0.39) A 1.10 (0.29) N
1.02 (0.13) N 1.12 (0.46) N 1.97 (0.52) A 0.72 (0.17) N 1.18 (0.27) N 0.81 (0.16) N
4.13 (1.85) A 0.67 (0.20) N 3.67 (0.50) A 0.25 (0.12) D 1.47 (0.18) N 0.42 (0.14) D
2.00 (0.56) A 0.93 (0.29) N 3.92 (1.14) A 0,00 D 0.72 (0.07) N 0.58 (0.20) N
3.77 (1.25) A 0.53 (0.21) D 3.46 (1.59) A 0.65 (0.21) N 0.37 (0.22) D 0.69 (0.26) N
4.16 (1.19) A 0.53 (0.28) D 2.29 (0.69) A 0.21 (0.11) D 0.66 (0.36) N 0.21 (0.06) D
0.72 (0.13) N 0.68 (0.22) N 0.91 (0.18) N 0.38 (0.15) D 0.62 (0.19) N 0.51 (0.19) D
3.27 (0.79) A 0.84 (0.40) N 2.95 (0.60) A 0.06 (0.04) D 0,.76 (0.30) N 0.28 (0.10) D
1.50 (0.34) A 0.72 (0.19) N 1.15 (0.32) N 0.46 (0.20) D 0.83 (0.42) N 0.35 (0.11) D
1.35 (0.34) N 0.53 (0.20) D 4.47 (1.65) A 0.58 (0.23) N 0.50 (0.18) D 0.70 (0.27) N
2.07 (0.66) A 2.11 (0.66) A 1,15 (0.41) N 0.76 (0.15) N 0.85 (0.32) N 0.65 (0.20) N
0.77 (0.18) N 7.34 (6.65) A 3.52 (0.90) A 0.71 (0.24) N 2.95 (1.84) A 0.78 (0.22) N
0.80 (0.15) N 0.71 (0.31) N 1.75 (0.25) A 1.91 (0.52) A 0.97 (0.17) N 1.18 (0.35) N
3.32 (2.52) A 2.06 (1.86) A 2.44 (2.10) A 0.26 (0.37) D 0.50 (0.43) D 0.62 (0.30) N
Fibroblast growth 
factor 7 EIF4EBP3Gene
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In the present study, Tre-2 oncogene was found to be over-represented in 80% of the 
GPTC and I/APTC groups (Figure 7). Tre-2 is a recombinant gene isolated from NIH3T3 
cells transfected with human Ewing’s sarcoma DNA. Genetic elements of Tre-2 originate 
from chromosomes 5, 18 and 17. Our examined field of Tre-2 oncogene is mapped onto the 
17p13 chromosome region. Many researchers have demonstrated that this oncogene is 
consistently transcribed in various human cancer cells (159). Expression of Tre-2 in normal 
somatic cells, however, has not yet been reported. Tre-2 oncogene seems to encode a 
nonfunctional Rab (GAP). Regions flanking the TBC (Tre-2/Bub2/Cdc16) domain may be 
crucial for catalytic activity. These domains are predicted to encode GTPase-activating 
proteins (GAPs) for Rab family G proteins. Martinu et al. (160) have identified this oncogene 
as a novel regulator of the Arf6-regulated plasma membrane recycling system. Masuda-
Robens et al. have demonstrated that Tre-2 coprecipitated specifically with the active forms of 
Cdc42 and Rac1 in vivo, which play fundamental roles in transformation and actin 
remodeling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Copy number alterations of six chromosomal regions in two disease course thyroid carcinomas.  
('A' group: PTC of good disease outcome; 'B' group: intermediate and aggressive type of PTC)  
 
Amplification
No change
Dele tion
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Our study showed amplified regions of TB10 in greater extent in I/APTC (62.5%), 
whereas in the case of GPTC group the quantity of DNA gains could be detected in only 20% 
of the cases. This is a significant difference between the two groups based on the outcome of 
the disease. Chiappetta et al. (161) have shown that TB10 gene expression can function as a 
possible tool in the diagnosis of thyroid neoplasias, since TB10 positive staining was found in 
all human thyroid carcinoma, particularly in the anaplastic histotypes. Many researchers have 
demonstrated that TB10 acts as an actin-mediated tumour suppressor (162). Some 
observations suggest that TB10 plays a significant role in the cellular processes controlling 
apoptosis (163). Other authors have shown that the TB10 gene is highly expressed in human 
thyroid carcinoma cell lines and tissues, whereas its expression is almost undetectable in 
normal thyroid; furthermore, TB10 gene expression can function as a useful marker for 
diagnosis and prognosis of a large variety of human cancers (162). In a study by Takano et al. 
(158), TB10 mRNA is highly over-expressed in human and experimental thyroid tumours and 
its expression is abundant in undifferentiated thyroid carcinomas (158, 164). These results 
seem to be closely related to our results in connection with genomic rearrangement. TB10 
gene overexpression is a general event in human carcinogenesis (162). Overexpression of 
TB10 was showed in thyroid, pancreatic, gastric, breast, ovarian, uterine, colon, esophageal 
cancer and germ cell tumours. Lee et al. (165) have described that overexpressed TB10 
significantly inhibited vascular endothelial growth factor-induced endothelial cell 
proliferation, migration, invasion and tube formation in vitro.  
The examined Image EST (Acc. No. R78712) is mapped to the middle of the AKAP13 
gene. In the case of this region, our results indicated DNA gains in one case of the GPTC 
group and in an ascending quantity in the I/APTC. We can postulate that the AKAP13 gene is 
affected; however, further analysis is needed to provide this hypothesis. AKAP13 anchors 
both protein kinase A and 14-3-3, and by this means inhibits the Rho-GEF activity of the 
AKAP-Lbc signaling complex (166). Alternative splicing of this gene results in at least 3 
transcript variants encoding different isoforms containing a dbl oncogene homology (DH) 
domain and a pleckstrin homology (PH) domain. The DH domain is associated with guanine 
nucleotide exchange activation for the Rho/Rac family of small GTP binding proteins, 
resulting in the conversion of the inactive GTPase to the active form capable of transducing 
signals.  
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In two regions we found DNA losses, in one case out of which – the EIF4EBP3 gene – 
indicated a decreased copy number in many cases during our experiments. This protein is the 
negative regulator of protein byosinthesis and the initiation of translation; in other words, it 
represses translation. DNA losses were detected in 70% of the GPTC and only in 33% of 
I/APTC. The KIAA0549 gene was under-represented in half of both groups. When examined, 
the sixth gene, namely FGF7, demonstrated both DNA gains and losses in small quantity, but 
this rearrangment was greater in the case of I/APTC. FGF family members possess broad 
mitogenic and cell survival activities, and are involved in a variety of biological processes, 
including embryonic development, cell growth, morphogenesis, tissue repair, tumour growth 
and invasion. Unfortunately, we do not have knowledge on the role these rearrangements of 
genes can play within the tumourigenesis progress. 
Our results indicate that synchronous detection of over-representation of TB10 and 
Image EST (Acc. No. R78712) can become a good diagnostic marker for aggressive thyroid 
carcinoma. 
7.4. QRT-PCR-based exponential amplification for microarray gene expression profiling 
Global RNA expression analysis using microarray technology allows the identification 
of genes that are differentially expressed in tumour versus normal tissues. In this case the 
elimination of overamplified cDNA is also extremely important, for this reason we developed 
an alternative exponential sample amplification method. Total RNA was reverse transcribed 
and amplified with two PCR protocols resulting in DNA samples from early phase (13th–15th 
cycles) and late exponential, early saturation phase (21st cycle), similarly to the proving of the 
reliability of the improved DOP-PCR, which can amplify the whole genome. Reproducibility 
and reliability of the methods were determined performing cDNA microarray and 
confirmative QRT-PCR experiments on LPS-treated mouse macrophage cDNA prepared in a 
different manner.  
Our exponential sample amplification protocol preserves the original expression ratios 
and allows unbiased gene expression analysis from minute amounts of starting material.  
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7.5. Analysis of the gene expression pattern of parallel expression of αIIbβ3 and αvβ3 
integrins in human melanoma cells using microarray technology 
In cancerous tissues new vessels are required to provide cancer cells with nutrients and 
are targets for invading cancer cells themselves. At the beginning of its natural history, a 
cancer is not vascularised, and it does not grow beyond 2 mm in size unless vascularisation 
has occurred. The switch to the angiogenic phenotype is a critical point in tumour progression 
(167) and depends on the additive effect of progressive genetic alterations (168).  
The effect of αIIbβ3-transfection on gene expression was tested using a homemade 
3200 cDNA microarray (43, 150). The fastest growing and most vascularized clone (19H) 
was selected and compared to the mock cells, 3.1P to reveal the molecular pathomechanism 
of large growth and cell survival. We defined those genes to be regulated by αIIbβ3 
transfection in melanoma cell cultures, in the case of which the average-fold change (increase 
or decrease) of the 4 data points was at least 2.0-fold.  
Forty-eight genes in 19H cells corresponded to such strict criteria from the 3200 
analysed; 36 genes were found to be upregulated and 12 have been downregulated. Among 
the downregulated genes, there were no known angiogenic/endothelial ones represented; 
however, among the 19 known genes upregulated in 19H cells compared to 3.1P, 3 could be 
considered endothelial-specific, such as CD34 antigen, endothelin receptor type B and 
prostaglandin I-2 synthase, the changes of which were also confirmed by QRT-PCR analysis 
(data not shown).  
Parallel expression of the two β3-integrins in human melanoma cells induced 
modulation not only of bFGF but of other genes as well, which is demonstrated by microarray 
analysis. Interestingly, 3 out of 19 known genes upregulated significantly in αIIbβ3-
transfected 19H cells are endothelial cell-specific genes, CD34, endothelin receptor B and 
prostaglandin I-2 synthase. Recapitulation of an embryonic endothelial/angioblastic genetic 
program, called vasculogenic mimicry (169), resulting in vivo formation of tumour cell lined 
vascular channels, was recently described and documented in case of human melanoma and 
other tumours (170). There have been several genes identified to be responsible for this 
vasculogenic phenotype including VE-cadherin, CD34, TIE2, EphA2, LAMC2, endoglin, 
EDG1, ESM1 and EDF1 (171). 
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VIII. CONCLUSIONS 
In many cases only a minute amount of partially degraded genomic DNA can be 
extracted from archived clinical samples. Forensic analyses, tests on biopsy samples, prenatal 
diagnosis and many other investigations have access to very little starting material. 
Investigations of the genetic background of intratumour heterogenity require manipulation of 
minute amounts of neoplastic tissue on a cellular scale, often below the amounts required for 
routine CGH. A method to overcome the small quantity of the DNA available is to perform 
whole genome amplification. One commonly used method is DOP-PCR, due to its simplicity 
and degree of success. In our study a new QRT-PCR-based DOP-PCR amplification method 
was developed, on the basis of which we have proved the preservation of the original copy 
number of different chromosomal regions in amplified genomic DNA.  
This improved genomic amplification technique was also applied in the case of two 
clinical investigations, during which the molecular imbalances of tumours were detected by 
microarray based CGH analysis. In the first case we analysed the MCC and the seven years 
later appearing tonsillar tumour in order to assess the genetic relationship of the tumours. On 
the basis of our results we have demonstrated that the tonsillar tumour can be pathogenetically 
regarded as a second field tumour.  
The improved DOP-PCR technique was also employed for detection of molecular 
patterns of PTCs of different disease courses. The question arises as to whether genomic 
differences (markers) are to be found at the appearance of the disease, or an unfavorable 
outcome can be predicted that could allow a more effective treatment for the patient. Our 
CGH-array and QRT-PCR results have shown rearrangements of six regions of the genome, 
which can play a role in the tumourigenesis progress, and synchronous detection of some of 
these genes can become a good diagnostic marker for the detection of malignant thyroid 
carcinoma.  
 After reaching a certain tumour size, tumour cells need to be provided with a sufficient 
amount of oxygen and nutriment. It was demonstrated that the transfection of integrin αIIbβ3 
into human melanoma cells promoted their in vivo growth and cell survival. We have revealed 
nineteen known genes upregulated in transfected melanoma cells; three could be considered 
endothelial-specific by performing microarray experiments, which can provide explanation 
for a part of underlying pathomechanism of increased cancer growth and angiogenesis. 
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Improved DOP-PCR–Based Representational
Whole-Genome Amplification Using Quantitative
Real-Time PCR
Lilia´na Z. Fehe´r, MSc,* Margit Bala´zs, PhD, DSc,w Ja´nos Z. Kelemen, MSc,* A´gnes Zvara, PhD,*
Istva´n Ne´meth, MD,z Zolta´n Varga-Orvos, MD,* and La´szlo´ G. Puska´s, PhD*
Abstract: In many cases, only a minute amount of partially
degraded genomic DNA can be extracted from archived clinical
samples. Diverse whole-genome ampliﬁcation methods are
applied to provide suﬃcient amount of DNA for comparative
genome hybridization, single-nucleotide polymorphism, and
microsatellite analyses. In these applications, the reliability of
the ampliﬁcation techniques is particularly important. In PCR-
based approaches, the plateau eﬀect can seriously alter the
original relative copy number of certain chromosomal regions.
To eliminate this distorting eﬀect, we improved the standard
degenerate oligonucleotide-primed PCR (DOP-PCR) technique
by following the ampliﬁcation status with quantitative real-time
PCR (QRT-PCR). With real-time detection of the products, we
could eliminate DNA overampliﬁcation. Probes were prepared
from 10 diﬀerent tumor samples: primary and metastatic
melanoma tissues, epidermoid and bronchioloalveolar lung
carcinomas, 2 renal cell carcinomas, 2 colorectal carcinomas,
and a Conn and Cushing adenoma. Probes were generated by
using nonampliﬁed and ampliﬁed genomic DNA with DOP-
PCR and DOP-PCR combined with QRT-PCR. To demon-
strate the reliability of the QRT-PCR based ampliﬁcation
protocol, altogether 152 relative copy number changes of 44
regions were determined. There was 85.6% concordance in copy
number alterations between the QRT-PCR protocol and the
nonampliﬁed samples, whereas this value was only 63.8% for
the traditional DOP-PCR. Our results demonstrate that our
protocol preserves the original copy number of diﬀerent
chromosomal regions in ampliﬁed genomic DNA than standard
DOP-PCR techniques more accurately.
Key Words: degenerate oligonucleotide-primed PCR (DOP-
PCR), genome ampliﬁcation, quantitative real-time PCR, copy
number changes
(Diagn Mol Pathol 2006;15:43–48)
H igh-throughput genomic analysis requires largeamounts of template; however, the typical yield of
DNA from individual samples can be often limited. The
primary drawback of the use of laser capture microscopy
in DNA analysis is that microdissections yield insuﬃcient
nucleic acids due to low genomic DNA recovered from
small sample sizes. With samples such as these, the ability
to conduct sample ampliﬁcation becomes imperative, to
ensure that enough material is available for genetic
analysis. Not only the amount but also the quality of
genomic DNA obtained from various samples is impedi-
ment for further studies. For example, paraﬃn-embedded
tissues often provide partially degraded low-quality
DNA. Therefore, developing a whole-genome ampliﬁca-
tion method which is not entirely dependent on high-
quality DNA is eminently important to provide an
extensive supply of DNA for large-scale genetic studies1
such as metaphase comparative genomic hybridization
(CGH),2 array CGH,3 single-nucleotide polymorphism
(SNP) genotyping,4 microsatellite genotyping,5 single-
stranded conformational polymorphism (SSCP),6 loss of
heterozygosity (LOH),7 and sequence analysis.8 Gene
ampliﬁcations and deletions are common in tumors and
can inﬂuence tumorigenesis and metastatic potential.
Traditional CGH can detect aneuploidies, deletions, and
unbalanced translocations. There are 3 basic techniques
to amplify the entire genomic DNA: PCR-based ap-
proaches,5–15 strand or multiple displacement ampliﬁca-
tion (SDA or MDA),16 and T7-based linear ampliﬁcation
(TLAD).17
The SDA and MDA isothermal methods employ
the unique biochemical properties of Phi29 DNA poly-
merase to amplify linear DNA. These techniques are
based on the rolling circle ampliﬁcation by which circular
DNA molecules such as plasmids or viruses frequently
replicate. These rolling circle ampliﬁcation methods were
initially adapted for the ampliﬁcation of large circular
DNA templates18,19 and more recently for the ampliﬁca-
tion of genomic DNA.16 The drawback of SDA is that the
eﬃciency of ampliﬁcation depends on the length of the
template. TLAD is applicable for the ampliﬁcation of
genomic DNA of varying fragment size and quality, andCopyright r 2006 by Lippincott Williams & Wilkins
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it is based on a protocol devised by Phillips and Eberwine
for the ampliﬁcation of mRNA for cDNA microarrays.17
The interspread repetitive sequence PCR15 was the
ﬁrst PCR-based genome ampliﬁcation method which used
primers designed to anneal to Alu repeats within the
genome. This strategy was further improved to amplify
speciﬁc DNA ﬂanked by Alu repeats by using the so-
called restricted-PCR technology.20 An alternative meth-
od,9 termed the linker adapter technique PCR (LA-PCR),
involved restriction digestion of the DNA and ligation of
adaptors to serve as priming sites for subsequent PCR. In
principle, the ligation-mediated PCR (LMP) is very
similar to the LA-PCR method.9,10 Nonetheless, this
approach has not been widely applied, likely due to
technical diﬃculties involved. PCR-based genome ampli-
ﬁcation methods, primer extension preampliﬁcation
(PEP),11,12 and DOP-PCR13,14 techniques have been
developed for the ampliﬁcation of genomic DNA starting
from as little as a single cell. The original PEP protocol
involves a 50-cycle PCR program using a 15 bp long
oligonucleotide primer; however, via this approach only
B78% of the genome from a single haploid cell can be
copied.11 The DOP-PCR technique is increasingly being
applied for simultaneous ampliﬁcation of multiple loci in
target DNA using oligonucleotide primers of partially
degenerate sequences13; however, the ampliﬁed DNA
does not cover the genome completely. Contrary to other
PCR-based ampliﬁcation methods (Alu-PCR, IRS-PCR),
DOP-PCR is a species-independent technique. The
protocol is adapted for the use of microdissected,
formalin-ﬁxed, and paraﬃn-embedded tissue in compre-
hensive genetic analyses.21
DOP-PCR and PEP protocols amplify DNA in an
exponential fashion, making them highly susceptible to
biases, and they have a tendency to speciﬁcally over-
represent or downrepresent certain sequences. The major
disadvantage of PCR-based protocols is that this could
distort the ratio of the starting genomic imbalances.22
Recently, Wang et al23 have described a modiﬁed DOP-
PCR protocol for balanced ampliﬁcation of genomic
DNA; however, the ampliﬁcation status has not been
followed during PCR. In their protocol, genomic DNA
was digested with a restriction enzyme, and tagged linkers
were ligated to the products before ampliﬁcation. In our
protocol, direct ampliﬁcation of genomic DNA can be
performed without any pretreatment of the samples. Our
improved protocol of DOP-PCR includes QRT-PCR to
follow the cycling status which results in a more reliable
and reproducible sample ampliﬁcation.
MATERIALS AND METHODS
Tissue Specimens
Melanoma tissues were obtained from the Depart-
ment of Dermatology, University of Debrecen, Hungary.
Primary melanoma (location: face) and metastatic tumor
(location: lymph node) were removed from the same
patient at the same time. The relative amount of tumor
cells was a minimum of 70% in all lesions as conﬁrmed
after hematoxylin and eosin staining by light microscopy.
Epidermoid, bronchioloalveolar lung carcinoma, 2 renal
cell carcinoma, and 2 colorectal carcinoma specimens
were obtained from the Institute of Pathology, Szeged
University. Conn and Cushing adenoma samples were
obtained from Semmelweis University, Budapest. High–
molecular-weight DNA was extracted according to a
standard procedure starting from 50mg of tissue.24,25
Chromosomal CGH and image analyses were performed
as described earlier in details elsewhere.25
Preparation of DOP-PCR Amplified and
Overamplified Genomic DNA
Genomic DNA (20 ng) from each sample was
ampliﬁed with a modiﬁed version of the DOP-PCR
protocol by using a RotorGene 3000 QRT-PCR instru-
ment (Corbett Research, Mortlake, Australia) to follow
the ampliﬁcation.14,26 The DNA concentration was
assessed spectrophotometrically by NanoDrop (Rock-
land, DE). Reactions were performed in a total volume of
100 mL. The cycling parameters were as follows: heat start
at 951C (15minutes), 8 cycles denaturation at 941C (50
seconds), annealing for 2minutes from 451C to 721C with
a 0.21C/s ramp, and extension at 721C (90 seconds). After
8 cycles, the reaction mix was divided into two 50-mL
aliquots and SybrGreen was added to both (1 ﬁnal
concentration, Molecular Probes, Eugene, USA). The
following cycling protocol was performed in a real-time
PCR instrument: denaturation at 951C (40 seconds),
annealing at 581C (60 seconds), and extension at 721C
for 80 seconds. To avoid overampliﬁcation of the
products, cycling was terminated just before the reaction
reached the plateau (ie, at 13–15 cycles); in contrast, the
overampliﬁed genomic DNA was obtained from PCR
with 21 cycles.
The PCR products were puriﬁed with PCR-puriﬁ-
cation columns (Bioneer, Daejeon, Korea). In the
reactions, UN primer (50-CCGACTCGAGNNNNN-
NATGTGG-30) was used in 1 mmol/L concentration.13
The reactions were performed with 1 ABsolute QPCR
Mixes (ABgene, Surrey, UK).
Confirmatory Quantitative Real-Time PCR
QRT-PCR was carried out in a ﬁnal volume of
20 mL with 20 ng nonampliﬁed or ampliﬁed genomic
DNA in a RotorGene 3000 instrument. The reactions
were performed with 5 pmol/each forward and reverse
gene-speciﬁc primers in 1 ABsolute QPCR Mix
(ABgene, Surrey, UK) with SybrGreen (1 mmol/L ﬁnal
concentration, Molecular Probes) with the following
protocol: heat start for 15minutes at 951C, 45 cycles of
25 seconds denaturation at 951C, 25 seconds annealing at
591C, and 25 seconds extension at 721C. Fluorescent
signals were collected after each extension step at 721C.
Curves were analyzed with the RotorGene software,
using dynamic tube and slope correction methods,
whereas ignoring data from cycles close to baseline.
Primers were designed by using the PrimerExpress soft-
ware (Applied Biosystems, Foster City, CA). Relative
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ratios were normalized to the Ct values of the metallo-
peptidase 1 gene as an internal control and calculated
with the Pfaﬄ method.27 The sequences of PCR primers
used in this study were deposited to http://160.114.60.33/
Data1/. All the PCRs were performed 3 times in separate
runs.
RESULTS AND DISCUSSION
DOP-PCR is a simple method for whole-genome
ampliﬁcation in comprehensive genetic studies (CGH,
SSCP, SNP, and microsatellite genotyping) that is
increasingly being applied for simultaneous ampliﬁcation
of multiple loci in target DNA. DOP-PCR utilizes
oligonucleotide primers with partially degenerate se-
quences close to their 30-end.13 DOP-PCR is a species-
independent approach which produces suﬃcient amounts
of DNA for analyzing clinical tumor samples, for
prenatal diagnosis, and for many other investigations. A
comparison of several DOP-PCR methods is also
described by Larsen et al.21 Unfortunately, PCR-based
protocols often result in misrepresentation of the genome,
with some regions being overrepresented or even lost. The
reliability of PCR-based ampliﬁcation mostly depends on
the exponential phase during cycling. At the late cycles of
ampliﬁcation, the original copy number of chromosomal
regions can be changed and the method provides false
results. The plateau eﬀect28,29 is the result of a marked
shift of the overall mass balance in favor of the reaction
product. Diﬀerent factors seem to be responsible for the
attainment of the plateau rather than a single factor or
parameter, as readdition of presumably exhausted re-
agents at late cycles did not cause the reaction to proceed
with increased eﬃciency.30 The plateau eﬀect is caused by
the accumulation of product molecules, usually the
consequence of the signiﬁcant degree of annealing
between complementary strands of the products, rather
than between the primers and template. Furthermore, the
ﬁnite amount of enzyme molecules present will be unable
to extend all the primer-template complex in the given
extension time.31
Here, we present a more reliable PCR-based
genome ampliﬁcation procedure, developed as an alter-
native sample ampliﬁcation method which follows the
ampliﬁcation status by QRT-PCR. With real-time detec-
tion of the products, DNA overampliﬁcation could be
diminished. After initial ampliﬁcation of the genome,
SybrGreen dye is added to the reaction mix and a second
ampliﬁcation step is applied in a QRT-PCR instrument.
The cycling is performed until the reaction reaches the
plateau (Fig. 1).
To compare the original gene copy number of
diﬀerent templates generated by using the traditional
DOP-PCR and with the protocol using QRT-PCR, 44
genes were selected for conﬁrmation by using QRT-PCR
analysis in cases of 2 melanoma samples. Genes were
selected on the basis of metaphase CGH data performed
earlier.25 The QRT-PCR was performed on DNA
samples obtained from primary and metastatic melanoma
tissues resected from the same patient along with normal
DNA prepared from peripheral blood of a healthy
individual as a control. Altogether 88 relative copy
numbers were determined on 3 diﬀerent templates:
nonampliﬁed as control, ampliﬁed with DOP-PCR, and
ampliﬁed with our protocol: DOP-PCR in combination
with QRT-PCR (Fig. 1). In traditional DOP-PCR
protocol, we applied 21 cycles for each reaction; however,
genomic DNA was PCR ampliﬁed with our combined
DOP-PCR-QRT-PCR method in 13 to 15 cycles, which
were suﬃcient to reach early saturation phase.26 The copy
numbers of selected genes were normalized to the copy
number of the metallopeptidase 1 gene. This single-copy
gene did not show any alteration in copy number in either
melanoma sample and gave reproducible results in all
cases. Relative copy number change that resulted in less
than 0.5 meant loss of genetic material (heterozygous
loss). If this value was greater than 1.5, it was deﬁned as
gain or gene ampliﬁcation at that certain chromosome
location (duplication of one allele). The results of the
conﬁrmatory QRT-PCR are shown in Table 1.
Genomic changes (no change, loss or gain of copy
number) were determined for all the 44 genes in each
method on both samples (primary melanoma and
FIGURE 1. Whole-genomic DNA amplification using QRT-
PCR. Diagram of the primary, metastatic melanoma tissue,
and normal peripheric lymphocyte. The amplification halted
at the 13th cycle, the amplified genomic DNA (2) was
generated in the exponential phase of the reaction; the
overamplified genomic DNA (1) was isolated from reactions
halted at the 21st cycle; number 3 denotes for the
nontemplate control.
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TABLE 1. Comparison of Copy Number Changes of Several Gene loci Obtained from Primary and Metastatic Tumour Samples
Relative to Normal Tissue by Using Non-Amplified and Different Amplified Genomic DNA as Templates. Light Gray:
Altered Relative Copy Number at Certain Chromosomal Regions in the Amplified Sample Compared to Control,
Non-Amplified Sample
Chrom.
Location
Gene Product
(Acession No.)
Type of
Melanoma
Non-Ampliﬁed
(SD)
DOP-PCR+QRT-PCR
(SD)
DOP-PCR
(SD)
Metaphase
CGH
Loss of chromosomal regions
12q14.3 Chaperonin cont. t-complex
polypept. 1b (AF026293)
Primary 0.43 (0.21) 0.27 (0.28) 2.20 (0.39)
Deletion
Metastatic 0.44 (0.12) 0.27 (0.03) 0.31 (0.31)
17p13 Human clone 23665 (U90913) Primary 0.50 (0.07) 0.39 (0.03) 0.31 (0.05)
Deletion
Metastatic 0.48 (0.01) 0.33 (0.03) 0.48 (0.07)
17p13.1 15S-lipoxygenase (U78294) Primary 0.50 (0.08) 0.50 (0.06) 1.77 (0.10)
Deletion
Metastatic 0.51 (0.02) 0.44 (0.12) 1.44 (0.00)
2p23 Anaplastic lymphoma kinase
(Ki-1) (NM_004304)
Metastatic 0.57 (0.03) 0.56 (0.28) 0.28 (0.13) Deletion
10q26.13-q26.3 Dedicator of cytokinesis 1
(NM_001380)
Primary 0.58 (0.34) 0.52 (0.06) 0.74 (0.05) Deletion
Genes with no change
2p23 Anaplastic lymphoma kinase
(Ki-1) (NM 004304)
Primary 1.11 (0.07) 0.68 (0.03) 2.77 (0.95) No change
2p25.3 Myelin transcription factor
1-like (BC071612)
Primary 1.16 (0.09) 0.50 (0.17) 0.74 (0.16) No change
Metastatic 0.06 (0.01) 0.40 (0.09) 0.54 (0.06) Deletion
10p12.1 G protein-coupled receptor
158 (AY528411)
Primary 0.87 (0.04) 0.52 (0.03) 1.47 (0.05) No change
Metastatic 0.64 (0.06) 0.59 (0.02) 1.25 (0.07) Deletion
9p23-p24.3 Prot. tyrosine phosphatase,
receptor D (NM_130392)
Primary 0.83 (0.02) 0.53 (0.22) 1.63 (0.93)
Deletion
Metastatic 0.85 (0.16) 0.58 (0.25) 0.69 (0.29)
11p15.5 p27-BWR1B (AF037066) Primary 0.89 (0.06) 0.92 (0.03) 0.90 (0.12)
No change
Metastatic 0.82 (0.31) 1.13 (0.08) 0.72 (0.06)
11q23 Apolipoprotein A-I
precursor (X02162)
Primary 0.76 (0.04) 0.86 (0.38) 0.90 (0.12)
No change
Metastatic 0.90 (0.07) 0.82 (0.32) 0.75 (0.10)
1q23 CD48 antigen (B-cell
memberane protein) (M37766)
Primary 1.07 (0.11) 0.69 (0.14) 0.48 (0.12)
No change
Metastatic 1.33 (0.18) 0.90 (0.36) 0.49 (0.14)
9q33.1 Astrotactin 2 (BC010680) Primary 1.01 (0.10) 0.49 (0.16) 0.66 (0.25)
No change
Metastatic 1.17 (0.32) 0.59 (0.65) 0.65 (0.15)
1p31 Leptin receptor (U66497) Primary 0.86 (0.01) 1.10 (0.02) 1.27 (0.23)
No change
Metastatic 0.77 (0.07) 1.03 (0.2) 0.57 (0.05)
2q35 Fibronectin 1 (X02761) Primary 1.03 (0.11) 0.99 (0.16) 0.99 (0.31)
No change
Metastatic 1.14 (0.17) 1.11 (0.06) 1.24 (1.03)
5q11.2 Integrin, alpha 2 (M28249) Primary 1.20 (0.19) 0.97 (0.16) 0.48 (0.06)
No change
Metastatic 1.18 (0.20) 0.91 (0.05) 0.35 (0.30)
7q31 Met proto-oncogene (J02958) Primary 1.05 (0.23) 0.82 (0.07) 0.87 (0.06)
No change
Metastatic 1.31 (0.04) 1.10 (0.03) 0.41 (0.06)
19q13.3 OTK18 (D50419) Primary 1.18 (0.12) 0.51 (0.02) 1.01 (0.55)
No change
Metastatic 1.03 (0.10) 0.56 (0.01) 0.44 (0.06)
14q11.2-13.1 Ribonuclease k6 precursor
gene (U64998)
Primary 1.19 (0.06) 0.80 (0.03) 1.22 (0.15)
No change
Metastatic 1.31 (0.05) 1.11 (0.06) 0.93 (0.12)
14q22.3-q23.1 Retinoblastoma-binding
protein 1 (S66427)
Primary 1.24 (0.09) 0.82 (0.01) 1.34 (0.03)
No change
Metastatic 1.43 (0.04) 1.12 (0.16) 0.99 (0.31)
14q23-24.1 RNA pol. transcriptional
regulation mediator (U78082)
Primary 1.15 (0.12) 0.17 (0.03) 1.22 (0.10)
No change
Metastatic 1.14 (0.04) 0.89 (0.06) 1.17 (0.10)
4p14 Ubiquitin carboxyl-terminal
hydrolase L1 (X04741)
Primary 0.90 (0.14) 0.35 (0.27) 0.62 (0.25)
Ampliﬁcation
Metastatic 0.98 (0.19) 0.60 (0.48) 0.80 (0.04)
16p12-13.2 Epithelial amiloride-sensitive
Na channel g (X87160)
Primary 1.23 (0.15) 1.10 (0.11) 1.17 (0.24)
No change
Metastatic 1.30 (0.07) 1.05 (0.11) 1.14 (0.10)
11q13.1-13.3 Cell cycle checkpoint control
protein (U53174)
Primary 1.03 (0.13) 0.84 (0.20) 0.67 (0.13)
No change
Metastatic 1.14 (0.13) 0.97 (0.14) 0.63 (0.03)
15q23-25 Neuromedin B precursor
(M21551)
Primary 1.35 (0.13) 1.31 (0.14) 2.27 (2.07)
No change
Metastatic 1.22 (0.10) 1.42 (0.05) 2.16 (1.91)
15q15-q21.1 Fibroblast growth factor 7
(M60828)
Primary 0.89 (0.12) 0.68 (0.11) 0.91 (0.02)
No change
Metastatic 0.82 (0.10) 1.02 (0.05) 0.48 (0.06)
16p13.3 N-methylpurine-DNA glycosylase
(M74905)
Primary 1.28 (0.04) 2.00 (0.17) 0.82 (0.11)
No change
Metastatic 1.34 (0.12) 1.73 (0.03) 0.78 (0.15)
19q13.3-4 Electron-transfer-ﬂavoprotein b
(X71129)
Primary 1.24 (0.06) 1.12 (0.10) 0.99 (0.41)
No change
Metastatic 1.11 (0.04) 0.93 (0.18) 0.45 (0.06)
1p33-34.1 Mitotic centromere-associated
kinesin (U63743)
Primary 1.05 (0.18) 0.67 (0.01) 0.50 (0.06)
No change
Metastatic 1.03 (0.11) 0.83 (0.07) 0.51 (0.02)
2q32-33 Amyotrophic lateral sclerosis
2 (AB011121)
Primary 1.10 (0.37) 1.37 (0.09) 1.41 (0.11)
No change
Metastatic 1.11 (0.22) 1.31 (0.05) 0.75 (0.24)
14q31 Galactocerebrosidase (D86181) Primary 1.46 (0.12) 0.68 (0.10) 0.50 (0.01)
No change
Metastatic 1.41 (0.04) 0.87 (0.08) 0.55 (0.08)
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metastatic tumor), and all the 88 values were compared
with each other. In case of the QRT-PCR protocol,
88.6% of the copy number changes matched to the
nonampliﬁed samples, whereas traditional DOP-PCR
resulted in only 63.6% accuracy. The correlation coeﬃ-
cient for the comparison of the nonampliﬁed and the
DOP-PCR ampliﬁed genomic DNA was only 0.27,
whereas this value was signiﬁcantly increased to 0.65
when the same protocol was used, but the ampliﬁcation
status was followed by QRT-PCR.
To demonstrate the diﬀerences in relative copy
numbers, which were obtained with diﬀerent ampliﬁcation
methods, a scatter plot was prepared (Fig. 2). In case of
our combined method, most of the genes had relative copy
numbers similar to those of the nonampliﬁed method,
whereas traditional DOP-PCR distorted the relative copy
numbers detected in the non-ampliﬁed samples.
To strengthen the extension of the preliminary
observations, a larger number of specimens were further
analyzed. Ampliﬁed samples from epidermoid, bronchio-
loalveolar lung carcinoma, 2 renal cell carcinoma, 2
colorectal carcinomas, and Conn and Cushing adenoma
samples were processed as described earlier. Copy
number changes of 8 diﬀerent chromosome regions were
followed by QRT-PCR. Nonampliﬁed and ampliﬁed
samples obtained from traditional DOP-PCR technique
and from our improved protocol were analyzed. The
results of copy number changes can be seen at http://
160.114.60.33/Data2/. In the cases of the analyzed 8
tumor samples, there was 84.4% concordance in copy
number alterations between the QRT-PCR protocol and
the nonampliﬁed samples, whereas this value was only
64% for the traditional DOP-PCR.
In conclusion, our method improved the traditional
DOP-PCR technique for whole-genome ampliﬁcation.
Improved reliability of the QRT-PCR-controlled DOP-
PCR was conﬁrmed by the analysis of 152 copy number
changes in ten tumor samples. We assume that one of the
most distorting eﬀects of the DOP-PCR technique in the
study of ampliﬁed genomic DNA is the overampliﬁcation
of the products. Overampliﬁcation has a dramatic
distorting eﬀect on the original genomic rearrangements
and can generate false result. This eﬀect can be decreased
by adding QRT-PCR to the original protocol. Because
DOP-PCR is a widely used technique and the preserva-
tion of the original genome set is especially important in
genomic studies, we propose to include QRT-PCR to
follow and control the ampliﬁcation status.
TABLE 1. (continued)
Chrom.
Location
Gene Product
(Acession No.)
Type of
Melanoma
Non-Ampliﬁed
(SD)
DOP-PCR+QRT-PCR
(SD)
DOP-PCR
(SD)
Metaphase
CGH
15q25 Image EST R78712 (R78712) Primary 1.22 (0.09) 0.76 (0.03) 0.68 (0.25)
No change
Metastatic 1.22 (0.17) 0.91 (0.03) 0.65 (0.05)
2q31.1 Recepin (U03644) Primary 0.96 (0.00) 0.60 (0.08) 0.82 (0.11)
No change
Metastatic 0.91 (0.25) 1.00 (0.00) 1.01 (0.05)
20q13.12 Image EST 364782 (AA034412) Primary 1.25 (0.11) 0.49 (0.02) 1.11 (0.34)
No change
Metastatic 1.40 (0.12) 0.50 (0.07) 1.31 (0.03)
3p12 Roundabout, axon guidance
receptor (BC057243)
Primary 1.20 (0.06) 1.31 (0.21) 0.80 (0.11) No change
Metastatic 1.13 (0.07) 0.97 (0.24) 2.89 (0.12) Ampliﬁcation
7p15 CG1 (U97198) Primary 1.14 (0.13) 0.79 (0.05) 1.71 (0.30) No change
4p14 Amyloid beta precursor prot.
binding B2
Primary 1.03 (0.11) 1.49 (0.7) 0.55 (0.11) Ampliﬁcation
3q26.31 N-acetylated a-linked acidic
dipeptidase 2 (AF04099)
Primary 1.34 (0.09) 1.05 (0.17) 1.65 (0.40) No change
Gains of chromosomal regions
7p15 CG1 (U9718) Metastatic 1.52 (0.08) 0.92 (0.00) 2.63 (0.78) No change
4p14 Amyloid beta precursor
protein-binding B2 (BC02794)
Metastatic 1.50 (0.13) 1.51 (0.08) 0.81 (0.03) Ampliﬁcation
10q26.13-q26.3 Dedicator of cytokinesis 1
(NM 001380)
Metastatic 1.52 (0.07) 0.43 (0.00) 0.86 (0.24) Deletion
3q26.31 N-acetylated a-linked acidic
dipeptidase 2 (AF 04099)
Metastatic 1.56 (0.06) 1.67 (0.18) 1.09 (0.15) Ampliﬁcation
1p36.21 Cardiodilatin-atrial natriuretic
factor (AL021155)
Primary 1.80 (0.21) 0.80 (0.04) 1.14 (0.19)
Ampliﬁcation
Metastatic 2.08 (0.20) 0.86 (0.09) 1.48 (0.02)
6p25.2 Cell death protein (RIP) (U50062) Primary 1.71 (0.05) 1.60 (0.32) 1.23 (0.16)
Ampliﬁcation
Metastatic 1.58 (0.05) 1.69 (0.31) 2.33 (0.28)
18q21.3-q22 UV-B repressed sequence,
HUR 7 (X98307)
Primary 1.56 (0.15) 1.91 (0.03) 1.74 (0.03)
No change
Metastatic 1.54 (0.12) 2.48 (0.65) 0.17 (0.38)
6p12.2 Polycystic kidney, hepatic
disease 1 (AY074797)
Primary 1.61 (0.21) 1.64 (0.17) 1.09 (0.10)
Ampliﬁcation
Metastatic 1.62 (0.21) 1.72 (0.62) 0.85 (0.07)
17q11.2-q12 Amiloride-sensitive cation
channel 1 (BC075043)
Primary 3.12 (1.10) 1.61 (0.05) 1.69 (0.22)
Ampliﬁcation
Metastatic 2.02 (0.40) 1.49 (0.12) 0.95 (0.20)
17q23 Breast carcinoma ampliﬁed
sequence 3 (BC001250)
Primary 1.69 (0.06) 1.74 (0.04) 4.23 (1.98)
Ampliﬁcation
Metastatic 2.08 (0.22) 2.14 (0.06) 0.62 (0.02)
5q21.3 F-box, leucine-rich repeat
protein 17 (BC063316)
Primary 1.75 (0.03) 1.63 (0.02) 4.77 (2.47)
Ampliﬁcation
Metastatic 2.64 (1.08) 2.46 (0.67) 1.73 (0.56)
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FIGURE 2. Scatter plot of relative copy number of genes in
primary and metastatic melanoma samples obtained with 3
different protocols. Values of copy number changes are in log2
scale. Only those genes were selected which values obtained
by the any one of protocols were above +0,58 and below 1.
The black squares and triangles mean those values which are
different from the relative copy numbers of nonamplified
samples.
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Abstract Merkel cell carcinomawas diagnosed in a 79-year-
old Caucasian woman. The tumour was localised to the upper
lip and was in stage T2. After successful cryosurgery and a 7-
year tumour-free period, a new tumour developed in her
palatine tonsil. Histologically and immunohistochemically,
this resembled the tumour in the lip. The regional lymph
nodes were devoid of metastasis. The paraffin-embedded
material of the two tumours and the unaffected lymphatic
tissue were analysed with DNA microarrays for comparative
genomic hybridisation to assess the genetic relationship of the
tumours. In both tumours, regions on 2p and 10p were
commonly over-represented, while 41 regions on chromo-
somes 1–4, 6, 8–9, 11 and 14–22 were commonly under-
represented. Chromosomes 1, 3, 4, 16–18 and X were most
frequently involved in the DNA losses. In gene copy numbers
in the two tumours, 31 chromosome locations were found to
be differently affected. The partly similar and partly different
molecular patterns indicated a genetic relationship between
the tumours and excluded the possibility that the tonsillar
tumour was a metastasis. The findings suggest that a genet-
ically altered field was the reason for the development of the
tonsillar cancer; thus, it can be regarded pathogenetically as a
second field tumour.
Keywords Merkel cell carcinoma . Second field tumour .
Comparative genomic hybridisation . DNA microarray .
Chromosome imbalances
Introduction
Merkel cells are found in the skin and in those parts of the
mucosa derived from the ectoderm [11]. These cells are the
origin of a rare, malignant neuroendocrine tumour that
occurs predominantly in the sun-exposed areas of the skin
called Merkel cell carcinoma (MCC) [1, 2, 4, 19, 20, 22,
28]. Local recurrence and regional or distant metastases gen-
erally develop within a short period of time. Oropharyngeal
metastasis is very rare, and metastasis to the palatine tonsil
has been described in only one case [27]. A perioral or in-
traoral localisation of the MCC is very infrequent: [13, 20] to
date, 10 cases of MCC of the lip [35] and 14 cases of intraoral
MCCs have been described [3, 16, 20]. During the past
decade, we treated and followed up an elderly woman with
MCC of the upper lip. After a long tumour-free period, an
anaplastic carcinomawith neuroendocrine features developed
in her palatine tonsil, raising the possibility of a late hae-
matogenous metastasis, a second field tumour or a second
primary tumour.
The term “secondary field tumour” was introduced in
1953 by Slaughter et al., who examined slides from patients
with head and neck cancer [29]. It was observed that all of
the epithelium beyond the margins of the tumours dis-
played histological alterations, and 11% of the patients
were found to have more than one independent area of
malignancy. The authors concluded that the mucosa of the
head and neck had undergone a change, perhaps due to
carcinogen exposure, and was, therefore, more susceptible
to the development of foci of malignant transformation.
Organs in which field cancerisation has been described
since then are the oral cavity, oropharynx, larynx, lung,
oesophagus, colon, skin, vulva, cervix, breast, renal pelvis,
ureter and bladder [5–7, 10].
The determination of molecular patterns of first and sec-
ond tumours has become a valuable tool to explore the
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relationship between them: similar aberrations indicate a
metastasis, partly different aberrations indicate a second
field tumour and different aberrations denote a second pri-
mary tumour [5, 6, 10]. In the present study, we identified
the molecular patterns with comparative genomic hybrid-
isation (CGH) with microarray technology. Array-based
CGH consists of a series of mapped artificial bacterial
chromosomes or sequenced cDNA clones on glass slides,
to which DNA from test and control samples is hybridised
[8, 19–21, 30]. This approach allows the determination of
copy number changes of chromosome regions without a
need for tissue cultures and the preparation of metaphase
spreads, as DNA extracted from a tumour specimen is used.
Another major advantage of CGH is that archived speci-
mens can be also studied. We applied human cDNA micro-
arrays as a tool, DNA from paraffin-embedded tumour
materials (from both the primary and secondary tumours)
as test probes and DNA from normal lymph nodes as con-
trol probes.
Previous CGH studies of MCCs have identified divergent
regions that are affected, with a small number of similarities
between the samples analysed. Recurrent chromosomal im-
balances detected using CGH analysis were loss of 3p, 4p15-
pter, 10q, 13q and 17p and gains of 1q, 3q, 5p, 6, 8q, 18 and
20 [12, 24, 33, 34]. In the present study, we detected some of
the previously found regions and also numerous novel re-
gions with chromosomal imbalances. Copy number changes
of nine chromosome regions detected by CGH were ana-
lyzed using real-time quantitative polymerase chain reaction
(QPCR). Potential oncogenes, tumour suppressor and apo-
ptotic genes mapped to regions detected as changed were
also recorded. The results suggest that a genetically altered
field was the reason for the development of the tonsillar
cancer; thus, it can be regarded pathogenetically as a second
field tumour.
Materials and methods
Case report
Between 1970 and 2003, 4418 patients with malignant
orofacial tumours were treated in our clinic. One of these
patients suffered from MCC. A 79-year-old Caucasian
woman presented with a tumour in her upper lip. She was
an outdoor worker and never smoked. She was disturbed
only about the aesthetics. The physical examination re-
vealed a 2–3-cm firm, compact mass in the skin of the
upper lip on the left side. It was sharply separated from its
surroundings and had a teleangiectatic surface (Fig. 1). The
tumour was classified as stage T2. No regional lymph-node
metastasis was detected. Surgical resection of the tumour
and removal of the regional lymph nodes were suggested,
but she refused it. As an alternate therapy, a biopsy was
taken, and cryotherapy was applied according to the stan-
dard protocol. Light microscopy revealed that the tumour
was confined to the dermis and was sharply separated from
the epidermis (Fig. 2a). The tumour cells were arranged
in nests and cords. Cytologically, the tumour cells were
monomorphic, the nuclei were round and the chromatin
pattern was finely granular and “dusty”. The nucleoli were
small; often two or even three were detected. The cytoplasm
was scanty. The mitotic rate was high (six to ten figures/
high-power field). The Grimelius staining was negative.
The results of immunostainings are shown in Table 1 and
Fig. 2. The histological and immunohistochemical features
pointed to MCC of the lip. Following the histological
diagnosis, distant metastases in the lungs and bones were
searched for, with negative results.
In the 7-year follow-up, the patient was in a tumour-free
condition. After 7 years, she was admitted to the County
Hospital with a left palatine tonsillar tumour. This tumour
was resected in part, and the regional lymph nodes were
removed. Histologically, the tumour displayed features of
anaplastic carcinoma (Fig. 3). The results of immunostain-
ings are summarised in Table 1. The histological and
immunohistochemical features pointed to MCC of the lip.
Following the histological diagnosis, distant metastases in
the lungs and bones were searched for, with negative
results.
The morphological appearance of the tumour resembled
that of the MCC of the lip. A further excision was per-
formed 3 months later. The morphological and immu-
nohistochemical features of the tonsillar tumour were
essentially the same as observed 3 months earlier. The
patient died at home on the 20th postoperative day. Au-
topsy was not performed.
Sample preparation, labelling
Paraffin-embedded tissues (200–500 mg) were deparaffin-
ised in hexane and washed with ethanol. DNAwas purified
Fig. 1 Tumourous mass sharply separated from the surroundings in
the skin of the upper lip
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by using the DNA purification kit from Macherey-Nagel
(Düren, Germany) according to the manufacturer’s instruc-
tions. First, 100 ng genomic DNA from each sample was
amplified with a modified version of the DOP (degenerate
oligonucleotide primed) PCR protocol using a real-time
PCR instrument to follow the amplification [9, 15]. Re-
actions were performed in a total volume of 100 μl. The
cycling parameters were as follows: heat start at 95°C for
4 min, 8 cycles of 94°C denaturation for 50 s, 45°C an-
nealing for 2 min to 72°C with 0.2°C/s and extension at
72°C for 90 s. After the 8 cycles, the reaction mix was
separated into two 50-μl portions, and SybrGreen was
added to the mix (1× final concentration, Molecular
Table 1 Immunohistochemical findings
Immunohistochemical markers Lip tumour Tonsillar tumour
AE1/AE3 +++ +++
Cytokeratin 20 20
Paranuclear dots +++ ++
Chromogranin ++ +
Synaptophysin – –
TTF – –
HMB–45 – –
CEA – –
Lymphoid markers – –
Fig. 2 Merkel cell carcinoma
of the lip. A Small, monomor-
phic tumour cells fill the dermis
arranged in nests and cords. The
nuclei exhibit moulding. Hae-
matoxylin-eosin ×200. B Chro-
mogranin positivity of tumour
cells ×400. C Paranuclear dots
by cytokeratin-20 staining ×400
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Probes, Eugene, USA). The following cycling protocol was
performed in a real-time PCR instrument, RotorGene 2000
(RotorGene, Sydney, Australia): denaturation at 95°C for
40 s, annealing at 58°C for 1 min and extension at 72°C for
80 s. The cycling was performed just before the reaction
reached the plateau to avoid over-amplification of the
products (usually in 18–22 cycles). The PCR products were
purified on PCR-purification columns (Bioneer, Daejeon,
Korea). Next, 100 ng purified DNA was labelled with
another round of PCR in the presence of Cy3-dUCTP (0.05
mM) in a total volume of 50 μl with the same parameters
for 20 cycles as in the second PCR. In all these reactions,
UN primer (5′-CCGACTCGAGNNNNNNATGTGG-3′)
was used in a 1-μM concentration [31]. The reactions
were performed with ExTaq DNA polymerase in 1× buffer
(Takara, Tokyo, Japan). The labelled PCR products were
purified with the PCR purification kit (Bioneer). The eluted
DNA was dried in a Speed-Vacuum.
Hybridisation, scanning, data processing
The labelled DNA was reconstituted in ChipHyb hybrid-
isation buffer (Ventana Discovery, Tuchon, USA) contain-
ing 20 μg human Cot DNA and 5 μg salmon sperm DNA
(Invitrogen). Hybridisation was performed on human
cDNA microarrays having 3200 gene-specific samples in
duplicate in 200 μl using the Ventana hybridisation station
(Ventana) at 42°C for 8 h [25, 26]. After hybridisation, the
slides were washed twice in 0.2×sodium saline citrate at
room temperature for 10 min and then dried. Scanning and
data analysis were performed as described previously [21].
Briefly, data presented in this study were calculated from
the results of four data points obtained from two separate
labelling and hybridisation protocols. The background-
corrected intensity data was filtered for flagged spots and
weak signal. Technical replicates on the same array were
averaged. Data were excluded in cases where technical
replicates were significantly different. Normalisation was
Fig. 3 A Anaplastic carcinoma
of the tonsil. Hematoxylin-eosin
×200. B Chromogranin positiv-
ity in the tumour cells ×400. C
Some tumour cells display
paranuclear dots by cytokeratin-
20 staining ×400
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performed using the print-tip LOWESS method [36]. Next,
we used the one-sample t-test to determine the genes to be
regarded as changed in copy number. Logarithm was taken
from each ratio to fulfil the t-test’s requirement for a normal
distribution. Genes for which the mean of log-ratios across
the biological replicates was equal to zero at a significance
level α=0.05 were considered to have an unchanged copy
number. However, genes with a P value smaller than α and
where the average-fold change (over- or under-representa-
tion) of the four data points were at least twofold were
considered as changes in DNA copy number.
Real-time QPCR
The confirmatory real-time QPCR was performed on a
RotorGene 2000 instrument with gene-specific primers and
the SybrGreen protocol on non-amplified genomic DNA.
Reactions were performed in a total volume of 20 μl (50 ng
genomic DNA from each sample, 5 pmol/each forward and
reverse primer, 1× BioRad SYBRGreen buffer, BioRad,
Hungary) with the following protocol: denaturation for 10
min at 95°C, and 45 cycles of 25 s denaturation at 95°C, 25
s annealing at 59°C and 25 s extension at 72°C. Fluorescent
signals were collected after each extension step at 72°C.
Curves were analysed with the RotorGene software, using
dynamic tube and slope correction methods, ignoring data
from cycles close to baseline. Primers were designed by
using the ArrayExpress software (Applied Biosystems).
Relative ratios were normalised to the Ct values obtained
with the dihydrofolate reductase gene probe and calculated
with the Pfaffl method [23]. The PCR primers used in this
study are listed in Table 2. All the PCRs were performed
four times in separate runs.
Results
CGH analysis
We analysed the primary MCC and the tumour of the tonsil,
applying CGH with DNA from paraffin-embedded tumour
material as the probes. Relative DNA losses and gains were
determined for each tumour sample by normalising the
intensities to the values obtained after hybridisation with
labelled probes from normal lymphoid tissue.
Using microarray-based CGH, numerous changes in
chromosome copy numbers were observed in both tumours
investigated. Both tumours showed complex DNA copy
number changes, with an abundance of DNA losses and a
few DNA gains. Of the regions, 41 were detected with a
DNA loss and 4 regions with a DNA gain (Table 3). CGH
revealed regions on 2p and 10p to be commonly over-
represented and regions on 1p, 1q, 2p, 2q, 3p, 3q, 4q, 5q,
6p, 6q, 7q, 8p, 9p, 9q, 11p, 11q, 12q, 14q, 15q, 16p, 16q,
17p, 17q, 18q, 19p, 20p, 21q, 22q and X to be commonly
under-represented. Chromosomes 1, 2, 3, 17 and 18 were
most frequently involved in the DNA losses. According to
the intensity ratios, monosomy of the X chromosome is
postulated. Besides the commonly affected regions, 31 addi-
tional chromosome locations were found to be differently
affected in gene copy numbers in the two tumours. Common,
primaryMCC-specificandsecondarytumour-specificchanges
are listed in Table 3.While 22 regions could be observed with
the secondary tonsil cancer-specific DNA loss, only 6 regions
were specifically under-represented in the case of the primary
MCC. All other DNA losses were common in both tumours.
Only2 regions, 2p23and10p15, exhibitedcommongains, and
3regions,2p25,12q12and15q14,showedover-representation
in the case ofMCC.
Potential oncogenes and tumour suppressor and apo-
ptotic genes mapped to regions detected as changed were
Table 2 Sequences of the oligonucleotides (5′-3′) used in this study
Gene Chromosome
location
Forward primer Reverse primer Product
size (bp)
Steroid 5-alpha-reductase 2 2p23 CAGAAGCCCCAAGCAACTTT CCTTCTTGAACAGGTCCTGAGAA 69
Hepatocyte nuclear
factor-3 alpha
14q12-q13 CTCAAGAGTTGCTTGACCGAAA GGGCCATCTGTGGGTAGAGA 67
Zinc finger protein 19q13.43 GAAATTTCCCTGCCAGACCTT CATGAAGCCCCACTCTGAGAGT 73
Androgen receptor
(dihydro-testosterone receptor)
Xq12 CGGAAATGATGGCAGAGATCA TGGGCTTGACTTTCCCAGAA 66
C8FW phosphoprotein 8q24.13 GGACGATACCCCTTCCATGA GTCCACGCCGAATTTTGG 61
Cardiac myosin binding
protein-C
11p11.2 GCCTAAATCCGAGCATCTGTTT TGCACTCTCAGGGAATTTGAGA 70
EST 15q14 CCTGATTCCAGAAAAGCAAGTGT CACTGAGATTACCGGGCATGA 76
Cytochrome P450,
subfamily XIA
15q22 CTGGTGCAAGTGGCCATCTA AATTTTCCGGGTCGAAGAAGA 64
EST similar to
phosphatidylcholin
transfer protein
17q23 CACAAGGCTATGCACAAAGCA GGAAACTGAGGCGTCAAGATG 68
Dihydrofolate reductase 5q14 CTGTCATGGTTGGTTCGCTAAA TGCCGATGCCCATGTTC 60
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also analysed. The genes mapped to regions that were
changed in both tumour samples are listed in Table 4,
while changes characteristic of only one tumour are pre-
sented in Table 5.
Confirmation of CGH data
The copy number changes of several chromosome regions
detected using CGH were submitted for QPCR analysis.
Specific primers were designed (Table 2) and used to
amplify affected DNA regions of the genome using non-
amplified genomic DNA as template. Relative ratios were
normalised to the copy numbers of the dihydrofolate reduc-
tase gene, because this did not show any alteration in copy
number in either tumour and gave reproducible results in all
cases. Nine regions exhibiting DNA losses or gains in both
tumours were selected for QPCR. In seven cases, the com-
mon alterations were confirmed, while in two cases, only
MCC-specific changes could be detected (Table 6).
Discussion
MCCs are highly divergent when analysed for chromosome
aberrations [12, 24, 34]. Reported recurrent chromosomal
imbalances detected using CGH analysis were loss of 3p,
10q, 13q and 17p and gains of 1q, 3q, 5p and 8q [34]. In the
present study, we could also detect the loss of 3p and 17p,
but none of the above-mentioned amplified regions could
be confirmed (Table 3, Fig. 4). In another study, only 3 of
the 10 MCCs exhibited common gains and losses, and they
shared a gain of 8q21-q22 and a loss of 4p15-pter [24]. In
the present study, the 4p16 region was also found to be
deleted in both the primary and secondary tumours.
Unfortunately, to date, no known tumour suppressor gene
has been mapped to this region (Table 4). Speleman’s group
detected losses involving the entire chromosome 10 or
Table 3 Common and individual gains and losses of Merkel cell
carcinoma and the tonsillar tumour detected using comparative
genomic hybridization
Deletion Amplification
Both tumours 1p36, 1p31, 1p13, 1q21–23, 1q32,
1q42.13, 2p13, 2p11.2,
2q35, 3p21, 3q13.2, 3q14.3, 3q26–
28, 4p16, 4q21, 5q35,
6p21, 6q24, 7q21, 8p21, 8q24, 9p12,
9q34, 11p11.2, 11q13,
11q23.3, 12q24.1, 14q11.2, 15q23–
24, 16p13–12, 16q24,
17p13, 17q12, 17q23, 18q12, 18q21,
19p13, 20p13, 21q22,
22q13.1, X monosomy
2p23, 10p15
Merkel cell
carcinoma
11p11.2, 11q12.3, 12q13, 16p13.1,
17q21.1, 17q25
2p25, 12q12,
15q14
Mesopharynx 1p34.1–32.2, 1p21–22, 1q42, 2q37,
4p16.3, 4q28.3, 5q11.1,
5q22, 5q31–32, 7p14, 8p22–24.13,
10q21.1, 11pter-p15.5,
12q14.3, 14q11.2, 14q31–32, 15q11–
13, 16q23–24, 17q21.3-q23,
20q13.1, 21q22.13, 22q11
–
Table 4 Apoptotic genes and tumour suppressors mapped to
regions with common chromosomal aberrations. Apoptotic and
tumour suppressor genes in bold character. Apoptotic and tumour
suppressor-related genes in italics in brackets
Chromosome
location
Apoptotic genes Tumour suppressors
In both
tumours
1p36 DFFB, TP73, CASP9
(CDC42, MFN2)
UBE4B, TUSC3, PRDM 2,
C1orf1, ALPL (E2F2,
TP73)
1p31 – CLCA2
1p13 – ST7L
1q21–23 MCL1, DAP3,
TNFSF6 (MUC1,
APCS, CRP, SELL)
2p13 MAD
3p21.3 (CCR3) RASSF1, BAP1 (SEMA3B)
3q26–28 (ETV5, OPA1) TSBF1
4p16 (GAK)
4q21 (SNCA)
5q35 (PDLIM7)
6p21 BAK1, TNF (HSPA) (CDKN1A)
6q24 SASH1 (PLAGL1)
8p21 BNIP3 (CLU) PDGFRL (CNOT7,
PDLIM2)
8q24 (RNF139)
9q34 TRAF2 (ABL1)
11p11.2 (MADD)
11q13 DPF2, BAD, FADD
(RELA, CCND1,
RAD9A)
DOC-1R, MEN1 (ST3,
CCND1, SHANK2)
11q23.3 THY1
12q24.1 (SCA2)
16p13–12 ASC TSC2
16q24 WFDC1, GAS8,
MGC15419, CBFA2T3
17p13 TP53, HIC1, OVCA2,
DPH2L1
17q12 (CCR7) (MPP3)
18q21 (BCL2) DCC, SERPINB5 (E2F5)
19p13 DIRAS1 (TJP3, SMARCA4,
GIPC3)
21q22 (MX1)
22q13.1 (HMOX1) ST13
Xp22.1 (SH3KBP1)
Xq12 ING2
Xq28 RPL10
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partial loss of the chromosome 10 long arm in one-third of
the MCC cases they analysed with a possible loss of
heterozygosity of 10q23, including the PTEN tumour-
suppressor gene [33]. In our case, deletion of this region
was not observed in either tumour sample.
In previous observations, series of MCCs showed no
evidence of high-level amplification [34]. Recurrent gains
of chromosomes 1, 6, 18q and 20 were detected in 2 cases
[12]. In our case, only two regions, 2p and 10p were com-
monly over-represented. In a very recent study, 19 primary
MCCs were analysed by CGH, and, in 13 samples, ex-
tensive gains and losses were detected [17]. It was shown
that a majority of the alterations were gains, while only a
few common losses were detected, mainly in regions 4q,
13q and 16q. Neither of our gains was found in any of the
19 cases they analysed. Most of the losses were detected in
at least 1 case reported in the above-mentioned study, but
the 13 MCCs exhibited a very heterogeneous pattern, with
diverse regions with losses.
Our CGH results revealed several new and a few other
previously known chromosomal regions that have been
presumed to be involved in the pathogenesis of MCC. We
found 2 common gains and 41 common losses in the two
samples. However, in 31 chromosome locations, we ob-
served differences in gene copy numbers between the two
tumours. From the results obtained by CGH analysis, we
believe that the mesopharynx cancer and the MCC of the
lip derived from the same, genetically altered field; thus,
the mesopharynx cancer can be regarded as a second field
tumour. From the results obtained using CGH analysis, we
hypothesise that Merkel cells in two adjacent anatomical
sites, i.e. in the lip and mesopharynx, underwent same
precancerous genetic alteration, and both tumours arose
from a common cell clone. If our hypothesis is correct, the
mesopharynx cancer can be regarded as a second field
tumour.
Several oncogenes and tumour-suppressor and apoptotic
genes were assumed to be changed in their copy number, as
many of them were mapped to the regions having changes
in their copy number in one or both of the tumours (Table 4
and Table 5). The limitation of this list is that, in these
cases, the deletions of the genes themselves were not
proved in this study; only those regions were determined
that were located to certain regions or proximity to regions
where DNA segments on the microarrays originated.
The microarray-based CGH techniques used in this study
could result in distorted data, especially when paraffin-
embedded tissue is the target. Another limitation of this
study is that the deleted regions were determined using
hybridisations based on complementary cDNA—genomic
DNA annealing events, which could generate more biases.
In consequence of the above problems, we determined the
reliability of the results obtained by the CGH microarray
using real-time QPCR. Ten genes were selected to follow
Table 5 Apoptotic genes and tumour suppressors mapped to regions
with chromosomal aberrations specific to Merkel cell carcinoma or
tonsillar tumour. Apoptotic and tumour suppressor genes in bold
character. Apoptotic and tumour suppressor related genes in italics in
brackets
Chromosome
location
Apoptotic genes Tumour
suppressors
In Merkel cell carcinoma
11p11.2 (MADD)
12q13 (CDK2, KRT18, NR4A1,
WNT1)
17q25 BIRC5
In mesopharynx
1p34.1–32.2 FABP3
3p22–21 ADPRTL3
5q11.1 (LOC145908)
5q22 MCC
5q31–32 C5orf7
10q21.1 (CDC2)
11pter-p15.5 (CTSD, HRAS) MRVI1
14q31–32 SIVA
16q23–24 (LOC145908) CBFA2T3
21q22.13 RUNX1
22q11 BID MYO18B
Table 6 Confirmation of comparative genomic hybridisation data using quantitative real-time polymerase chain reaction (QPCR). Only
two common losses could not be confirmed. Gains are indicated as grey background
Microarray data confirmed using
QPCR
Clone name Accession
no.
Chromosome
location
Distance
Both tumours Steroid 5-alpha-reductase 2 (SRD5A2) M74047 2p23 31724
Hepatocyte nuclear factor-3 alpha U39840 14q12-q13 36052
Zinc finger protein AF020591 19q13.43 63450
Androgen receptor (dihydrotestosterone receptor) M23263 Xq12 63075
C8FW phosphoprotein AJ000480 8q24.13 126404
ESTs, Highly similar to Phosohatidylcholine transfer
protein
AA933627 17q23 54340
Cytochrome P450, subfamily XIA M14565 15q23–24 70670
Merkel cell carcinoma EST N22765 15q14 no data
Cardiac myosin binding protein-C U91629 11p11.2 49310
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the copy number changes by QPCR. Of the ten genes, one
exhibited no changes in the copy number found using CGH
microarray analysis in all cases: the dihydrofolate reductase
gene. Therefore, it was used as an internal control. The
copy numbers of all the other nine genes (sequences and
chromosome locations are listed in Table 2, accession
numbers are listed in Table 6) were related to this inner
control. We used DNA purified from normal lymphoid
tissue as control and determined copy number changes of
the other two tumours (Table 3, Fig. 4). We confirmed the
deletions in seven cases for both tumours, and two were
confirmed for only MCC. Although the number of the
confirmatory real-time QPCRs was limited and, therefore,
does not allow determine the reliability of the CGH
methods, the main purpose of the study was to determine
the relation of the two tumours, not a precise determination
of the deleted regions.
In summary, the partly different molecular patterns
obtained using CGH, the similar histological features and
the close proximity to the primary tumour indicate that the
tonsillar cancer was a second field tumour. The common
origin was further confirmed, because of three early markers
(9p, 3p and 17p) two of them (9p and 17p) were common in
both cancer samples, one (17p) bearing the tp53 tumour
suppressor marker gene. The common copy number changes
do not support the possibility that the tonsillar cancer was a
second primary tumour. The tonsils are very rare and un-
usual sites of metastatic disease in MCC. There are three
reports in the literature describing oropharyngeal metastasis
of a MCC [18, 27, 31]. In all these reports, the metastasis
occurred within 24 months after resection of the primary
tumour. In our case, it was clinically very unlikely that the
tonsillar tumour was a metastasis of the MCC of the lip,
because no local recurrence, regional lymph-node metastasis
or distant haematogenous metastases were observed in the
7-year follow-up. In harmony with the clinical situation,
the molecular patterns of the two tumours were not similar,
therefore, the possibility of a metastasis could be rejected.
Although the concept of second primary tumours and field
cancerisation has been formulated for oral and oropharyn-
geal squamous cell carcinomas [5], our results indicate that
Merkel cells in adjacent anatomic sites may also be the
targets of field cancerisation.
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Parallel expression of aIIbb3 and avb3 integrins in human melanoma cells
upregulates bFGF expression and promotes their angiogenic phenotype
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Previous studies indicated that transfection of the platelet integrin
aIIbb3 into human melanoma cells expressing integrin avb3 pro-
moted their in vivo (but not in vitro) growth and cell survival. To
reveal the underlying pathomechanism, we have analyzed the
angiogenic phenotype of aIIbb3 integrin-transduced human mela-
noma cells expressing integrin avb3. Upon heterotopic or ortho-
topic (intracutaneous) injections into SCID mice, the aIIbb3
integrin-overexpressing clones, ESL, ESH, 19L and 19H, grew
more rapidly than the mock transfectant (avb3 expressing) clone,
3.1P. Morphometry demonstrated an increased intratumoral
microvessel density in 19L and 19H tumors compared to 3.1P.
Immunocytochemistry and ﬂow cytometry indicated that vascular
endothelial growth factor (VEGF) is constitutively expressed in
the majority of the cells of both the mock and the aIIbb3 integrin-
transfected clones. However, the mock transfectant clone, 3.1P,
did not express basic ﬁbroblast growth factor (bFGF) at protein
level (<1%), unlike the aIIbb3 integrin-transfected clones, 19L
and 19H, (33.9 and 84.1%, respectively). Quantitative PCR analy-
sis of 6 related human melanoma clones with various levels of
aIIbb3 integrin expressions revealed a correlation between the
aIIb protein and bFGF mRNA expressions. Furthermore, cDNA
microarray analysis of the 19H cells revealed 12 downregulated
and 36 upregulated genes [among them 3 upregulated vasculo-
genic mimicry-genes (CD34, endothelin receptor B, Prostaglandin
I-2 synthase)] when compared to 3.1P cells. The altered bFGF
expression may be inﬂuenced by integrin-linked signaling, since
b3-endonexin is upregulated in aIIbb3-transfected cells and tyro-
sine kinase inhibitors downregulate bFGF both at mRNA and pro-
tein levels. We propose here that the illegitimate expression of
aIIbb3 integrin in human melanoma cells already expressing
avb3 integrin may alter their in vivo growth properties due to the
modulation of their angiogenic phenotype.
' 2005 Wiley-Liss, Inc.
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Progression of human melanoma is a highly efﬁcient process
compared to other malignant tumors since a few millimeters thick
tumor (a very small primary in the case of other malignancies) can
colonize regional lymph nodes or visceral organs. It is therefore
extremely important to understand the molecular mechanisms
behind this highly aggressive behavior. Previous studies indicated
that the autocrine growth regulation of melanoma acquired at the
switch from a less invasive radial to a more invasive vertical
growth phase involves bFGF expression.1,2 On the other hand,
overexpression of v3 integrin is also associated with the inva-
sive growth3,4 and metastasis5,6 of melanoma. IIb3 integrin
(GpIIbIIIa) is the predominant adhesion receptor of platelets and
the expression of the integrin IIb chain is megakariocyte-spe-
ciﬁc. It is involved primarily in platelet activation, since it is
expressed in a low afﬁnity state and binds ﬁbrinogen only upon
activation. We have previously shown the illegitimate expression
of IIb3 integrin in human melanoma,7,8 involved in the same
phases of tumor progression as v3. Recently we found that the
transduction of IIb3 into v3-expressing human melanoma
cells did not affect the in vitro but promoted the in vivo growth of
tumor cells due to decreased apoptosis.8 We have postulated that
one possible factor behind the increased in vivo growth is vascula-
rization. Therefore, we have analyzed the gene expression changes
of IIb3-transfected human melanoma clones with special atten-
tion to their angiogenic phenotype.
Material and methods
Human melanoma cells
The WM983B cell line that does not express IIb3 on the cell
surface was a kind gift of M. Herlyn (The Wistar Institute, Phila-
delphia, PA). Mock transfected WM983B cells (3.1P) and IIb
and 3 transfected WM983B cells (19L and 19H) have been
described earlier.8 New IIb and 3 transfected WM983B cell
clones, ESL and ESH, have been isolated as described before.8
19H transfected cell line was subcloned by limited dilution to
obtain 7D7 and 8F3 subclones. The parental cell line was grown
in RPMI-1640 medium supplemented with 5% FBS and antibiot-
ics (Sigma Chemical Co., St. Louis, MO) in a 5% CO2 humidiﬁed
atmosphere at 378C. Transfected cells were maintained in medium
containing G418 (Gibco BRL, Gaithersburg, MD).
Tumor growth in SCID mice: Orthotopic growth
Five SCID mice/group were anaesthetized by intraperitoneal
administration of Nembutal (70 mg/kg), the thighs of the animals
were shaved and 105 tumor cells in 5 l Hank’s balanced salt solu-
tion (HBSS) were inoculated intradermally, under a dissecting
microscope by using a precision syringe (diameter of 0.15 mm,
Hamilton). Volume measurements of palpable tumors were made
on day 10 and 13 by using a precision dermatometer (length 
width2  p/6).
Lung colonization
Tumor cells (106/200 l) were injected into the tail vein of
SCID mice and after 60 days mice were terminated by Nembutal
overdose and lungs were isolated, ﬁxed and surface colonies were
counted under a stereomicroscope.
Liver colonization
Tumor cells (106/200 l) were injected into the spleen of SCID
mice and after 30 days mice were terminated by Nembutal over-
dose and the liver was isolated, ﬁxed and surface colonies were
counted under a stereomicroscope.
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Intracardiac injection
Tumor cells (106/200 l) were injected into the left cardiac ven-
tricle of SCID mice under anesthesia and after 60 days mice were
terminated by Nembutal overdose and visceral organs (lung, liver
and brain as well as bones of the lower extremities) were isolated,
ﬁxed and surface colonies (visible colonies in case of bones) were
counted under a stereomicroscope. To conﬁrm metastases, speci-
mens were embedded into parafﬁn and H&E stained sections were
also analyzed microscopically.
Immunohistochemistry
On day 13, 3 tumors of each group were removed and frozen in
isopentane cooled in liquid nitrogen. Five micrometer frozen sec-
tions were ﬁxed in methanol (10 min, 208C), blocked in 0.1%
bovine serum albumin (BSA) and immunostained with a rat mono-
clonal antibody against mouse CD31 (60 min, 378C, 1:100 dilu-
tion, Pharmingen, San Diego, CA), a goat anti-human VEGF
antibody (60 min, 378C, 10 (g/ml), (R&D Systems, Wiesbaden-
FIGURE 2 – Microvascular density of the primary tumors of trans-
fected human melanoma clones. (a,b) Immunohistochemistry of
intratumoral vessels in primary tumors of human melanoma clones
(confocal microscopy). Cryosections of 13-day-old tumors have been
labeled for microvessels using a rat monoclonal anti-CD31 antibody
and a rabbit anti-rat-FITC conjugate. (a) ¼ 3.1P (mock transfected
clone); (b) ¼19H (IIb3-transfected high expressor). (c) Morphom-
teric determination of microvascular density of the primary tumors
of transfected human melanoma clones. Vessels identiﬁed by immu-
nohistochemistry (as in a,b) were counted on 5 different 200x ﬁelds
of 3 parallel specimens. Data are expressed as mean 6 SEM (n ¼
15). *p < 0.01 compared to 3.1P, determined by ANOVA single
factor analysis.
FIGURE 1 – Growth of melanoma clones in SCID mice. (a) 106
tumor cells were injected into the spleen of SCID mice and the size of
the primary was determined on the 30th day when animals were termi-
nated by Nembutal overdose. Data are expressed in g (mean 6 SD,
n ¼ 5). *p < 0.05. (b) One hundred thousand tumor cells were
injected intradermally into the animals, tumor diameters were meas-
ured and the tumor volume was calculated on the 10th and 13th post-
injection days as described. Data are expressed in mm3 (means 6
SEM, n ¼ 5). *p < 0.05, **p < 0.001.
TABLE II – INCIDENCE OF METASTASIS IN VARIOUS ORGANS OF 3
INTEGRIN TRANSFECTED HUMAN MELANOMA CLONES1
Lung (i.v.) Liver (i.s.) Brain (i.c.) Bone (i.c.)
clone
3.1P 100 100 100 83
ESL 83 100 50 80
ESH 100 100 75 75
19L 86 100 60 40
19H 100 80 100 75
1Tumor cells (106/animals) have been injected i.v. for lung colony
assay, intrasplenically for liver colonization and intracardially for
brain and bone colonization. Experiments have been terminated fol-
lowing various periods as described in Materials and Methods, and
macroscopic colonies have been caunted under stereo microscope.
Each group contained at least 5 SCID mice. Data are incidence of
metastatic colonies expressed in % of animals.
TABLE I – SURFACE 3 INTEGRIN EXPRESSION IN HUMAN MELANOMA
CLONES (FLOW CYTOMETRY)1
Clone IIb 3 v3
3.1 mock 0.66 6 0.7 80.0 6 3.2 44.0
ESL 6.7 6 3.4 64.0 6 3.0 31.0
8F3 8.0 79.0 nd
19L 12.3 6 4.9 67.0 6 5.6 10.5
ESH 22.5 6 7.7 69.3 6 2.3 13.0
19H 27.2 6 3.9 78.0 6 6.2 28.4
1Data are in % of positive cells (IIb and 3: mean 6 SEM, n ¼
3–6, v3: average of 2 samples), nd ¼ not determined.
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Nordenstadt, Germany) or a goat anti-human bFGF antibody
(60 min, 378C, 10 (g/ml), (R&D Systems). FITC-conjugated rabbit
anti-rat and anti-goat IgG antibodies (45 min, 378C, 1:50, Jackson
Immunoresearch Lab, Inc., West Grove, PA) were used as secondary
antibodies. Following nuclear staining with 5 M TOTO-3 in PBS
(20 min, 208C, Molecular Probes, Inc.) slides were mounted and
viewed by confocal laser scanning microscopy (Bio-Rad MRC
1024, Munich, Germany). Counts of intratumoral blood vessels
FIGURE 3 – Immunocytochemical expression of angiogenic cytokines in transfected human melanoma clones (ﬂow cytometry). 106 cells
from each studied clone were ﬁxed in MetOH and labeled with anti-VEGF or anti-bFGF antibodies. The speciﬁcally bound primary antibod-
ies were detected by an appropriate FITC-labeled secondary antibody. As negative control, isotype-matched nonimmune IgG was used
instead of the primary. At each experimental point a minimum of 104 cells were measured for ﬂuorescence and expressed on logarithmic
scale. (a) Original printouts: 1–4 ¼ bFGF expression, 5–8 ¼ VEGF expression. 1,5 ¼ negative control, 2,6 ¼ 3.1P mock transfected clone,
3,7 ¼ 19L IIb3-transfected low expressor clone and 4,8 ¼ 19H IIb3-transfected high expressor clone. (b) Graphical visualization of
VEGF and bFGF protein expression in human melanoma clones as determined by ﬂow cytometry. Data are expressed in % of positive cells.
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were determined visually by ﬂuorescence microscopy in 200
ﬁelds within the entire tumor mass.
Flow cytometry
For immunoﬂuorescence labeling suspended cells were ﬁxed
with 1% buffered paraformaldehyde (PFA) for 15 min at room
temperature permeabilized with 0.2% saponin for 10 min. Nonspe-
ciﬁc antibody binding was blocked using PBS containing 1%
BSA. The following mouse monoclonal antibodies were used:
50 g/ml of anti-CD41 (anti-IIb), anti-CD61 (anti-3) (both
from Dako, Glostrup, Denmark) and 12.5 g/ml of anti-v3
complex (Chemicon, Hofheim, Germany). Cells incubated with
the appropriate isotype control IgG were used as negative controls.
The bound primaries were detected with a biotinylated anti-mouse
Ig (1:100; Vector Laboratories, Inc., Burlingame, CA) followed by
Streptavidin-FITC (1:100; Amersham, Little Chalfont, England).
To detect the expression of pro-angiogenic molecules, 106 tumor
cells/sample were ﬁxed in methanol (10 min, 208C) incubated
with goat anti-human VEGF antibody (60 min, 208C, 10 g/ml,
R&D Systems) or goat anti-human bFGF antibody (60 min, 208C,
10 (g/ml), (R&D Systems) revealed by a FITC-conjugated sec-
ondary anti-goat antibody (Jackson ImmunoResearc Labs, West
Grove, PA).
The percentage of positive cells was determined by a FACStar
ﬂow cytometer (Becton Dickinson, Sunnyvale, CA). Cells were
considered positive when the ﬂuorescence intensity was above that
of 95% of the control cells labeled without the primary.
Inhibition of signal transduction in vitro
To inhibit protein kinase C activity, in vitro cultured tumor cells
were pretreated with Calphostin C (Kamiya Biomedical Co.,
Thousand Oaks, CA) for 25 hr at a concentration of 5 M using
light activation. For the downregulation of PKC, we have exposed
tumor cells to 8 ng/ml PMA (phosbol-12-myristate-13-acetate;
Sigma Chemical Co.) for the same period of time. To inhibit pro-
tein tyrosine kinases, tumor cell cultures were pretreated with
Genistein or Staurosporine (Calbiochem) for 25 hr at a concentra-
tion of 100 g/ml.
Quantitative PCR
Total RNA were extracted from the cells growing in cell culture
using Tri-Reagent (Sigma Aldrich Co, Pool Dorset, UK) accord-
ing to the manufacturer’s protocol. Purity of the nucleic acid tem-
plates was elevated by extra-puriﬁcation with DNA-freeTM
(Ambion, Austin TX). One microgram of total RNA were reverse
transcribed from each sample using deoxy (d)-NTPs (0.5 mmol/L
each), random primer (ﬁnal concentration 3 M), RNasin1 ribo-
nuclease inhibitor (Promega) (0.4 U/l), DTT (ﬁnal concentration
10 mM), reverse transcriptase buffer (containing 250 mM Tris-
HCl, pH 8.3, 375 mM KCl and 15 mM MgCl2) and M-MLV
reverse transcriptase (200 U/reaction; Sigma Chemical Co.).
Twenty l samples were incubated for 50 min at 378C and then at
858C for 10 min. The sequences of bFGF primers were the follow-
ing: 50-GCC ACA TCT AAT CTC ATT TCA CA-30 and 50-CTG
GGT AAC AGC AGA TGC AA-30. The sequences of endothelin
receptor type B primers were 50-GCT CTT AAC AAC TTC CAG
GAT ATT C-30 and 50- CAA CAA CTA AAC TGC TCT CTC
ATT T-30. The sequences of (3-endonexin primers were 50-CAC
TGA AGT TGG ATG GTC TGT TA-30 and 50-TTC ATT TGA
TAG TCC ATT TCT GTG C-30. (The primers were designed for
the 111 amino acid coding sequence of the 3-endonexin cDNA,
which is common in the 3 different splice isoforms of the 3-
endonexin).
The real-time PCR analysis for mRNA expression of bFGF,
CD34, endothelin receptor typeB, prostacyclin synthase and 3-
endonexin standardized by coamplifying these genes with the
housekeeping gene -actin (primers: 50-GTG GGG CGC CCC
AGG CAC CCA-30 and 50-GTC CTT AAT GTC ACG CAC GAT
TTC-30). The real-time PCR reaction was run on the iCycler iQTM
(Bio-Rad) using standard conditions, namely, optimized concen-
tration of primers (ﬁnal concentration 200 nM), IQTMSYBR1
Green Supermix (containing 100 mM KCL, 40 mM Tris-HCL, pH
8.4, 0.4 nM of each dNTP, 6 mM MgCl2, 50 U/ml iTaq DNA poli-
merase, SYBR Green I and 20 nM ﬂuorescein) and 2 l cDNA. A
no template control (containing water) was used as negative con-
trol for every different primer-pair. The cycling parameters of the
bFGF real-time PCR analysis were 958C (3 min), 40 cycles of
958C (30 sec), 618C (30 sec) and 728C (1 min). The cycling
parameters of the 3-endonexin real-time PCR analysis were
958C (3 min), 40 cycles of 958C (30 sec), 608C (30 sec) and 728C
(1 min). The starting quantity of gene expression in the sample
was determined by comparison of unknown to a standard curve
generated from a dilution series of template DNA of known con-
centration. CT values were converted into relative concentration
values by scaling from 1 to 1 between the expression control and
the highest value of the samples using the autothreshold ﬁt.
Construction of microarrays
Construction and use of microarrays were performed as previ-
ously described.9,10 Brieﬂy, 3,200 cDNA inserts from human
cDNA libraries (melanoma, lymphocytes, heart and mixed tissue
libraries) were ampliﬁed and puriﬁed with MultiScreen-PCR plate
(Millipore), resuspended in 50% dimethylsulfoxide/water and
arrayed on FMB cDNA slides (Full Moon BioSystems, Sunnyvale,
CA) by using a MicroGrid Total Array System (BioRobotics, Cam-
bridge, UK) spotter with 16 pins in a 4  4 format. DNA elements
were deposited in duplicate. The diameter of each spot was approxi-
mately 200 m. After printing, DNA was UV crosslinked to the
slides (Stratagene, Stratalinker, 700 mJ). Postprocessing and block-
ing of the microarrays were performed as described previously.11
Microarray probe preparation and hybridization
RNA isolation from 5  106 cells was carried out with the RNA
isolation kit of Macherey-Nagel (Macherey-Nagel, Du¨ren, Ger-
many) according the manufacturer’s instruction. RNA was eluted
from the silica membrane and stored at 808C in the presence 30 U
of Prime RNAse inhibitor (Fermentas, Vilnius, Lithuania). The
quality and quantity of isolated RNA was checked by electrophore-
sis and spectrophotometry (NanoDrop, Rockland, DE) respectively.
For probe preparation, 4 g of total RNA was reverse tran-
scribed using poly-dT primed Genisphere Expression Array 350
Detection system (Genisphrere, Hatﬁeld, PA) in 20 l total vol-
ume using 20 Unit RNAsin (Fermentas), 1 ﬁrst strand buffer and
200 Units of RNAse H () point mutant M-MLV reverse tran-
scriptase (Fermentas). All the other probe preparation steps were
FIGURE 4 – Immunohistochemical detection of bFGF in transfected melanoma cells and in their primary tumors. (a,b) Fluorescence micro-
scopy. In vitro cultured human melanoma clones, 3.1P (a) and 19H (b) have been ﬁxed in paraformaldehyde, permeabilized with 0.5%TritonX-
100 for 1 min and labeled for bFGF with goat anti-human bFGF and visualized by FITC-conjugated anti-goat antibody, where the nuclei have
been labeled with propidium iodine (red). Note the rare cytoplasmic green signal in 3.1P cell population (a), compared to the strong uniform label
in 19H cells (b). (c,d) Confocal microscopy. Frozen sections of 13 day old orthotopic tumors were ﬁxed and labeled with goat anti-human bFGF
as above but the nuclei were labeled by TOTO-3 (blue). (c)¼3.1P, (d)¼19H clones. Note the high frequency of cytoplasmic reaction for bFGF in
the majority of tumor cells in transfected 19H tumor (d) as compared to the rare positivity in the case of the mock transfectant 3.1P clone (c).
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done according the manufacturer’s instruction (Genisphere).
cDNA was hybridized onto human cDNA microarrays in a Ven-
tana hybridization station (Ventana Discovery, Tuchon, State) by
using the ‘‘antibody’’ protocol. First hybridization was performed
at 428C for 6 hr in ‘‘Chiphyb’’ hybridization buffer (Ventana) and
then 2.5 l of each Cy5 and Cy3 capture reagents were added to
the slides in 200 l Ribohyb hybridization buffer (Ventana) and
incubated at 428C for 2 hr. After hybridization, the slides were
washed in 0.2 SSC twice at RT for 10 min and then dried and
scanned.
Microarray analysis
Each array was scanned under a green laser (543 nm for Cy3
labeling) or a red laser (633 nm for Cy5 labeling) using a ScanAr-
ray Lite (GSI Lumonics, Billerica, MA) scanning confocal ﬂuores-
cent scanner with 10 m resolution (laser power: 85% for Cy5 and
90% for Cy3, Gain: 80% for Cy5 and 75% for Cy3). Scanned out-
put ﬁles were analyzed using the GenePix Pro3.0 software (Axon
Instruments, Inc., Foster City, CA). Each spot was deﬁned by
automatic positioning of a grid of circles over the image. The
average and median pixel intensity ratios calculated from both
channels and the local background of each spot were determined.
An average expression ratio (MeanR, denotes the average of local
background corrected pixel intensity ratios) was determined for
each spot. Normalization was performed by the global Lowess
method. Those data were ﬂagged and excluded where the replicate
spots from a different site of the same array were signiﬁcantly dif-
ferent. We deﬁned those genes to be regarded in melanoma cell
cultures, where the average-fold change (increase or decrease) of
the 4 data points were at least 2.0-fold.
Results
Parallel expression of IIb3 and v3 integrins promotes
ortho- and hetero-topic growth of human melanoma cell lines
The 5 IIb3 transfected human melanoma clones expressed
surface IIb at different levels (6.7–27.2%) compared to the 3.1P
mock transfected clone (0.7%) as determined by ﬂow cytometry
(Table I), while the 3 expression was similarly high in all the
clones studied (64–80%). v3 expression was high in the mock
cells and was maintained, although at a lower levels in most of the
transfected clones (Table I).
IIb3 transfected human melanoma clones were injected het-
erotopically into the spleen of SCID mice. All the clones were
tumorigenic but the IIb3-transfected clones (ESL, ESH, 19L
and 19H) grown signiﬁcantly more rapidly than the mock cells,
3.1P (Fig. 1a), as was observed in case of s.c. growth reported
before.8 Next, selected IIb3-transfected human melanoma
clones (3.1P, 19L and 19H) were injected orthotopically (intracu-
taneously) into SCID mice. All these clones started to grow, which
was detectable from days 7–10. However, it became apparent
again that the IIb3-transfected clones, 19L and 19H, grew sig-
niﬁcantly faster at orthotopic site than the mock transfectant in the
early phase of tumor development (Fig.1b, p < 0.05 and p <
0.001, respectively).
Next we have tested whether the IIb3-transfection affected
organ colonization potential of human melanoma clones. We have
used 3 different models (intravenous, intrasplenic and intracardiac
injections), but we have not seen signiﬁcant alterations in the
metastatic potential of transfected clones compared to the mock
cells, 3.1P (Table II).
Parallel expression of IIb3 and v3 integrins promotes
vascularization and the angiogenic phenotype of human
melanoma cells
Intracutaneously growing human melanoma xenografts have been
removed on day 15, snap frozen, sectioned and labeled for mouse
CD31 to visualize intratumoral blood vessels (Fig. 2a,b). Tumors of
the transfected clones, 19L and 19H, contained more intratumoral
blood vessels than that of the mock transfected 3.1P cells, and the
difference was signiﬁcant in case of the 19H tumor (Fig. 2c).
Next we analyzed the immunocytochemical expression of the
major angiogenic cytokines of melanoma, VEGF and bFGF, in the
IIb3-transfected human melanoma clones, 19L and 19H, by
ﬂow cytometry. Data indicated that VEGF is constitutively
expressed in the majority of the cells of both the mock and the
IIb3-transfected clones (Fig. 3a,b). However, the mock trans-
fected clone, 3.1P, did not express bFGF at protein level (<1% of
the cell population, Fig. 3a,b), unlike the IIb3-transfected
clones, 19L (33.9%) and 19H (84.1%), where a signiﬁcant propor-
tion of the tumor cell population was positive (Fig. 3a,b). In vitro
cultured tumor cells were also stained for bFGF protein and the
data supported the observations made by ﬂow cytometry that the
cells of the IIb3-transfected 19H clone are heavily positive for
bFGF protein (Fig. 4a,b). We have questioned if this difference in
bFGF expression was maintained in the intracutaneously growing
tumors; therefore cryosections have been labeled for bFGF protein
and analyzed by confocal microscope. The 3.1P tumor barely con-
tained bFGF positive cells, but the IIb3-transfected tumor
(19H) was identiﬁed by a predominating population of tumor cells
with strong cytoplasmic bFGF labeling (Fig. 4c,d).
Parallel expression of IIb3 and v3 integrins correlates with
altered gene expression proﬁle of human melanoma cells
Next we questioned whether the IIb3 transduction into
v3-positive human melanoma clones affected bFGF expression
at transcriptional level. We collected 6 human melanoma clones
with various levels of IIb3 and v3 integrin expressions
(Table I) and tested for bFGF mRNA levels. The quantitative-
PCR analysis revealed that bFGF mRNA level increased parallel
with IIb3 protein expression in the analyzed clones, where the
highest bFGF expressions detected in clones with the highest pro-
portion of IIb3 positive cells, 19L, ESH and 19H, respectively
(Fig. 5). However, after a log increase of both IIb3 or bFGF
expressions, a further increase in integrin expression (clones ESH
and 19H) does not necessarily result in further upregulation of
bFGF (19H), suggesting a more complex association between the
regulation of the 2 genes.
Next we tested the effect of IIb3-transfection on gene
expression using a homemade 3.2K cDNA microarray9,10 that did
not contain a bFGF probe. For this purpose, we used the fastest
growing and most vascularized clone, 19H, and compared it to the
mock cells, 3.1P. We deﬁned those genes to be regulated by
FIGURE 5 – bFGF mRNA levels in transfected melanoma clones
determined by quantitative PCR. Parallel demonstration of IIb-pro-
tein expression (derived from Table I) and bFGF mRNA expressions
in transfected clones calculated from CT values which were converted
into relative concentration values by scaling from 1 to 1 between the
expression control and the highest value of the samples using the auto-
threshold ﬁt (Bio-Rad). Left axis: IIb protein expressed in % of posi-
tive cells. Right axis: bFGF expression in Q-PCR relative units.
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IIb3-transfection in melanoma cell cultures, in the case of
which the average-fold change (increase or decrease) of the 4 data
points was at least 2.0-fold. Forty-eight genes in 19H cells corre-
sponded to such strict criteria from the 3,200 analyzed; 36 genes
were found to be upregulated and 12 have been downregulated
(Table III). Among the downregulated genes, there were no known
angiogenic/endothelial ones represented; however, among the 19
known genes upregulated in 19H cells compared to 3.1P, 3 could
be considered endothelial-speciﬁc, such as CD34 antigen, endo-
thelin receptor type B and prostaglandin I-2 synthase, the changes
of which were also conﬁrmed by q-PCR analysis (data not
shown).
Based on this information, we have postulated that an altered
signaling activity in the IIb3-transfected clones may play a role
in the changes in gene expressions, including bFGF. Q-PCR anal-
ysis of the expression of a 3 integrin-associated signaling mole-
cule, 3-endonexin, indicated a 2.5–5-fold increase in the
expression of this gene in various transfected clones compared to
3.1P (Fig. 6a). Again, similarly to bFGF expression (Fig. 5), there
was no linear correlation between the IIb (Fig. 5) and 3-endo-
nexin expression levels in transfected clones. Next we used tyro-
sine kinase (Genistein, Staurosporine) and PKC (Calphostin C)
inhibitors to modulate cellular signaling in the 19H IIb3-trans-
fected clone and measured the consequences on bFGF mRNA and
protein expressions as determined by q-PCR and ﬂow cytometry.
These studies indicated that 25 hr exposure to tyrosine kinase
inhibitors resulted in a decrease, while PKC-inhibition resulted in
an increase in bFGF message (Fig. 6b). Measurement of the cyto-
plasmic bFGF protein by immunocytochemistry conﬁrmed these
observations, since both tyrosine kinase inhibitors (Genistein and
Staurosporine) signiﬁcantly inhibited the expression in transfected
19H cells (Fig. 6c).
Discussion
Recently we have shown that transfection of IIb3 integrin
into human melanoma cells constitutively expressing v3 pro-
motes in vivo growth due to decreased apoptosis.8 Our analysis of
the possible explanation for this phenomenon indicated that the
IIb3 transfected clones are more vascularized than the clone
expressing v3 alone providing an explanation for the increased
in vivo growth. Based on our results, the studied clones constitu-
tively express VEGF, but bFGF mRNA and protein expressions
are induced only in the IIb3 transduced clones. In agreement
with previous studies,6 we found that the expression of IIb3
parallel with v3 integrin does not modify the organ selectivity
of the metastatic potential of human melanoma cells, suggesting a
speciﬁc modulatory effect of IIb3 integrin on the angiogenic
phenotype.
bFGF was shown to be an autocrine growth factor of human
melanoma which is involved in proliferation, survival and inva-
siveness of transformed melanocytes.2,11 The biological signiﬁ-
cance of its expression is demonstrated by experiments where
bFGF or FGFR1 were used successfully as molecular targets to
prevent in vivo growth of melanoma.12 Meanwhile bFGF is one of
TABLE III – GENES OVEREXPRESSED IN TRANSFERRED CLONE 19H VS. MOCK CONTROL, 3.1P
Fold Ac.No Name
2,002048 D84124 Prostaglandin I-2 (prostacyclin) synthase
2,013939 AA933627 ESTs, Highly similar to PHOSPHATIDYLOCHOLINE
TRANSFER PROTEIN [Bos Taurus]
2,014675 D21235 Human mRNA for HHR23A protein, complete cds
2,035672 AA195261 EST
2,045783 R06710 EST
2,053254 AA524013 EST
2,065131 AA251134 EST
2,108728 A1024091 EST
2,132049 AA526945 EST
2,13392 D83780 Human mRNA for KIA0196 gene, complete cds
2,156721 L76927 Galactokinase 1
2,173375 D131168 Endothelin receptor type B
2,177483 AA731863 EST
2,23487 AA648933 ESTs, Weakly similar to homologous to
mouse Rsu-1 (H.sapiens)
2,302858 AC004262 Homo spiens chromosome 19, cosmid R29368
2,307286 L34408 Homo Sapiens (clone B3B3E13)
chromosome 4p16.3 DNA fragment
2,332845 AA483426 EST
2,366137 AA843532 EST
2,387688 AA748199 EST
2,387747 X62535 Diacylglycerol kinase, alpha (80kD)
2.403949 M10942 Human metallothionein-le gene (hMT-le)
2,418433 Y00971 Phosphoribosyl pyrophosphate synthetase 2
2,463528 N64780 EST
2,613085 AA927480 EST
2,624854 AA521146 EST
2,650112 AF001862 Human SLP-76 associated protein
mRNA, complete cds
2,660733 R17461 IMAGE EST
2,684187 AA576731 EST
2,735851 AA707308 EST
2,77783 U07857 Signal recognition particle 14 kD protein
2,785849 X54232 Glypican 1
2,821762 AA741117 EST
2,950237 A1055892 EST
2,987556 X52943 TRANSCRIPTION FACTOR ATF-A AND ATF-A-DELTA
3,07509 S53911 CD34 antigen (hemopoietic progenitor cell antigen)
4,460516 L03411 Radin blood group
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the most ubiquitous angiogenic cytokine that plays a signiﬁcant
role in vasculogenesis, as well as in physiological and pathological
neoangiogenesis.13 It was repeatedly shown in melanoma that sev-
eral angiogenic cytokines including VEGF are responsible for the
angiogenic phenotype,14,15 but these studies pointed to the signiﬁ-
cant contribution of bFGF. This assumption was further corrobo-
rated by the effects of downmodulation of FGF using antisense
therapy,16 resulting in decreased vascularization. Our observation
in our study on the upregulated bFGF expression in a constitutive
VEGF background in the more angiogenic human melanoma
clones further supports these data. Upregulation of bFGF during
the progression of human melanoma was reported at the transition
from the radial to the invasive vertical growth phase.2 Studies on
human samples demonstrated that v3 integrin expression is
constitutive in primary melanomas, while the IIb3 expression
increased with tumor thickness.8,17 We suggest that in human mel-
anoma, overexpression of v3 integrin may correlate with VEGF
expression, while the emergence of the illegitimate expression of
the IIb3 integrin in a later stage of the disease (vertical growth
phase) may contribute to the upregulation of bFGF expression,
providing both another autocrine growth factor as well as another
angiogenic cytokine for melanoma cells.
Parallel expression of the two 3-integrins in human melanoma
cells induced modulation not only of bFGF but other genes as
well, which is demonstrated by microarray analysis. Interestingly,
3 out of 19 known genes upregulated signiﬁcantly in IIb3-trans-
fected 19H cells are endothelial cell-speciﬁc genes, CD34, endo-
thelin receptor B and PGI-2 synthase. Recapitulation of an
embryonic endothelial/angioblastic genetic program, called vascu-
logenic mimicry,18 resulting in in vivo formation of tumor cell-
lined vascular channels, was recently described and documented
in human melanoma and other tumors.19 There have been several
genes identiﬁed to be responsible for this vasculogenic phenotype
including VE-cadherin, CD34, TIE2, Eph2A, LAMC2, endoglin,
EDG1, ESM1 and EDF1.20
AlphaIIb3 transfection into v3-expressing human mela-
noma cells, demonstrated here, correlated with the overexpres-
sion of certain vasculogenic genes (bFGF, CD34, ENDRB and
PGI-2 synthase), suggesting that 3 integrin signaling could be
one of the potential molecular mechanisms behind this genetic
reprogramming. v3 integrin is involved in survival signaling
in melanoma cells21 mediated either through FAK or Shc using
the Ras-Raf-MAPK pathway22,23 as well as PI3K.24 On the other
hand, it was shown in murine melanoma cells, spontaneously
expressing IIb3 (but not v) integrin, that 3 signaling is con-
stitutively active and the ligation induced further activation of
PKC.25 Based on the observations that tyrosine kinase inhibitors
downregulated bFGF expression in IIb3-transduced 19H cells
while PKC inhibitor upregulated it, we suggest that the integrin-
linked classical tyrosine signaling cascade might be involved in
the upregulation of bFGF and other gene expressions in IIb3-
transfected human melanoma cells. 3 integrin is unique among
integrins, since its cytoplasmic domain is associated with a sig-
naling mediator that is a transcription factor: the 3-endonexin
protein.26,27 The fact that 3-endonexin is also upregulated in
the IIb3-transfected clones suggests that this integrin-linked
signaling protein may also be involved in the observed altera-
tions in the angiogenic geno- and pheno-types of human mela-
noma cells.
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FIGURE 6 – Modulation of signal transduction in IIb3- trans-
fected human melanoma clones. (a) q-PCR analysis of the expression
of 3-endonexin mRNA in IIb3-transfected ESL, 19L and 19H
cells compared to the mock-transfected 3.1P clone. Data are normal-
ized for the expression of -actin and are in relative units (mean of 2
parallel samples). (b) q-PCR analysis of bFGF mRNA in 19H cells
treated with Staurosporine (Stau), Genistein (Gen, 100 g/ml) or Cal-
phostin C (Cal, 5 M) for 25 hr at 378C. Data are normalized for the
expression of -actin and are in relative units (mean of 3 parallel sam-
ples). (c) Effect of protein kinase inhibitor pretreatments on the
expression of bFGF protein in melanoma cell lines as detected by
immunocytochemistry and ﬂow cytometry. Adherent cells were pre-
treated with the inhibitors for 25 hr at 378C (Genistein, Gen and Staur-
osporin, Stau: 100 g/ml). Following incubation, cells were
suspended, ﬁxed in MetOH and have been labeled for bFGF and
measured by ﬂow cytometry as in case of Figure 3. Data are expressed
as mean ﬂuorescence intensity 6SD (n ¼ 3). *p < 0.05 determined by
ANOVA single factor analysis.
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Abstract
Conventional approaches to target labeling for gene expression analysis using microarray technology typically require relatively
large amounts of RNA, a serious limitation when the available sample is limited. Here we describe an alternative exponential sample
ampliWcation method by using quantitative real-time polymerase chain reaction (QRT-PCR) to follow the ampliWcation and elimi-
nate the overampliWed cDNA which could distort the quantitative ratio of the starting mRNA population. Probes generated from
nonampliWed, PCR-ampliWed, and real-time-PCR-ampliWed cDNA samples were generated from lipopolysaccharide-treated and
nontreated mouse macrophages and hybridized to mouse cDNA microarrays. Signals obtained from the three protocols were com-
pared. Reproducibility and reliability of the methods were determined. The Pearson correlation coeYcients for replica experiments
were r D 0.927 and r D 0.687 for QRT-PCR-ampliWcation and PCR-overampliWcation protocols, respectively. 2 test showed that
overampliWcation resulted in major biases in expression ratios, while these alterations could be eliminated by following the cycling
status with QRT-PCR. Our exponential sample ampliWcation protocol preserves the original expression ratios and allows unbiased
gene expression analysis from minute amounts of starting material.
 2004 Elsevier Inc. All rights reserved.
Keywords: Exponential sample ampliWcation; Quantitative real-time PCR; Microarray; Gene expression proWling
Microarray technology has led to powerful advances
in identifying genetic proWles and to the ability to screen
thousands of individual genes that may be diVerentially
expressed in diVerent samples [1]. cDNA microarray
analysis requires relatively large amounts of total RNA
(10–20g). However, some sources of RNA have limited
yield, in addition, the quality of RNA can vary substan-
tially, depending on the method of isolation, the pres-
ence of endogenous RNases, and other factors that may
be introduced during an experiment. The need for repli-
cate hybridization increases the demand for RNA even
further [2].
To circumvent this issue, signiWcant eVort has been
focused on approaches to reduce the RNA requirement
per hybridization through the use of in vitro-transcrip-
tion (IVT)1-based [3–6,17] or PCR-based [2,7,8,17,18]
ampliWcation technologies. With respect to RNA ampli-
Wcation strategies, T7 polymerase IVT is currently the
most commonly used and well documented ampliWca-
tion protocol [3,17]. Although successful strategies for
* Corresponding author. Fax: +36 62 432576.
E-mail address: pusi@brc.hu (L.G. Puskás).
1 Abbreviations used: IVT, in vitro transcription; QRT-PCR, quan-
titative real-time PCR; LPS, lipopolysaccharide; RT, reverse transcrip-
tion; SSC, standard saline citrate.
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signiWcantly reducing RNA requirements have been
developed, IVT-based ampliWcation procedures have
several notable shortcomings. Methods require multiple
steps and are time consuming, labor intensive, and
costly. Moreover, if RNA is very limited, consecutive
rounds of IVT ampliWcation are required to generate
suYcient material for hybridization [9,10], which adds
further complexity to the procedure and reduces the line-
arity of the ampliWcation.
PCR has a number of potential advantages: it is faster
and more cost eVective and oVers an almost unlimited
degree of ampliWcation. A number of variations on PCR
labeling have been described [11–14], including those
using template switching PCR [15–19], commercialized
by Clontech in their SMART PCR cDNA synthesis kit
[5]. While these methods demonstrated the potential of
the approach, they focused little attention on the rela-
tionship between the degree of ampliWcation and the
Wdelity of the ampliWed material with respect to the
starting mRNA population. However understandable
concerns about the faithfulness of PCR ampliWcation
have held back the widespread adoption of the approach
by the microarray community [2,20,21]. Because the reli-
ability of PCR-based ampliWcation depends mostly on
the exponential phase during cycling, we therefore devel-
oped an alternative sample ampliWcation method, which
follows the ampliWcation status by quantitative real-time
PCR (QRT-PCR). With real-time detection of the prod-
ucts we could eliminate DNA overampliWcation which is
of great risk when using traditional cycling and in-gel
analysis of the products.
Materials and methods
Cell culture, RNA isolation, and quality assessment
Mouse macrophage cell lines were cultured in Dul-
becco medium with 10% bovine serum albumin. Cells
without and with induction with 1g/ml LPS for 2 h
were harvested. Total RNA was extracted using Nucleo-
spin RNA II kit (Macherey-Nagel, Düren, Germany).
The RNA concentration was assessed spectrophotomet-
rically by NanoDrop (Rockland, DE, USA) and the
quality was monitored by Agilent 2100 Bioanalyzer
(Agilent Technologies, Waldbronn, Germany). Total
RNA was used for microarray analysis and for QRT-
PCR.
Preparation of cDNA targets for signal ampliWcation
For probe preparation, 1g of total RNA was
reverse-transcribed using poly(dT)-primed Genisphere
Expression Array 350 Detection system (Genisphere,
HatWeld, PA, USA) according to the manufacturer’s
instruction. cDNA with Cy5 capture sequence was
hybridized onto mouse cDNA microarray containing
3200 mouse cDNA samples in duplicate. Postprocessing
and blocking of the microarrays were performed as
described previously [17].
Preparation of PCR-ampliWed and PCR-overampliWed 
labeled probes
Reverse transcription (RT) reactions were carried out
in a Wnal volume of 20l with 1g mouse macrophage
total RNA, 75 pmol universal T7T25V primer (5-GGCC
AGTGAATTGTAATACGACTCACTATAGGGAG
GCGG(T)25 V-3), 75 pmol FOR primer (5-TGTCTG
CAGTGGTAACAACGCAGAGTACGCGGG-3),
30 U Prime RNase Inhibitor (Eppendorf, Hamburg,
Germany), 2.5 mM each dNTP, and 200 U RevertAid H
Minus M-MuLV Reverse Transciptase (MBI Fermen-
tas, Vilnius, Lithuania) in 1£ reaction buVer (MBI Fer-
mentas) at 42 °C for 2 h in a total volume of 20l. RNA
and the primer mixture were denatured at 70 °C for
5 min before RT reaction. The reaction was terminated
by heat inactivation at 70 °C for 15 min. The RT reaction
mixture was diluted three times with nuclease-free water;
1l of the diluted reaction mix containing RNA from
approximately 15 ng total RNA was used for QRT-PCR
using iQ SYBR Green Supermix (Bio-Rad, Hercules,
CA, USA). QRT-PCR analysis for cDNA ampliWcation
was carried out in a total volume of 50l with 1l of the
diluted RT product, 50 pmol T7T primer (5-GGCC
AGTGAATTGTAATACGACTCACTATAGGGAG
GCGGTTT-3), 50 pmol FOR primer in 1£ iQ SYBR
Green Supermix (Bio-Rad). QRT-PCR was performed
in a Rotor-Gene 2000 (Corbett Research, Mortlake,
Australia) with the following protocol: 21 cycles of 25 s
at 95 °C for denaturation, 25 s at 60 °C for annealing,
and 4 min at 72 °C for extension. The reaction was halted
in the exponential phase of the ampliWcation at 13–15
cycles depending on the ampliWcation proWle. Overam-
pliWed cDNA was obtained from PCR with 21 cycles.
The PCR mixtures were puriWed with the MinElute
PCR PuriWcation Kit (Qiagen, Courtaboeuf, France)
according to the manufacturer’s instructions; 1g puri-
Wed PCR-ampliWed DNA was transcribed in a total vol-
ume of 20l using RiboMAX T7 Express System
(Promega, Madison, WI, USA) according to the manu-
facturer’s instructions. The ampliWed aRNA was puri-
Wed using Nucleospin RNA II kit (Macherey-Nagel) and
50g ampliWed aRNA was labeled with Cy5 during RT
using 75 pmol random heptamer primer, 0.1 mM d(G/T/
A)TPs, 0.06 mM dCTP, 0.04 mM Cy5-dCTP (Amersham
Biosciences, Uppsala, Sweden), 30 U Prime RNase
Inhibitor (Eppendorf), 200 U RevertAidTM H Minus
M-MuLV Reverse Transciptase (MBI Fermentas) in 1£
reaction buVer (MBI Fermentas). The aRNA, primer,
and RNase inhibitor were denatured at 70 °C for 5 min
and cooled on ice before adding the remaining reaction
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components. After 2 h incubation at 37 °C, the aRNA
was hydrolyzed with NaOH (250 mM Wnal concentra-
tion). The labeled cDNA was puriWed with the MinElute
PCR PuriWcation Kit (Qiagen) according to the manu-
facturer’s instructions.
Array hybridization and data analysis
Hybridization was done by Ventana Discovery
hybridization station (Ventana Discovery, Tucson, AZ,
USA). The probes were dissolved in 200l hybridization
buVer (Ventana). Denaturation was performed at 75 °C
for 6 min, hybridization was done at 42 °C for 6 h, and
washing was done at 37 °C with 2£ SSC. After hybrid-
ization the arrays were washed with 0.2£ SSC for 1 min.
The slides were scanned with confocal laser scanner
(ScanArray Lite, GSI Lumonics, Billerica, MA, USA).
Image Wles were analyzed with the GenePix Pro 3.0.5
program (Axon, Union City, CA, USA). After auto-
matic Xagging, manual Xagging was performed to
exclude spots having irregularities such as scratches and
dust particles. Data obtained by the median of feature
pixels were accepted only if 30% of pixels were above 2£
standard deviation of the background intensity.
Quantitative real-time PCR
Real-time PCR was carried out in a Wnal volume of
20l with 1l 1:5 dilution of diluted cDNA mixture,
10 pmol gene-speciWc Forward and 10 pmol Reverse
primer in 1£ iQ SYBR Green Supermix (Bio-Rad) with
the following protocol: 25 s at 95 °C for denaturation, 25 s
at 60 °C for annealing, and 15 s at 72 °C for extension.
The primers were designed using Primer Express software
(Applied Biosystems, Foster City, CA, USA) (sequences
are listed in Table 1). The relative expression of each gene
was normalized to that of mouse -actin. Nontemplate
control sample was used for each PCR to check the geno-
mic DNA contaminations of cDNA template. Analysis of
the results was done using the PfaZ [22] method.
Results and discussion
cDNA ampliWcation with QRT-PCR
One of the primary concerns of researchers conduct-
ing PCR-based cDNA ampliWcation for microarray
analysis is its weaker reproducibility. To address this
issue we intended to eliminate biases introduced by
overampliWcation and thus to improve the reliability of
PCR-based cDNA ampliWcation for microarray experi-
ments by using real-time quantitative PCR. Experi-
ments were designed to investigate the reliability and
reproducibility of the traditional and the real-time
PCR-based exponential ampliWcation protocols. For
control nonampliWed samples, the dendrimer-based sig-
nal ampliWcation method (Genisphere) was used. Four
hybridizations were performed using LPS-treated and
nontreated mouse macrophages with the ampliWed and
nonampliWed probes to compare the reliability and the
reproducibility of the methods used. Total RNA (1 g)
was reverse transcribed and 15-ng aliquots were PCR
ampliWed with two protocols resulting in DNA samples
from early phase (13th–15th cycles) and late exponen-
tial, early saturation phase (21st cycle) (Fig. 1A). By fol-
lowing the ampliWcation status with SYBR green
labeling in the real-time PCR instrument, reactions were
halted at the appropriate cycle. After DNA isolation the
quality and quantity of ampliWed cDNA were assessed
by gel electrophoresis and spectrophotometry (Fig. 1B).
For generating microarray probes with sample ampliW-
cation, PCR and a subsequent in vitro transcription
were used to obtain ampliWed RNA as described earlier
Table 1
Primers used in QRT-PCR
Gene product Forward primer Reverse primer
-Actin TTCAACACCCCAGCCATGT GCATACAGGGACAGCACAGCC
Alcohol dehydrogenase 5 AGTGCATTGGCAACGTGAAG TGACACCCCAGCCTTTGTG
AMP activated protein kinase GTGGCTCTGGGCATCTTTGT CGCCCTTTCTCATCCACTACA
Angiogenin-3 precursor ACAATGAGCCCATGTCCTTTG GCCAGAGTTGGAGGAATCACA
Anti-oxidant protein 2 TCCAGTCGAGAAGGACGATAACA GTCAGGGCCAAAAATGAACAC
Aspartyl aminopeptidase GGGTCAGAGAGTGCACAAGGA GGCTGAGATGCGCCGTAGT
Basigin AGCCGCATGGCAGCC ATGGTAACCAACACCAGGACCT
Ly-6 alloantigen CAGGAAGACCTCTGCAATGCA TAGCGGTCCCAGAGTGCCT
Metallothionein CAAATGTACTTCCTGCAAGAAAAG GCAGCCCTGGGAGCACTT
Osteoprotegerin GAAAGCAGCGTGCAGCG TCAAGGCAAGAAGCTGCTCTG
N-myc downstream regulated 4 GGTGCCCAATGCCAAGAC TCCTCAGCAGGTGCATTATCTC
Non muscle tropomyosin 5 ACTTGGAACGCACGGAGG TCTGATCTGTTCATCCATCTCTC
Peroxisomal t-2-enoyl-Coa reductase TCCCGGAAGCTGGACAGA AGCTGGAGGGAGGCAGAGA
Procollagen, type I,  1 GACAAGGGTGAGACAGGCGA CCCTGGAGACCAGAGAAGCC
Serine hydroxymethyl transferase 2 GGCCCCCGCGTTGA AAAATCGACGACTCTACGGAAGTC
Serine/threonine kinase 10 GCGGCTACCCAAGATCCA TGTGCAGGCTCTTCTTGTACATG
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[17]. PCR-ampliWed cDNA (1 g) was used forin vitro
transcription. On average 81.2 g (§6.6g) aRNA was
generated. The presence of SYBR Green had no eVect
on the eYciency of the reaction (data not shown).
AmpliWed RNA was labeled using direct Cy5 incorpo-
ration during RT. Probes were hybridized onto mouse
cDNA microarrays having 3200 features in duplicate.
To determine the reproducibility of the sample ampliW-
cation protocols hybridizations derived from four inde-
pendent reactions were analyzed. The Pearson
correlation coeYcients for the replica experiments were
r D 0.927 and r D 0.687 for the exponential and for the
saturated samples, respectively. The Pearson correlation
coeYcient for the control method, where no sample
ampliWcation was performed, was r D 0.941. The corre-
lation coeYcients of the exponentially ampliWed sam-
ples were comparable with the nonampliWed control
coeYcients, which conWrms our hypothesis that the
QRT-PCR protocol improved the reliability of the
PCR-based ampliWcation.
Gene expression changes of 3200 genes of mouse
macrophages in response to LPS treatment were fol-
lowed by mouse-speciWc cDNA microarrays. To demon-
strate diVerences in results obtained with the two
diVerent ampliWcation protocols, 10 genes from each of
the up-regulated, down-regulated, and nonchanged
genes having diVerent expression ratios with the expo-
nential and overampliWcation techniques are shown in
Table 2. Among the selected genes there were few with
nonsignifcant changes (marked with * in Table 2) in
either method. From the relative expression values of the
30 selected genes it can be concluded that overampliWca-
tion resulted in biased expression ratios, while in the case
of QRT-PCR-based exponential ampliWcation the start-
ing mRNA ratios remained unchanged; 13 of 30 genes
exhibited diVerent expression ratios in the case of over-
ampliWed samples, while only 4 genes had diVerent
expression ratios when the exponential ampliWcation
protocol was applied in comparison to the results of the
nonampliWed samples.
Among the 3200 genes examined in the control, sig-
nal-ampliWcation-based microarray experiments an
average of 1045 showed signiWcant intensity ratio rela-
tive to background and 9.09% (95 genes) showed altered
expression: 56 genes exhibited signiWcant down-regula-
tion and 39 were up-regulated due to LPS. In the case of
the exponential ampliWcation QRT-PCR protocol 1127
genes showed signiWcant intensity ratio and 10.04% (118
genes) showed altered expression: 62 genes exhibited
signiWcant down-regulation and 56 were up-regulated.
In the PCR-overampliWed-based microarray experi-
ments an average of 924 genes showed signiWcant inten-
sity ratio relative to background and 7.68% (71 genes)
showed altered expression: 38 genes exhibited signiW-
cant down-regulation and 33 were up-regulated. There
were numerous genes with altered expression in the
cases of the exponential ampliWcation and the nonam-
pliWed control methods, which exhibit no change when
overampliWed samples were tested (see examples in
Table 2). This discrepancy might be due to the satura-
tion eVect of the nonfollowed ampliWcation protocol in
late cycles.
ConWrmation of gene expression changes with QRT-PCR
To verify exact individual gene expression changes
obtained with the protocols tested QRT-PCR analysis
was performed on 15 genes. Genes were selected from
those shown in Table 2. -Actin gene was used as a con-
trol. Ten independent samples were generated from
ampliWcation reactions for each protocol using the same
total RNA as starting material to determine the repro-
ducibility of cDNA ampliWcation. The results are shown
in Table 3. One-sample Student t test was performed on
Fig. 1. cDNA ampliWcation with QRT-PCR. (A) QRT-PCR diagram of the LPS-treated mouse macrophage. With the QRT-PCR halted at the 14th
cycle, the ampliWed cDNA (a2) was generated in the exponential phase of the reaction; the overampliWed cDNA (a1) was isolated from reactions
halted at the 21st cycle; a3 denotes the nontemplate control. (B) Electrophoretic assessment of cDNA-ampliWcation-based QRT-PCR from LPS-
treated mouse macrophage. Lanes 2 and 3 contained ampliWed cDNAs obtained from the exponential phase; lanes 4–6 were loaded with overampli-
Wed samples; lane 1 is a 100-bp DNA ladder (Bioneer, Daejeon, Korea).
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each of the 15 genes to assess signiWcant expression
changes. The resulting p values were interpreted with
regard to categorical data: down-regulated, up-regu-
lated, and not changed. We referred to a gene as regu-
lated when the corresponding p value was below 0.05. In
Table 3, it can be seen that relative gene expression
ratios obtained with the overampliWcation protocol
resulted in higher p values and thus nonsigniWcant ratios
in 10 of 15 cases, while in the case of exponential ampliW-
cation only 5 values were above 0.05 and in the case of
nonampliWcation protocol all of the p values were below
0.05.
Using expression data, inferences on the inXuence of
the cDNA ampliWcation method on expression ratios
could be made with the use of the 2 test for count data
[23]. In this test gene expression changes (no change, up-
or down-regulation) were determined for all the 15
genes in each method; 15 values from each method were
compared to each other. The p value was resulted in
p D 0.8807 for the comparison of the nonampliWed and
the exponentially ampliWed cDNA. This p value
suggests good correlation with the results obtained
by the two methods. In case of overampliWed cDNA
the p value was 0.0291. This low value indicates signiW-
cant diVerences between gene expression ratios
obtained by the overampliWed and the nonampliWed
protocols.
To demonstrate diVerences in ratios obtained with
diVerent ampliWcation protocols, a scatter plot, for those
genes whose expressions were changed in response to
LPS treatment in the case of the nonampliWed protocol,
was constructed Fig. 2. Expression ratios for these genes
obtained by the exponential and overampliWed protocols
are also presented. In the case of the exponential proto-
col most of the genes had expression ratios similar to
those of the nonampliWed protocol, while most of the
ratios obtained with the overampliWed method lie in the
“nonchanged +1 to ¡1 zone” and had diVerent values.
Table 2
Selected genes with altered expression in response to LPS treatment in mouse macrophages compared to non-treated cells
Light gray: diVerent Log ratio in the nonampliWed sample compared to the exponentially ampliWed cDNA sample; dark gray: similar Log ratio in the
nonampliWed and exponentially ampliWed samples but diVerent with the overampliWed sample.
* Values above and below +1 and ¡1, respectively, however, with nonsigniWcant changes.
Gene product (Accession No.) NonampliWed SD Exponential SD OverampliWed SD
Down-regulated genes
AMP-activated protein kinase (AF036535) ¡1.43 0.27 ¡2.18 0.48 ¡0.95 0.63
Angiogenin-3 precursor (NM_177544) ¡1.08* 0.36 ¡1.68 0.22 0.09 0.78
Arginase II (BC023349) ¡1.23* 0.34 ¡1.02 0.42 ¡1.54 0.39
B-cell translocation gene 2 (NM_007570) ¡1.35* 0.48 ¡1.98 0.35 ¡0.91 0.26
Ly-6 alloantigen (X04653) ¡2.12 0.23 ¡2 0.73 ¡0.01 0.54
Memb. metallo endopeptidase (BC034092) ¡1.56 0.47 0.23 0.52 0.98 0.36
Peroxisomal t-2-enoyl-Coa red. (BC013530) ¡1.87 0.14 ¡2.18 0.41 ¡0.07 0.72
Retinol dehydrogenase 7 (BC024603) ¡1.06 0.16 ¡1.35 0.14 ¡1.68 0.57
Serine hydroxymethyl trans. 2 (NM_028230) ¡1.94 0.36 ¡1.28 0.23 1.07* 0.39
Vacuolar proton tr. ATPase d (AY137757) ¡1.25 0.31 ¡2.12 0.83 ¡1.01* 0.85
Genes with no change
Alcohol dehydrogenase 5 (BC062879) ¡0.42 0.26 ¡0.38 0.12 1.1* 0.79
 Tubulin 7 (NM_009449) 0.23 0.43 ¡0.02 0.22 0.72 0.35
Basigin (D00611) 0.84 0.17 0.62 0.65 0.68 0.59
 Tubulin 5 (NM_011655) 0.53 0.21 1.62 0.44 0.85 0.66
Cathelin-like protein (X94353) 0.67 0.35 ¡0.53 0.29 0.78 0.43
Heat shock protein 86 (M57673) 0.37 0.84 0.86 1.09 ¡0.04 0.67
NADH dehydrogenase a 1 (BC052817) ¡0.18 0.72 0.04 0.36 ¡0.23 0.55
Nonmuscle tropomyosin 5 (NT_039260) 0.51 0.64 0.57 0.45 ¡0.17 0.37
Osteoprotegerin (BC049782) 0.76 0.47 0.47 1.04 0.88 0.12
Procollagen, type I,  1 (UO3419) 0.19 0.27 0.32 0.36 0.86 0.49
Up-regulated genes
Amyloid beta precursor prot. (AY011334) 1.25* 0.73 1.33* 0.87 0.95 0.56
Anti-oxidant protein 2 (AF004670) 1.18 0.25 1.24* 1.2 0.76 1.04
Aspartyl aminopeptidase (AF005051) 1.25* 0.93 0.86 0.57 0.37 0.53
Interleukin 12  (BC057212) 1.04 0.27 1.05* 0.62 1.18* 0.82
Matrix metalloproteinase 2 (NM_008610) 1.25* 0.47 1.03* 0.65 0.84 0.23
Matrix metalloproteinase 9 (NM_013599) 1.02 0.14 1.25* 0.37 1.34* 0.49
Metallothionein (K02236) 1.13* 0.39 1.21* 0.46 0.65 0.83
N-myc downstream regul. 4 (NM_145602) 1.47* 0.59 1.1* 0.62 ¡0.18 0.89
Pentaxin related (BC022176) 1.08* 0.93 1.34 0.38 1.52 0.51
Serine/threonine kinase 10 (NM_009288) 1.51 0.17 0.84 0.47 1.16* 0.53
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This means that in most cases overampliWcation
changed the original expression ratio observed in the
case of the nonampliWed sample.
To determine whether the overampliWcation protocol
distorts ratios more for highly abundant genes than for
less abundant genes we determined relative Ct values
from QRT-PCR experiments, which reXect the relative
mRNA copy number of the corresponding gene to -
actin in the sample. As seen in Table 3, genes having dis-
torted ratios in the overampliWcation method possessed
diVerent relative Ct values. This suggests that no speciWc
distortion eVect could be determined, although only 10
genes could be analyzed in our case. It would be interest-
ing to follow more genes with distorting ratios to study
this hypothesis in detail.
In conclusion, overampliWcation has a major distort-
ing eVect on the true expression ratios, while the method
using quantitative real-time PCR described here pre-
serves the original expression ratios and can be used in
microarray experiments.
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